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1 Introduction
1.1 Ubiquitin- and Ubiquitin-like Modifiers
Ubiquitin-like modifiers (UBLs) are a group of post-translational modifications which are
structurally characterized by their so called β-grasp fold spanning approximately 70 amino
acids (aa) and often reversibly conjugated to other proteins via their C-terminal glycine [1].
To date, the group of UBLs comprises 12 confirmed members and families presented and
summarized in Table 1 as well as additional putative UBLs [2]. Furthermore, prokaryotic
proteins with a similar protein fold, which are regarded as precursor for the ubiquitin
system were identified in recent years [3]. All UBLs contribute to the regulation of cellular
functions in their unique ways, together spanning all relevant processes in the cell from
protein degradation and DNA repair to immune control and autophagy [2, 4, 5]. The
most relevant and best studied UBLs are presented in detail below.
1.1.1 Ubiquitin
The founding member of the UBLs is the 76-aa containing polypeptide ubiquitin (Ub)
that received its name due to the ubiquitous presence and high conservation throughout
all eukaryotes [4]. It is translated as a linear precursor-protein of multiple head-to-tail
fused Ub-moieties or fused to other proteins and is processed rapidly by deubiquitinating
Ub/UBL β-grasp fold Ubiquitin 
N 
G 
G 
β4 
β3 
β5 
β1 
β2 
C 
Figure 1. Ub/UBL beta-grasp fold and ubi-
quitin structure. β-sheets are repre-
sented in green, α-helices in blue. Modi-
fied from Vierstra [1].
enzymes (DUBs) to create free Ub [1]. Indi-
vidual Ub-moieties show the characteristic
β-fold grasp consisting of 5 β-sheets and an
opposed α-helix (Fig 1), generating a high
structural stability against pH-shifts and
high temperatures [1,6]. Ub is liked to sub-
strate proteins via its C-terminal glycine
which is attached to an amino group of the
target protein, predominantly lysine (Lys),
forming an ε-isopeptide bond [7]. Apart
from its importance as the first polypep-
tide modifier, Ub is the best characterized
PTM of this group and in addition also the
most complex member, due to the ability
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to not only become conjugated to target proteins but also to other Ub-moieties to form
different and highly complex chain types [8]. Ub itself contains seven lysine (K) residues,
K6, K11, K27, K29, K33, K48 and K63 and all of them as well as the N-terminal
methionine are potential starting points for poly-Ub chain-building. Interestingly, distinct
types of ubiquitination are implied in different cellular functions (Fig 2). The “simplest”
Ub-modification, monoubiquitination, and if multiply attached multi-monoubiquitination,
is a frequent modification of histones, where it provides a base for protein interactions with
methyltransferases and other proteins [9]. Apart from this function, monoubiquitination
was described to play a role in protein localization and modulation of activity [8].
Substrate Substrate 
Substrate 
Substrate Substrate Substrate Substrate 
Substrate Substrate Substrate Substrate 
Monoubiquitination 
Multi-monoubiquitination Polyubiquitination I 
Polyubiquitination II 
branched, forked 
and modified chains 
linear K63 K48 K33 
K29 K27 K11 K6 
Protein interactions, protein localization 
and modulation of protein activity 
DNA damage response, 
mitophagy 
cell cycle 
control 
nuclear translocation, 
DNA damage  
response 
degradation, 
signaling 
TCR signaling, 
trafficking 
proteasomal 
degradation 
endocytosis, trafficking 
innate immunity 
innate immunity, 
selective autophagy 
unknown 
Ubiquitination 
Phosphorylation 
Acetylation 
Figure 2. Overview of the types of mono- and polyubiquitination and associated cel-
lular functions. Substrate proteins are represented in blue and ubiquitin-moieties in
green. K refers to the lysine utilized for chain assembly. Phosphorylation is illustrated
in yellow, acetylation in purple. Modified from Ye & Rape and expanded with recently
described functions from Akutsu et al. [8, 10].
In contrast, polyubiquitination adopts a variety of manifestations (Fig 2). The canonical
poly-Ub chain comprises of at least 4 Ub-moieties linked by K48 and targets modified
proteins for proteasomal degradation [4]. Additionally, K48 poly-Ub chains are also
implicated in non-proteolytic functions, e.g. activation and inactivation of certain
proteins [11]. In recent years, not only K48 but also other chain types were described to
7
1 Introduction
facilitate distinct functions. K6 and K27 polyubiquitination, for example, are implicated
in DNA damage response, while K11 poly-Ub chains control cell-cycle progression and
K29 and K33 play a role in different signaling cascades (Fig 2) [8, 10].
Most notably, chains that are methionine-linked and therefore often referred to as M1
chains as well as K63 chains adopt a more linear and open conformation than all the other
chains [12], leading to a distinct functional repertoire especially in regulation of protein
complex-building in innate immunity [13]. Additionally, K63 and M1 poly-Ub chains
are involved in autophagic processes, e.g. selective autophagy and endocytosis [10,14].
Although the functions of different chain types were extensively researched in the last
years and become more well described, novel chain-varieties emerge perpetually. The
most recent additions to the complexity of the ubiquitin-code entail branched, forked
and mixed-linkage Ub-chains [10] as well as post-translational modifications of ubiquitin
by kinases and acetylases. For those Ub-varieties, functional descriptions are limited to
a few cases [15]. Furthermore, hybrid-UBL chains were recently described, combining
ubiquitin and the UBLs SUMO and NEDD8 in distinct mixed chains [16,17].
In general, it is assumed that all Ub-chain types target proteins to a variety of
degradation pathways [14, 18] and all possible chain-types and -variations are being
utilized in vivo [10]. Although ubiquitination is implicated in a wide variety of functions,
other UBLs are important players in the regulation of cellular processes as well, and are
even involved in functions overlapping with those mentioned for ubiquitin.
1.1.2 SUMO
Small Ubiquitin-related Modifier (SUMO) is one of the most extensively studied UBLs
and present in 3 to 4 paralogs in vertebrates [19]. Although sequence identity of SUMO
to Ub is not high (18 %), it contains the typical β-grasp fold and is additionally able
to form poly-SUMO-chains [20] as well as hybrid Ub-SUMO chains [17]. Two of the 4
human paralogs, SUMO-2 and SUMO-3, often referred to as SUMO-2/3, share 95 %
of sequence identity and are readily conjugated to proteins, as is SUMO-4, which is
87 % identical to SUMO2 [19,21]. The last paralog, SUMO-1 has only 50 % similarity
to SUMO2 and additionally lacks the consensus motif needed to build poly-SUMO
chains [22]. However, only one SUMO-conjugating enzyme, Ubc9, is known so far and
is facilitating conjugation of all SUMOs [23]. Ubc9 is predominantly localized in the
nucleus and associated to filaments. Additionally, SUMOs themselves are spatially
restricted to nuclear compartments with exception of SUMO-3, which is also found in
the cytoplasm [24]. Nevertheless, SUMOylation is implicated in DNA repair, nuclear
transport and cell cycle progression as well as adaptation to stress stimuli, and over 600
putatively SUMOylated proteins are described so far [23]. Furthermore, SUMOylation
regulates innate immune components during viral infection and recently it was also shown
that Listeria monocytogenes impairs SUMOylation for efficient infection [25,26].
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1.1.3 NEDD8
Neuronal-precursor-cell expressed developmentally down-regulated 8 (NEDD8) has a
sequence identity of about 55 % as compared to ubiquitin and thus is the most similar
UBL [2,22]. NEDD8, like Ub and SUMO, is also able to form poly-NEDD8 chains through
different lysine residues as well as mixed chains with ubiquitin, then functioning as a chain
terminator [16,27]. The predominant function of NEDD8 is the activation of the cullin
sub-units of RING Ub-ligases enhancing their ligase activities [2]. Notably, NEDDylation
was recently found to be involved in a number of functions in transcriptional regulation
and signaling not linked to cullin activation [16,28]. In signaling processes, NEDD8 can be
attached to receptor tyrosine kinases, as described for EGFR and TGFßRII, by the E3-Ub
ligase c-Cbl which also ubiquitinates the receptors. Astonishingly, NEDDylation of EGFR
boosts subsequent ubiquitination and degradation while NEDDylation of TGFßRII leads
to prolonged signaling and stabilization [29,30].
1.1.4 ISG15
Interferon-stimulated gene 15 (ISG15) was the first UBL to be discovered and owes its
name to the fact that it is inducible by type-1 interferons (IFN) [19]. ISG15, in contrast to
ubiquitin, consists of 2 β-grasp folds with a sequence identity of 32 and 37 %, respectively
(Table 1), and is far less conserved among eukaryotes than ubiquitin, hinting towards
a specialized role in higher eukaryotes [31]. Indeed, ISG15 is not only conjugated to
lysine residues of target proteins but also secreted upon IFN-stimulation from different
cell types [32]. However, both forms show immunomodulatory functions especially in
immune responses to viruses but also to bacteria [5, 32–34]. To activate these specialized
functions, the ISG15 conjugation system is also induced by IFNs [31], restricting the
ISGylation of proteins to precise time frames and situations. Interestingly, patients with
an ISG15 deficiency do not develop severe viral infections, although ISG15 counteracts
viral infection and several viruses possess countermeasures against ISG15 [31,35]. Instead,
patients suffered from Mendelian susceptibility to mycobacterial disease (MSMD), which
is a rare disorder ultimately leading to susceptibility to Salmonella and Mycobacterium
tuberculosis as well as weakly virulent mycobacterial strains, indicating a primary role
of ISG15 in immunity against certain bacteria. Notably, ISG15 knock-out mice are also
susceptible to Listeria monocytogenes infections [34].
1.1.5 UFM1
Ubiquitin-fold modifier (UFM1) is a more recently discovered UBL with minimal sequence
identity (Table 1). Nevertheless, conjugation machinery and removing enzymes are
described, rendering the system functional [24, 36]. However, only few UFMylation-
targets are identified and the proposed physiological functions in erythroid development
and ER-stress response need to be strengthened by further results [19,37].
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Table 1. Known ubiquitin-like modifiers and regulatory enzymes. The information were
acquired from UniProt KB and assembled from literature [2,22,24]. Modified and extended
from Hochstrasser et al. [2]
UBL seq.
identity
[%]
Functions activating
enzyme(s)
conjugating
enzyme(s)
removing
enzyme(s)
ubi-
quitin
100 degradation,
immune system
regulation,
endocytosis,
chromatin
remodeling
UBA6 many many
NEDD8
(Rub1)
55 Activation of
Cullin E3-ligases
UBE1C-
APPBP
UBE2M
UBE2F [38]
UCHL3 [39],
SENP8 [40]
ISG15 32, 37 anti-viral immune
response [5]
UBE1L UB2E1,
UB2E2,
UB2L6
USP18 [41]
SUMO
(2-4)
18 DNA repair,
nuclear transport,
cell cycle
progression [42]
SAE1, SAE2,
Uba2-Aos1
UBC9 SENP1-7
[43]
UFM1 14 UBA5 UFC1 UfsP1,
UfsP2 [36]
Atg8 10 autophagy Atg7 Atg3
Atg12 17 autophagy Atg7 Atg10
FUBI 38
FAT10 32, 40 proteasomal
degradation [44]
UBA6
Urm1 12 Uba4 Ahp2
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1.1.6 Conjugation and Deconjugation of Ubiquitin
Ubiquitin and most of the UBLs are conjugated by a cascade of enzymes including three
major steps. Accordingly, the enzymes are named E1 for the activating enzymes, E2 for
the conjugating enzymes and E3 for the UBL ligases [4], while deconjugation is carried out
in a one-step reaction by deconjugating enzymes. For simplification purposes, Figure 3
illustrates this machinery only for ubiquitin, which is the best described modifier. For
most UBLs, the enzymatic reactions for both processes are assumed to be similar and
known activating, conjugation and deconjugating enzymes are listed in Table 1 [2, 22].
E1 
E2 
E2 
E3 
DUB ATP 
AMP 
+PPi 
E1 
E2 E3 
Substrate 
K 
E3 
E2 
Substrate 
K 
HECT 
+ RBR 
RING 
Substrate 
K 
Substrate 
K 
E3 
Substrate 
K 
DUB 
DUB 
E1 
E2 
E3 
Ub 
Ub 
Ub 
Ub 
Ub 
Ub 
Ub 
Ub 
Ub 
Ub 
Figure 3. Conjugation and deconjugation of UBLs using the example of ubiquitin. Ubi-
quitin is represented in green. The E1, E2 and E3 enzymes are parts of the conjuga-
tion machinery (gray) where E1 = activating enzyme, E2 = conjugating enzyme and
E3 = ligase. Deubiquitinating enzymes (DUBs) are presented in red and constitute the
deconjugating enzymes.
In the first step of conjugation, ubiquitin is linked to the active center cysteine (Cys)
residue of the E1 forming a thioester bond utilizing ATP. The now charged E1 then
associates with an E2 conjugation enzyme leading to the transfer of Ub to the E2
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enzyme via trans-thioesterification. Subsequently, the E2 enzymes interact with E3
ligases which recognize the substrate proteins and therefore are crucial for the specificity
of ubiquitination reactions.
For ubiquitin, two mechanisms of ligation are described (Fig 3). RING (Really interes-
ting new gene) domain-containing E3 ligases work as a bridge between the E2 enzyme and
the substrate and the Ub-moiety is directly transferred from E2 onto the substrate protein.
In contrast to that, HECT (Homologous to E6-AP Carboxyl Terminus) and RBR (RING
Between RING) domain-containing E3 ligase-dependent ligation occurs by transfer of the
Ub onto the ligase and the following transfer to the Lys of the substrate protein in two
distinct steps [45,46]. Finally, conjugation of Ub-moieties is repeated to create distinct
poly-Ub chains. In some cases, alternate E2 enzymes specialized in chain-elongation
are recruited to the E3 enzyme [46]. The conjugating reactions are compensated by
deconjugating enzymes, for Ub termed deubiquitinating enzymes (DUBs), which remove
ubiquitin from substrates using different modes of action (Section 1.2) and restore the
pool of free cellular ubiquitin.
In general, the conjugation machinery of Ub and UBLs is organized in a hierarchical
manner. While only two E1 enzymes are known in human, about 40 E2 and over 600
E3 ubiquitin ligases contribute to ubiquitination and formation of poly-Ub chains. At
least for SUMO and NEDD8, a similar complexity is assumed. However, for SUMO
only one E2 enzyme, UBC9, is known so far, while 2 conjugating enzymes are described
for NEDD8 (Table 1). In contrast to the conjugation cascade, deconjugation of Ub is
facilitated by about 90 DUBs in human [47]. For some of the other UBLs, deconjugation
enzymes are described, albeit not in high abundance (Table 1).
Nevertheless, deconjugating enzymes play an important role in regulation of ubiquitin
and UBL-mediated processes by shaping the modification of distinct proteins and add an
additional layer of control and specificity.
1.2 Deubiquitinating Enzymes
Deubiquitinating enzymes (DUBs) remove ubiquitin, and some additionally UBLs, from
substrate proteins. Although specific deconjugation enzymes for UBLs are described
(Table 1), DUBs are the most abundant group and are therefore further described.
In general, DUBs are isopeptidases, belonging either to the papain-like cysteine(Cys)-
proteases or zinc-dependent metalloproteases [48]. On the basis of sequence similarity
and core domains, DUBs are classified into five DUB-families (Table 2). Additionally,
there is one protein, monocyte chemotactic protein–induced protein 1 (MCPIP), that
also has deubiquitinating activity, but does not fit into one of the DUB-families defined
so far [49]. Notably, although all known DUBs are assigned to their families, for some of
them functional activity is unlikely, due to missing catalytic residues [50].
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Table 2. DUB-families, member numbers and reaction mechanisms. Member numbers
were taken from Coyne et al. [51] taking also putatively inactive and hypothetical DUBs
into account.
DUB-family Abbrev. reaction
mechanism
# of
members
Ubiquitin-Specific Proteases USP Cys protease 56
Ubiquitin C-terminal
hHydrolases
UCH Cys protease 4
Ovarian TUmor
domain-containing
OTU Cys protease 16
Macado-Josephin Disease
domain-containing
MJD Cys protease 4
JAB1/MPN/Mov34
metalloenzyme
domain-containing
JAMM metalloprotease 11
Apart from family-associated core domains, most DUBs contain a repertoire of other
domains, facilitating, e.g. protein- and ubiquitin-binding [52]. Those domains are
crucial for the regulation of DUB-activity and -specificity as they provide a distinct
protein environment by interaction with other proteins and thus promote formation of
multi-enzyme complexes [53]. Structural elucidation of DUBs, especially in complex
with ubiquitin moieties or activity-based probes, shows that DUBs undergo activating
rearrangements of the active-site upon substrate-binding. The deubiquitinase OTULIN
is even supported by a histidine (His) residue of ubiquitin, which completes the catalytic
triad of the DUB [12,53].
Furthermore, DUBs are regulated by a multitude of post-translational modifications,
e.g. acetylation, phosphorylation and ubiquitination [54], adding an additional layer of
activity-regulation.
Taken together, all these features generate DUB-specificity for different substrate groups,
which can be summarized as presented in Figure 4 and will be described hereafter.
Ubiquitin-chains can be removed by different mechanisms which are not restricted to
distinct DUB-families. First, recognition of distinct parts of poly-Ub chains leads to two
types of peptidase activities independent from substrate proteins (Fig 4A). Chains can
either be cleaved from the distal end of the chain by DUBs exerting exopeptidase activity
or cleaved amid the chain by endopeptidases. In contrast to that, chain amputation
directly at the substrate requires recognition of the respective protein and results in a
deubiquitinated protein and a free ubiquitin-chain (Fig 4B). The third mechanism of
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Ub-cleavage is the removal of single ubiquitin moieties from substrate proteins. DUBs
performing this task are either promiscuous or substrate-specific and are needed if DUBs
leave a Ub-stub behind after cleavage [46, 55]. Apart from different cleaving mechanisms,
DUBs exert specificity by substrate or chain-binding (Fig 4D-F). As mentioned before,
chain-specific DUBs are able to recognize different chain types and specifically cleave them.
For example, Cylindromatosis (CYLD), a USP, shows a preference for K63-linked chains,
but is only able to exert exopeptidase activity, leaving the proximal Ub attached [52,56].
In contrast, most OTU family members show linkage preferences. OTUD3, for example, is
able to cleave a chain at any Ub in a chain [57]. Another group of DUBs gains specificity
by recognizing the substrate of ubiquitination (Fig 4E) and remove ubiquitin either
directly at the target-protein by en bloc-cleavage or at the following Ub, also leaving a
stub behind. Notably, most of the USP family DUBs are believed to be substrate-specific
but promiscuous regarding chain types [45]. Last but not least, some DUBs are specific for
recycling activities, cleaving either unanchored Ub-chains or peptides linked to ubiquitin
(Fig 4F) by recognition of the glycine-glycine motif of ubiquitin or the Lys-anchored
peptide.
Substrate 
Substrate 
Substrate 
Substrate 
GG 
K 
A: endo- and exopeptidase D: linkage-specific 
Substrate 
E: substrate-specific B: en bloc 
C: mono-deubiquitination F: residue-specific 
Figure 4. Modes of action leading to DUB specificity at different levels. (A-C) Distinct
mechanisms of Ub-cleavage. (D-F) Mechanisms facilitating specificity by substrate
recognition. Adapted from Komander et al. and Heride et al. [46,55].
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Although these different mechanisms contribute to distinct specificities of DUBs
throughout the cells, categories of DUB functions are readily definable. Recycling, as
mentioned before, is one of them and important for restoring of the free ubiquitin pool
and rescuing Ub from degradation. However, the most prominent role of DUBs is to
remove single ubiquitin moieties and ubiquitin chains from substrates. While removal of
a degrading signal rescues substrate-proteins from proteasomal or lysosomal degradation,
removal of a non-degrading Ub-chain can lead to protein activation or inactivation [55].
Apart from chain cleavage, DUBs process the linear precursor proteins of ubiquitin to
obtain free, active mono-ubiquitin. The most sophisticated function executed by DUBs
is chain editing, whereby one Ub-chain type is substituted by another. This function
requires DUBs to either form complexes with E3 ligases or combine both ligating and
deconjugating activities [45, 55]. The most prominent example exerting this function
is the DUB A20 which has the ability to remove K63 poly-Ub chains from proteins
and subsequently to attach K48-linked chains to target the substrates for proteasomal
degradation [58].
1.2.1 Reaction Mechanisms
Two distinct biochemical reaction mechanisms underlie all cleavages realized by DUBs.
While most of the enzymes belong to the class of papain-like cysteine proteases (USP,
UCH, OTU, MJD), JAMM family DUBs utilize a cytidine deaminase-like metalloprotease
mechanism. Both reactions are illustrated below.
1.2.1.1 Papain-like Cysteine Proteases
Papain-like cysteine protease DUBs contain two catalytically active and highly conserved
residues, Cys and His, forming a catalytic dyad. Additionally, a third residue, usually
glutamine (Gln), glutamate (Glu) or asparagine (Asn), supports the reaction, but is
less important and not found in all Cys protease DUBs [55]. Following the binding to
a ubiquitinated substrate or poly-Ub chain, a nucleophilic attack of the Cys towards
the carbonyl carbon of the peptide bond occurs (Fig 5A). This attack then results in a
negatively charged transition state and the formation of an oxyanion which is stabilized by
nearby residues building an oxyanion-hole (Fig 5B). Subsequently, an acyl-intermediate
forms as the His imidazole ring donates a proton and the proximal ubiquitin is released,
while the distal Ub stays covalently liked to the active-site Cys. In a second reaction
step, a water molecule enters the reactive center (Fig 5C) and through hydrolysis again
evokes a negatively charged transition state with a tetrahedral intermediate (Fig 5D).
Finally, the distal Ub is released (Fig 5E) and the catalytic triad reverts to its original
state for further reactions [52,55,59].
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C 
D 
E 
Figure 5. Molecular reaction mechanism of papain-like cysteine protease DUBs. The
distal ubiquitin (C-terminus) is illustrated in red, the proximal ubiquitin (lysine side
chain) in blue. The residues of the catalytic triad are presented in black, highlighted in
light gray. Modified from Ndubaku & Tsui [59].
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1.2.1.2 Metalloproteases
In contrast to the cysteine protease class DUBs, no covalent interactions between Ub-
chain and enzymes occurs in JAMM metalloprotease DUBs although the general reaction
mechanism is similar. As the term metalloprotease suggests, a Zinc ion (Zn2+) is
coordinated by aspartate (Asp) and two His residues and is serving as the active ion.
Additionally, the substrate and a water molecule are coordinated by a serine (Ser) and
Glu. At the beginning of the reaction (Fig 6A), the substrate is coordinated by Glu,
Asp and Ser residues while a water molecule, activated by the Zn2+ ion, carries out a
nucleophilic attack against the carbonyl carbon of the peptide bond. This attack results
in a negatively charged tetrahedral intermediate state with Glu serving as a proton
acceptor (Fig 6B). The collapse of the intermediate then leads to cleavage of the substrate
chain and subsequently, both coordinated Ub-moieties are released (Fig 6C) [52,55].
A B C 
Figure 6. Reaction mechanism of JAMM metalloprotease DUBs. The proximal Ub is
illustrated in pink, the distal ubiquitin in blue, the water molecule in red. The catalytically
active residues are presented in black and highlighted in light gray. Orange dashed lines
represent ionic interactions. Modified from Komander et al. [55].
1.2.2 DUBs in Immunity and Bacterial Infection
Apart from the roles of DUBs in physiological processes like DNA repair, control of
receptors and channels and maintaining of the cellular ubiquitin balance [52], some DUBs
were shown to be crucial mediators of deubiquitination in innate and adaptive immune
responses [60].
For example, the USP-family deubiquitinase CYLD deubiquitinates TNF-receptor
associated factors (TRAFs) and thereby downregulates nuclear factor kappa B (NF-κB)
activation [61,62]. Additionally, CYLD forms a complex with a Ub-ligase and, by chain
editing from K63 to K48 chains, contributes to decreased inflammatory signaling [63, 64].
In combination, those findings suggest a potential value in inhibition of CYLD for control
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of inflammation and infection [60,65,66].
Another example is the OTU-family DUB A20, which is NF-κB responsive and has dual
deconjugating and ligating activities already mentioned above [58]. A20 is involved in a
negative feedback-loop regulating NF-κB at various levels, e.g by chain-editing on RIP1
[58]. Furthermore, A20 competitively binds E2-conjugation enzymes and ubiquitinates
them, thereby provoking shut-down of E3-ligases involved in NF-κB activation [58,67]
but also trims Ub-chains at other distinct protein complexes [68]. In contrast to CYLD,
abolishment of A20 does not simply attenuate NF-κB-dependent processes, but shifts the
cell or tissue homeostasis towards auto-reactivity and autoimmunity [68]. For example,
an A20-knockout in dendritic cells (DCs) leads to a hyper-sensitivity of mice towards low
doses of lipopolysaccharide (LPS) and subsequently to death [69].
Apart from these two prominent examples of deubiquitinating enzymes, several de-
SUMOylases and the deISGylase USP18 are involved in processes related to immune
responses [60]. Upon ISG15 induction, USP18 is also expressed during bacterial and
viral infections. Furthermore, USP18 regulates interferon (IFN)-β stimulated proteins at
the genome-level [60,70] and knock-out mice show an increased susceptibility towards
bacterial infections [52,60].
1.2.2.1 DUBs in Bacterial Infection
Interestingly, DUBs do not only play a crucial role in immunity, but are also influenced
by or influence themselves the course of infection with a whole series of pathogens [60].
CYLD, for example, is described as a negative regulator of E.coli pneumonia and
Haemophilus influenzae-induced inflammation and potentiates Streptococcus pneumonia
induced lethality [71–73]. In Listeria monocytogenes (Lm) infection, CYLD activity
also impairs the antibacterial immune response by inhibition of receptor-interacting
serine/threonine kinase 2 (RIPK2) and the interleukin (IL)-6/STAT3-mediated fibrin
production [66, 74]. In contrast, the truncated form of CYLD, sCYLD, augments
inflammatory responses in Lm infection [75] as does a deubiquitination-deficient truncation
of CYLD [65]. Other USP-family DUBs were also found to be involved in bacterial
infection:
• USP7 is decreased in Helicobacter pylori infection [76].
• USP10 is indirectly inhibited by the Cif toxin of Pseudomonas aeruginosa which
stabilizes the USP10-G3BP1 complex [77].
• USP22 is required for Francisella tularensis replication [78].
Apart from the USP-family, also DUBs from other families were described to be involved in
bacterial infection. OTUB1 attenuates bacterial internalization of Yersinia enterocolitica
and Y. pseudotuberculosis [79], while UCHL1 promotes internalization of Salmonella
enterica and Listeria monocytogenes [80].
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1.2.2.2 Bacterial DUBs
In addition to the influence on host-DUBs that pathogens exhibit, some viral and bacterial
pathogens did acquire or evolve enzymes with deubiquitinase activities, which allow the
pathogens to directly interfere with the host ubiquitin-system. Most of the bacterial
DUBs described so far are implicated in suppression of NF-κB activation or pathogen
survival e.g. chlamydial ChlaDUB1, Yersinia YopJ or Salmonella enterica SseL and
AvrA [60]. Notably, all of the bacterial DUBs identified to date are exclusively expressed
by Gram-negative bacteria.
In general, it is becoming obvious that DUBs regulate a multitude of immune response-
related processes and are of high importance for bacterial infections. Although functions
in Lm infection were described recently, especially for CYLD, information on the activity
of DUBs in the different stages of Lm pathophysiology is limited. To overcome this limits,
so called activity-based probes are a valuable tool to characterize DUB abundance and
activity.
1.3 Activity-based Probes for the Analysis of Deubiquitinating
Enzymes
Activity-based probes (ABPs) are small constructs for labeling and enrichment of enzyme
classes developed in the field of chemical proteomics for a multitude of enzyme classes. In
contrast to classical proteomics approaches, enzymes are enriched or detected on the basis
of their activity or affinity rather than sheer protein abundance [81]. As a consequence,
by using these probes for activity-based protein profiling (ABPP), it becomes possible
to assess the activity status of whole enzyme families [82]. Probes for the detection
of DUB activities are targeted towards the nucleophile of the active cysteine, thereby
allowing covalent labeling of cysteine-protease DUBs [83]. In general, DUB-probes
comprise of three modules (Fig 7A), a recognition or retrieval element, a specificity
element and a warhead also called reactive group. While warheads and recognition-
groups are most variable, for the specificity element, Ub-, SUMO-, NEDD8-, ISG15-
and UFM1-containing probes were utilized for the identification of active deconjugating
enzymes until now [36,84,85]. Equipped with a combination of the mentioned modules,
ABPs are utilized to label the DUB or deconjugating enzyme family of interest in gel-
or blot-based applications, e.g. immunoblotting. Detection of the labeled enzymes via
specific detection of a recognition element like an epitope-tag or fluorochrome enables the
comparison of the DUB activities of different sample states (Fig 7 B). Furthermore, ABPs
also allow for the enrichment of DUBs via a retrieval element like an epitope-tag or biotin
and subsequent characterization of the enriched enzymes by mass-spectrometry [86]. In
recent years, a battery of C-terminal electrophilic probes to label and enrich DUBs was
designed, some of which are described below.
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Figure 7. Key features of activity-based probes targeting Ub/UBLs and examples of
application. (A) Classical activity-based probes for DUBs comprise of a recognition
element (pink star), a specificity element, which is either a Ub-moiety or a UBL (green),
and a reactive group also termed warhead (red). (B) Prototypic applications of DUB
activity-based probes. Modified from Ekkebus et al. [83].
1.3.1 C-terminal Electrophilic Probes for DUB Profiling
The first C-terminal electrophilic probes for DUBs were designed in the Ploegh lab in
the early 2000s [87,88]. Among them, two Michael acceptor warheads, vinyl methyl ester
(VME) and vinyl methyl sulfone (VS) coupled to an HA-Ub construct showed broad
reactivity towards DUBs, while bromoethylamine (Br2) did bind to a smaller number
of known DUBs but for the first time detected an OTU-family DUB [88]. Because of
the labeling of fewer DUBs and the poor catalytic yield of HAUb-VS [89], HAUb-VME
developed into a widely used gold-standard for activity-based DUB profilings. The
second generation of HAUb-probes entailed 3 novel warheads with an unchanged HAUb
construct. While these probes did not outperform HAUb-VME in its DUB-binding, two
of the probes (HAUb-OEtVS and TF3BOK) enriched enzymes of the Ub conjugation
machinery [90].
The most recent additions to the DUB-reactive warheads in classical ABPs are C-
terminal alkynes, e.g. propargylate and derivatives. Those probes allow an enrichment of
DUBs which is at least comparable to HAUb-VME if not superior [91,92].
Additionally, not only warheads but also recognition elements were permuted to
generate different probe types. McGouran and colleagues developed fluorescent probes
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carrying the fluorescent group C-terminal of the VME-like warhead, reasoning that
this position leaves the Ub-fold intact and requires minimal protein manufacturing [93].
Another change to the recognition element was introduced by Claessen and colleagues
by adding biotin for enrichment and incorporating an additional, cleavable linker to
minimize the background caused by unspecific binding of proteins to the Streptavidin
beads [94].
However, those probes have limited substrate specificities: While DUBs often recognize
either two or more Ub-moieties, or attached Ub and substrate protein simultaneously, all
of the ABPs mentioned above fail to reproduce this distinct environment.
1.3.2 Probes Introducing Context-specificity
Recently, probe development led to the incorporation of context specificity especially for
the surroundings of Ub-chains. DUBs often have 2 or even 3 binding pockets to recognize
Ub-chain topologies and cleave their substrates from the proximal site (Fig 8A(1)). Thus,
classical C-terminal probes, which solely bind to the S1 site, are not able to make use
of the binding specificities of DUBs facilitated by UB-binding at the S1’ or S2 sites
(Fig 8A(2)) [83]. In order to overcome this limitations, a range of probes was developed
which introduces further specificity elements to the probe design. Most of the concepts
add a second Ub-moiety resulting in an internal Di-Ub probe, which then binds to the
S1’ and S1 binding sites of the captured DUB (Fig 8A(3)). Those Di-Ub probes aim to
recreate the native Di-Ub peptide bond (Fig 8B1) as effectively as possible (Fig 8B(2-5)).
Ubiquitin-Isopeptide Probes (UIPPs): The first published Di-Ub probes were the so
called Ubiquitin-Isopeptide Probes (UIPPs) refined and published during this study, which
harbor a peptide as an additional specificity element (Fig 8B(2)) [95,96]. Furthermore, a
glycine vinyl formic acid (VA) warhead was included to covalently capture DUBs, thereby
elongating the isopeptide bond by two atoms. Nevertheless, UIPPs mimicking K48 and
K63 Ub linkages were produced and successfully utilized for labeling of recombinant
deubiquitinases and DUBs in cell lysates thereby uncovering different binding specificities
[95].
In contrast to the other concepts, which will be described below (Fig 8B(3-5)), UIPPs
do not carry a full proximal ubiquitin moiety. This might cause decrease in facilitating Ub-
linkage specificity, but is a considerable advantage for the profiling of substrate specificity
(Fig 8A(4)). In this concept, merely the sequence of the peptide has to be interchanged for
a substrate protein sequence to enable substrate specificity profiling [95,96]. Additionally,
substrates are mostly larger than a single Ub-moiety and it is thus more likely that the
direct sequence surroundings of the Ub-binding site are involved in mediating specificity.
For the other Di-Ub concepts described so far, adaptation to substrate Ub-linkages
would be possible in principle, but require new synthesis protocols to be designed for the
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production of substrate-mimicking units.
Figure 8. Schematic representation of DUB probe-binding and different probes resem-
bling diubiquitin. (A) Ubiquitin and probe-binding modes of DUBs. (B) Overview of
probes mimicking diubiquitin to uncover chain specificities of DUBs in comparison to
native diubiquitin. The red triangle illustrates the position of the reactive warhead next
to the active-site cysteine. Modified from Ekkebus et al. [83]
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Other Di-Ub Probes: Apart from the UIPPs, further concepts for Di-Ub probes were
implemented in recent years. McGouran and colleagues used click chemistry to produce
full Di-Ub probes, which mimic all 8 Ub-linkages. Due to the similar warhead used and
the added click chemistry handle, these probes also have an elongated linker (Fig 8B(3)).
Especially for the M1 linkage, the authors speculate that this extended linkage influences
DUB-binding and specificity [97]. While Li and colleagues also used a vinyl amide
warhead in their Di-Ub probe (Fig 8B(4)), the linker between the 2 Ub-moieties closely
resembles the native bond. To realize this shorter linker, lysines at the proximal Ub where
mutated to cysteines [83, 98]. Another approach utilized chemical ligation to produce
Di-Ub probes for K48, K63 and linear chains with a dehydroalanine warhead [99]. An
interesting concept was presented by Mulder and colleagues, introducing a ligation handle,
which is used to construct Di-Ub probes with a linker closely resembling the isopeptide
bond of native Di-Ub (Fig 8B(5)). This approach resulted in a set of 7 Di-Ub probes
which bound specifically to recombinant DUBs. Additionally, the introduction of the
electrophilic warhead in the last step of the ligation allows for a broader spectrum of
reagents as well as the synthesis of more complex structures [100]. In contrast to the
described probes and concepts, Flierman and colleagues designed the first Di-Ub probes
which bind to the S2 and S1 site of DUBs. Those probes revealed that DUBs indeed
utilize those sites for the discrimination of Ub-chains [83] and are readily probable [101].
While a whole battery of different ABPs for the capture of DUBs was designed and
produced in the last years, most studies focus on the initial characterization of probes
either using recombinant enzymes or utilizing few cell lines, e.g. EL-4, to evaluate the
binding properties of novel probes. In contrast, only few studies utilized probes to
characterize samples of biological interest [102,103], for inhibitor studies [104,105] or to
detect pathogenic DUB-activities [94,106], leaving the potential of this concept largely
unexploited.
1.4 Listeria monocytogenes
Listeria monocytogenes (Lm) is a Gram-positive, rod-shaped, pathogen with an intra-
cellular life style, which is found ubiquitously in different environments e.g. soil, water,
animals, humans and also various food products. By ingestion of contaminated food such
as vegetables, meat or unpasteurized milk and cheese, the bacterium causes listeriosis, a
foodborne disease [107, 108]. While healthy patients either present febrile diarrhea or
are asymptomatic, in immunocompromised patients, the elderly and pregnant women
as well as newborns, life-threatening symptoms like meningitis, miscarriage or stillbirth,
sepsis and bacteremia may occur. Although the incidence of listeriosis in general is as
low as 0.1-0.9 cases per100,000 inhabitants (EU, 2011) the mortality is very high, ranging
from 20 to 30 % [108] and the incidence is rising constantly in the last years [109]. In
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Germany, listeriosis is counted among the diseases with the highest mortality regarding
those subjected to registration [110], and is therefore a great public health concern as a
re-emerging disease.
1.4.1 Cell Invasion
Lm as an intracellular bacterium is able to invade different cell types, including enterocytes,
hepatocytes, fibroblasts, as well as epithelial and endothelial cells [107]. While the entry
into phagocytic macrophages, which are a major target of Lm, is passive, entry-processes
into non-phagocytic cells are triggered by bacterial proteins [107].
Entry: To enter those cells, Lm binds to the cell surface utilizing its invasins Internalin A
(InlA) and Internalin B (InlB) in combination or separately (Figure 9). The cellular
receptor of InlA is the adhesion molecule E-cadherin, which is involved in adherens
junction formation [111]. InlA-mediated invasion is species specific, as InlA interacts
with human, guinea pig, and rabbit E-cadherin but not with the mouse and rat homologs.
Thus, oral infection of the latter organisms is ruled out, since Lm cannot cross the
intestinal barrier in these species, as the process is InlA-dependent [112].
The second internalin implicated in cell entry, InlB, interacts with the hepatocyte growth
factor receptor (HGFR/c-Met) functionally mimicking its natural ligand HGF, as well as
glycosaminoglycans and the receptor of the globular part of the complement component
C1q (gC1q-R) [111]. Furthermore, involvement of the transmembrane glycoprotein
CD44v6as a co-receptor of c-Met is suggested [113]. However, the role of the latter
three interactions is not clearly defined [114–116]. The InlB/c-Met invasion-axis is also
species-specific, allowing invasion in human, gerbil, mouse and rat but not in rabbit
and guinea pig [112]. Both invasins trigger rearrangement of the actin cytoskeleton and
endocytosis to facilitate cell invasion [111]. In addition, another virulence factor, Vip,
interacts with host Gp96 and crucially supports Lm infection in vivo [108,117].
Figure 9. Invasion, replication and
cell-spread of Lm in epithelial cells.
Listeria enters epithelial cells, disrupts va-
cuoles and, following replication, spreads
to neighboring cells, thereby allowing disse-
mination through tissue-barriers as well as
formation of reservoirs. Different stages of
cell invasion are driven by listerial proteins
which are presented in small boxes. InlA: In-
ternalin A, InlB: Internalin B, InlC: Inter-
nalin C, LLO: Listeriolysin O, Plc: Phos-
pholipase, ActA: actin assembly-inducing
protein. Modified from Pizarro-Cerda et
al. [111].
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Vacuolar Lysis and Cell-to-cell Spread: Following entry, Lm accomplishes rupture of
the bacteria-containing phagosomes to escape to the cytoplasm by utilizing its pore-
forming toxin listeriolysin O (LLO) as well as phospholipases A and B [108]. Once in the
cytoplasm, Lm is able to replicate and subsequently establish motility by polymerization
of host actin [112]. With the help of ActA, the actin assembly-inducing protein of Lm,
the bacterium recruits host components, e.g. the Arp2/3 complex, Enabled/vasodilator-
stimulated phosphoprotein (Ena/VASP) and profilin to finally bind actin and form
comet-tails driving motility and cell-to-cell spread [118]. Interestingly, ∆ActA mutants
of Lm are rapidly ubiquitinated and targeted to autophagy [119], revealing ActA-coating
as a potent interfering mechanism to subvert Ub-mediated host-processes.
Contact of the motile Lm with the cell membrane leads to formation of bacteria-
containing protrusions, allowing invasion of neighboring cells by utilizing another listerial
internalin, InlC [112]. Lysis of the secondary vacuole is dependent on LLO and phospho-
lipases B and C, and releases Lm into the cytoplasm of the newly infected cells [120].
1.4.1.1 Activation of c-Met by InlB
As briefly mentioned earlier, InlB binds to c-Met and activates the receptor-tyrosine
kinase by mimicking HGF despite of the structural and sequence differences between the
two ligands [121]. HGF consists of an α- and β -domain and interacts with the propeller-
like Sema-domain of c-Met (Fig 10A) [122]. In contrast, InlB mainly interacts with the
IgG-domains of c-Met, while only a small patch of the InlB inter-repeat shows binding to
the Sema-domain [123]. Most interestingly, although both ligands bind to c-Met utilizing
different surface patches of c-Met, both, HGF and InlB, evoke auto-phosphorylation and
activation of c-Met and down-stream signaling components [121,124].
Signaling: A prominent example of downstream signaling cascades is the Ras-MAPK
axis. Recruitment of adapter molecules like GRB2 leads to the activation of small
GTPases, e.g. Ras, the mitogen-activated protein kinase (MAPK) cascade. As a con-
sequence, terminal kinases like Erk1/2, JNK or p38 kinases are activated (Fig 10B) by
HGF and InlB alike, albeit with slightly different dynamics [124–126]. Finally those
kinases translocate to the nucleus, inducing different gene expression programs leading
to proliferation, transformation, differentiation and apoptosis [126]. Another commonly
activated transcription factor is the Signal transducer and activator of transcription 3
(STAT3), which upon phosphorylation, homodimerizes and also controls cell proliferation
and transformation [127, 128]. Furthermore, HGF-mediated activation of c-Met leads
to activation of the Phosphoinositide 3-kinase (PI3K)-Akt axis, either directly, or indi-
rectly via Ras. This axis ultimately activates further components, thereby augmenting
protein translation, cell growth and proliferation, and furthermore protects cells from
apoptosis [126]. Notably, PI3K-activation is critical for Lm to breach host barriers [129].
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Additionally, NF-κB is activated downstream of PI3K-Akt or Src-kinase signaling both
by HGF and InlB [126]. While in HGF-mediated signaling the induced proliferation and
survival benefits the cell, the immune-regulatory functions of NF-κB pose a problem for
Listeria.
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Figure 10. Overview of c-Met activation, signaling and receptor recycling following
binding of HGF or InlB (Listeria). (A) Activation of c-Met by HGF or InlB
interaction. Blue structure: ß-chain of HGF, yellow: c-Met Sema-domain, orange: c-Met
PSI and IgG-domain, red: InlB. Structures modified from Stamos and Niemann et
al. [122, 123] (B) Downstream-signaling following activation. SOS: son of sevenless,
GRB2: growth factor receptor-bound protein 2, MAPK: mitogen-activated protein
kinase, STAT3: Signal transducer and activator of transcription 3. Modified from
Trusolino et al. [126]. (C) Receptor fate after activation.
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Interestingly, InlC, which was described in the context of cell-to-cell spread, on a
molecular level interferes with this signaling cascade by targeting IκB and thereby
dampening NF-κB activation [130].
Receptor Internalization: Apart from the shared signaling cascades, both HGF and
InlB induce internalization of c-Met with similar dynamics via a clathrin-mediated
endocytosis mechanism [111,124,126]. More recently, also clathrin independent mecha-
nisms were debated [131,132]. However, the initial event leading to endocytosis is the
post-translational modification of c-Met (Fig 10C). Following auto-phosphorylation of
c-Met at the tyrosines (Y) 1234 and 1235 as well as Y1003, the ubiquitin-ligase c-Cbl
is recruited and ubiquitinates c-Met presumably in form of a multi-monoubiquitination
or K48 poly-Ub chains [133–136]. Although 13 ubiquitinated lysines are described for
c-Met (Table S1), the precise sites which are ubiquitinated following activation by HGF
or InlB are not known so far and knowledge of the role of ubiquitination and involvement
of DUBs is inconclusive until now [132,134,135,137].
After endocytosis, c-Met is sorted to multivesicular bodies via recruitment of the endosome-
localized hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs). Subse-
quently, the receptor is targeted to lysosomal degradation [132]. In recent years, receptor
recycling of c-Met was described in different settings after HGF-stimulation or constitutive
activation [138–140]. While for the related receptor tyrosine kinase EGFR (epidermal
growth-factor receptor) the processes themselves and the contribution of ubiquitination
are well described, knowledge for c-Met is limited [132,136].
Although qualitative differences between HGF and InlB-induced endocytosis and
signaling were described previously [124,141,142], addition of HGF is sufficient to evoke
invasion of InlB-deficient Lm mutants, suggesting major analogy between HGF and
InlB [143].
1.4.2 Listeria monocytogenes Infection
To cause the fatal symptoms of listeriosis mentioned earlier, Lm has to evade the host
immune system and disseminate from the gastrointestinal tract. After ingestion of
contaminated food, Lm is able breach of the intestinal barrier by rapid transcytosis in an
InlA-dependent manner (Figure 11) [144]. The significance of InlA is further emphasized
by the occurrence of functional InlA in 96 % of clinical as compared to 65 % in food
isolates [145]. After crossing of this first barrier, Lm is able to reach the bloodstream
via intestinal lymph nodes and then to cause a systemic infection. Interestingly, shortly
after dissemination into the bloodstream, Listeriae are already engulfed by dendritic cells
(DC) in the spleen where bacterial killing is initiated [146,147]. In total, only 5 to 10 %
of the bacteria are taken up by the spleen, while 90 % of the inoculum in intravenous
infection ends up in the liver and leads to mounting of a systemic immune response
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towards Lm. However, surviving Lm replicate within macrophages in the spleen and
liver, reaching a peak at about 2- 3 days after infection [148]. Besides the reservoirs
in liver and spleen, Lm is able to break through the blood-brain and placental barriers
alike. Notably, crossing of either of those barriers was reported to require InlA and InlB
activities interdependently [149,150].
Figure 11. Steps of Lm infection in vivo causing Listeriosis. After ingestion, Lm crosses
the intestinal barrier and disseminates systematically. Modified from Cossart and
Toledo-Arana [151].
1.4.2.1 Cellular Hepatic Immune Response to Listeria monocytogenes Infection
Kupffer Cells, Neutrophils and NK Cells: Upon systemic infection of the host, high
numbers of Lm enter the liver, where they are trapped by Kupffer cells (KCs) which are
the liver resident macrophage population (Fig 12). Additionally, KCs can promote an
inflammatory response by producing a number of cytokines including interleukin (IL) 1β
and 6 as well as tumor necrosis factor alpha (TNFα) [152]. However, the major signal
orchestrating the bactericidal inflammation in liver is the rapid Lm-induced necroptosis
of KCs. Those cells, which are then heavily infected with Lm, die as early as 4 h after
infection [153].
However, KCs as well as hepatocytes are capable of receptor-mediated activation of
IL-23 recruited neutrophils [154], which also contribute to Lm clearance, especially in
high-dose infections. Although different mechanisms for that protective effect, e.g. direct
killing of bacteria or stimulation of hepatocyte apoptosis, are discussed, recent results
suggest elimination of dead KCs and TNFα -secretion as probable functions [152,153,155].
In turn, TNFα in synergy with secreted IL-12 drive NK cell activation and subsequent
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IFNγ secretion. Interestingly, excessive IFNγ production by a specific NK cell subset
is advantageous to Lm as it impairs migration of phagocytic cells. Indeed, the listerial
protein p60 evokes the activation of host NK cells [156, 157]. Nevertheless, IFNγ also
confers resistance against Lm to hepatocytes, which are the major pool of intracellular
and associated Listeriae during liver infection [152].
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Figure 12. Immune responses to hepatic Lm infection. Schematic representation of different
cell types, cytokines and chemokines involved in the hepatic immune response to Lm.
ICAM: intercellular adhesion molecule, Mac-1: macrophage-1 antigen, CCL: che-
mokine (C-C motif) ligand, CXCL: chemokine (C-X-C motif) ligand, IL: interleukin,
TNF: tumor necrosis factor, IFN: interferon, STAT: Signal Transducers and Activa-
tors of Transcription, M-CSF: macrophage colony-stimulating factor, NK cell: natural
killer cell, MΦ: macrophage, Tip: tumor necrosis factor/inducible nitric oxide synthase-
producing. Adapted from Cousens and Wing [152].
Hepatocytes: Although hepatocytes are not professional immune cells, they contribute
to the immune response against Lm in different ways e.g. by killing of Lm, apoptosis,
interaction with other immune cells and secretion of cyto- and chemokines [152]. Most
importantly, hepatocytes also mount the systemic so-called acute-phase response (APR)
by secreting a whole arsenal of proteins aiming at the neutralization of invading pathogens
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as well as the limitation of tissue damage and promotion of repair processes [152,158].
Major regulators of the APR in hepatocytes are STAT3 and its crosstalk with NF-κB-
dependent signaling pathways [158]. Interestingly, STAT3, which is induced by IL-6, is
tightly regulated by deubiquitination facilitated by CYLD, and while a short form of
this deubiquitinase augments innate immunity, full-length CYLD restricts the immune
response towards Lm [66,74,75].
Infiltrating Monocytes, Macrophages and TipDCs: During the first days of infection,
inflammatory monocytes massively infiltrate the liver guided by a chemokine (C-C motif)
ligand 2 (CCL2) gradient created by the liver itself [159]. Once at their destination,
they rapidly differentiate into monocyte-derived macrophages (MoMs) or tumor necrosis
factor/inducible nitric oxide synthase-producing dendritic cells (TipDCs) [153, 160]
(Fig 12). TipDCs can serve as antigen presenting cells (APCs) during early infection,
locally activating CD8+ T cells following contact to Lm [161] and releasing TNFα
and nitric oxide (NO). In contrast, conventional DCs serve as APCs by migration to
neighboring lymph nodes and activate CD8+ T cells at a systemic level [148]. Once
differentiated, MoMs heavily proliferate as a response to hepatocytes-secreted IL-33 and
exhibit a highly bactericidal phenotype by producing reactive oxygen species (ROS)
and nitric oxide synthases (NOS) [148]. Notably, at day 3 p.i., once bacterial loads
are successfully controlled by the innate immune response, monocytes shift to an anti-
inflammatory, KC-like phenotype. This shift is initiated by increasing IL-4 levels in the
liver. Thus, acute inflammation is dampened and the liver is protected from excessive
tissue damage allowing the return to homeostasis [153].
Adaptive Immune Response: By way of DCs, both CD4+ and CD8+ T cells are
activated following Lm infection, and cytotoxic CD8 cells were found to be crucial for
complete Lm clearance [148]. To realize their anti-listerial role, CD8 T cells secrete IFNγ
to activate macrophages and additionally lyse infected cells by targeted excretion of
perforin and granzymes [162]. This primary T cell response reaches its peak at day 7
to 9 p.i and then decreases between days 9 and 14 [163]. In contrast, B cells only play
a minor role during Lm infection as antibodies are of limited use against intracellular
pathogens. However, B cells are involved in stimulation and maintenance of the T cell
response [148,162].
In general, the hepatic immune response to Lm is a sophisticated system composed of
interacting cell types and secreted messengers. Although some aspects were extensively
researched, protein regulation leading to the described phenotype often remains elusive.
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1.5 Sepsis - a Life-threatening Manifestation of Listeriosis
As mentioned previously, listeriosis may be accompanied by life-threatening symptoms,
especially in the elderly and immunocompromised patients [164]. In Germany, 609
cases of listeriosis were reported to the Robert Koch Institute in 2014 of which 34 were
pregnancy-related and 29 newborn-listeriosis cases. The evaluation of the data revealed a
generally increasing incidence in recent years with a saltatory increase of about 30 % in
2014 as compared to the previous year [110]. Furthermore, Preussel and colleagues report
an outstanding role of reduced immunocompetence for listeriosis acquisition and identify
cold cooked sausages as well as pre-sliced and packed cheese irrespective of variety as
main sources for infection in Germany [164]. In conjunction with a reported mortality of
listeriosis ranging between 15 and 30 % despite of adequate treatment [109], listeriosis
poses a major health care problem as a re-emerging disease.
Figure 13. Manifestations reported for lis-
teriosis cases in Germany in 2014. Data
were taken from the annual of notifiable disea-
ses 2014 (Infektionsepidemiologisches Jahrbuch
meldepflichtiger Krankheiten für 2014) published
by the Robert Koch Institute [110]. The slice re-
presenting sepsis cases is colored in red, while mild
listeriosis cases with fever as only symptom are
represented in blue. In total, 546 cases of non-
pregnancy associated listeriosis were reported in
2014, whereby reporting of multiple symptoms was
allowed.
Of the cases of non-pregnancy associated listeriosis reported in 2014, 41 % showed
fever as only symptom representing disease progression without complications (Fig 13).
Notably, of the severe manifestations reported, sepsis was the most common with 35 %
and thus nearly as frequent as uncomplicated cases [110]. In contrast, meningitis and
encephalitis, which show comparable mortalities were reported in 17 % of all cases, while
abscesses, endocarditis, septic arthritis and infections of other organs were less frequently
reported (Fig 13).
Sepsis, often found in listeriosis, is indeed a major problem in medicine and a leading
cause of death with word-wide increasing case numbers. The rapid progression often
leads to multi organ dysfunction and thus, to a high mortality even in intensive care
units (ICUs ) [165,166].
1.5.1 Course of Sepsis Progression
Sepsis, which is a life-threatening syndrome and not a disease per se, is classically defined
based on clinical criteria [167]. The foundation for diagnostics is the definition provided
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by Levy and colleagues, which is widely used in critical care and is based on the concept
of “systemic inflammatory response syndrome” (SIRS) introduced in 1992 [168,169].
SIRS: SIRS is likely to be caused by a number of infectious and non-infectious conditions
and occurs in patients without infection after trauma, thermal injury and inflammatory
processes as a part of the systemic immune response [169]. Clinically, SIRS is defined by
the following four criteria (Fig 14):
• abnormal body temperature, defined as either fever with a core temperature above
38 °C or hypothermia with a temperature less than 36 °C,
• an increased heart rate with more than 90 beats per minute (bpm), or 2 standard
deviations (SD) above the normal value for the patient age,
• an increased respiratory rate of 20 breaths per minute (Tachypnea) or a partial
pressure of Carbon Dioxide in arterial blood (PaCO2) smaller than 32 mmHg,
• abnormal white blood cell (WBC) counts with less than 4,000 or more than
12,000 cells per µl, or more than 10 % immature forms [168,170].
The extended definition added additional criteria, e.g. altered mental status, hyperglyce-
mia, hyperlactatemia and altered levels of C-reactive protein as well as procalcitonin in
plasma. Furthermore, a whole list of hemodynamic parameters was proposed [169]. Howe-
ver, clinical studies often use the simplified four-point definition of SIRS only [165,171,172],
as the extended one was primarily established to enable safe diagnostics in ICUs.
Sepsis: Sepsis is defined by the occurrence of at least 2 out of 4 SIRS criteria or “some” of
the extended criteria and a strongly suspected or documented infection (Fig 14) [168,169].
For the diagnosis, early signs of the immune response to infection are sufficient, even if
the infection itself is not verifiable [169]. The diagnosis of sepsis is not limited to bacterial
infections but includes fungi, parasites and viruses as infectious agents [170]. Notably,
not all patients developing a sepsis show two or more SIRS criteria. In a recent study,
1.5 % of the screened patients developed dysfunction of organs and had an infection while
displaying less than 2 criteria [165]. Additionally, not all patients that meet the SIRS
criteria and display an infection are categorized as septic by clinicians due to the distinct
characteristics of some infections, e.g. mild viral respiratory tract infections. Thus, the
latest perception of sepsis is “that [it] arises when the body’s response to an infection
injures its own tissues and organs” [173,174].
Nevertheless, the mortality rate of patients diagnosed with sepsis is estimated at 10
to 20 % and the estimated incidence is 75 to 120 cases per 100,000 population and is
rising [165,170].
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Figure 14. Emergence and progression of sepsis. Clinical criteria for the different states of
sepsis are given, starting from the classical 4-criteria definition of systemic inflammatory
response syndrome (SIRS). bpm: beats per minute, WBC: white blood cells. Definitions
were assembled according to the consensus definitions of sepsis published by the
ACCP/SCCM in 1992 [168]. For extended definitions, see full text.
Severe sepsis: In case of hypotension, tissue hypoperfusion, which can not be explained
by other causes than sepsis, or sepsis-induced organ dysfunction, the syndrome fulfills the
definition of severe sepsis (Fig 14) [168,169]. Hypoperfusion and hypotension may lead
to blood overacidification (lactic acidosis) and urine hypoproduction (oliguria) as visibly
symptoms used for diagnosis [175]. Along with the occurrence of organ dysfunction, the
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estimated fatality rate increases to 20 to 50 %, a recent study from Engel and colleagues
even reported a mortality of 55 % for severe sepsis in German ICUs [165,170].
Septic shock, multi organ dysfunctions and persistent critical illness: If organ dys-
function, hypoperfusion or hypotension persist despite of fluid resuscitation, patients are
classified as presenting a septic shock (Fig 14) [168] which once again raises the estimated
fatality rates to then 40 to 80 % [170].
After first organ dysfunctions occur, the syndrome often and quickly progresses towards
a multi organ dysfunction syndrome (MODS), which is diagnosed when homeostasis
cannot be maintained without intervention [169]. Due to exogenous organ support,
patients that would have died few years ago often survive but can develop persistent
critical illness (PCI). PCI has an estimated mortality of 20 to 40 % and patients are
frequently disabled [176].
While mortality of sepsis, severe sepsis and septic shock decreases due to improving ICU
management [170,177], the incidence increases world-wide, making sepsis a major cause
of death in hospitalized patients and a burden for the health care system [165,176].
1.5.2 Assessment of Sepsis and Prognosis of Progression - Current
Methods and Limitations
As sepsis is a syndrome and not a disease, diagnostics rely on physical examination,
radiographic and laboratory testing and often the clinician’s assessment that a patient
“looks septic” [169, 178]. To assess a patient’s status, several methods are applied
dependent on the purpose of the assessment. Among physicians, different scoring systems
are in use especially in ICUs, while academic scientists are in search for one or more
reliable diagnostic biomarkers [179]. The ultimate goal of this search is not only to define
sepsis by molecular markers, but to also enable distinction between SIRS and sepsis
as well as the different sepsis stages, and finally to predict the individual course of the
syndrome [179,180].
Scores: In critical care medicine, scoring systems are utilized to describe a patient’s
status and in part to predict the course of sepsis progression. Three prominent examples
are
• the sepsis-related/sequential organ failure assessment (SOFA),
• the acute physiology and chronic health evaluation II (APACHE II)
• and the simplified acute physiology score (SAPS II).
Additionally, a whole battery of other scoring systems exists [181–184]. To indicate the
capacity of these systems to discriminate between patients that die and patients that
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survive, the area under the curve of the receiver operating characteristic (AUCROC) is
utilized. A perfect test would yield a value of 1, while a result of 0.5 is no better than
chance alone. For predictive scoring systems, values above 0.8 are considered good, above
0.9 excellent. While SOFA is a solely descriptive score, assessing the patient’s status
each day, SAPS II and APACHE II allow an outcome-prediction with an AUCROC of
0.86 for both [184].
However, despite the remarkable predictive power of scoring systems, they do neither
contribute to the development of drugs against sepsis nor to the biochemical characteri-
zation of underlying processes.
1.5.2.1 Biomarkers in Sepsis
In recent years, several molecular markers were suggested, that are either of diagnostic
value, allowing discrimination between SIRS and sepsis, or of prognostic value, predicting
progression or outcome of the syndrome, or ideally both [179].
A first class of potential biomarkers includes molecules present in body fluids, especially
blood (Fig 15A). The main advantage of those molecules is the relatively simple access
through blood sampling and serum extraction.
C-reactive Protein: C-reactive protein (CRP) is synthesized in the liver during acute-
phase response and serves as a pattern recognition receptor (PRR) to activate the
complement system [185]. Following secretion, CRP is found in blood plasma. In sepsis
diagnostics, CRP is utilized to distinguish between non-infectious SIRS and bacterial
infection especially in pediatrics [179,186]. While the AUCROC for this application is
relatively good (0.77-0.92), due to its low specificity, CRP can not distinguish between
sepsis and other infection-related syndromes caused by bacterial infections [187,188].
Procalcitonin: Another acute-phase protein, procalcitonin (PCT), the precursor of the
hormone calcitonin, is also considered a biomarker for sepsis. Its serum concentration
rapidly increases following bacterial, fungal, or parasitic infection [180]. Furthermore,
the levels again decrease upon recovery after peaking at 24 to 48 h of infection, linking
long-lasting elevated levels with poor prognosis [180, 187]. However, although recent
studies indicate a role as indicator for sepsis, the results are not conclusive, hinting
towards a non-sufficiency as a stand-alone marker [180,188,189]. Although PCT showed
a good sensitivity and specificity for discrimination between sepsis and non-infectious
SIRS [190], in practice, PCT levels are only moderately more predictive than CRP
or the infection probability score (IPS), which is a combination of 6 parameters [180].
Furthermore, PCT is not detectable in some sepsis cases, increasing the risk of false
negative results [189].
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Angiopoietins: Two angiopoietins (Ang-1 and Ang-2) are antagonistic factors, which
compete for the tyrosine kinase receptor Tie2 on endothelial cells [179]. While in healthy
people Ang-1 levels are higher than Ang-2 levels, Ang-2 levels increase in inflammation,
as Ang-2 is released by endothelial cells (Fig 15A). This shifts the Ang-1 / Ang-2
equilibrium and causes leakage in microvasculature leading to endothelial activation
or even dysfunction [180]. In sepsis, both Ang-1 and Ang-2 levels are considered as
prognostic biomarkers. While low Ang-1 levels at submission to the ICU are associated
with a poor prognosis, Ang-2 levels correlate with scores of APACHE and SOFA, which
assess the severity of sepsis [191,192]. However, before angiopoietin levels are usable in
a clinical environment, analytical methods, thresholds and sample collection protocols
need to be defined clearly [180,192].
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Figure 15. Biomarkers in sepsis. (A) Biomarkers detectable in serum. (B) Surface molecules
of immune cells proposed as biomarkers either in a released or surface-bound state.
Abbreviations: C-RP: c-reactive protein, PCT: procalcitonin, pro-ADM: proadrenome-
dullin ,Ang-1: Angipoeitin-1, Ang-2: Angiopoeitin-2, uPAR: Urokinase plasminogen
activator surface receptor, CD14: cluster of differentiation 14, TREM-1: Triggering
receptor expressed on myeloid cells 1, sTREM-1: soluble TREM-1, CD64: Fc-gamma
receptor 1 (FcγRI), CTLA-4: cytotoxic T-lymphocyte-associated protein 4, BTLA: B-
and T-lymphocyte attenuator.
Proadrenomedullin: Proadrenomedullin (pro-ADM), secreted by a multitude of tissues,
is the stable pro-hormone of ADM, which has vasodilatory and immune modulating
functions and is implied in organ blood supply [187]. Pro-ADM is suggested as a prognostic
biomarker correlating with increasing severity and death but with no diagnostic value for
sepsis [187,193].
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Endocan: Endocan is a proteoglycan produced in endothelial cells and released as a
response to inflammatory stimuli [179]. Recent studies proposed a correlation between
endocan release into blood and severity of sepsis, occurrence of organ dysfunction and
mortality [179]. However, elevated endocan synthesis and release are not specific for
sepsis but also discussed as a marker for tumor progression and acute lung disorders [194].
In contrast to the molecular markers present in blood and body fluids and produced by
a wide variety of non-immune cells, some biomarker candidates are cell-surface proteins
expressed on different types of professional immune cells. While some of these markers
are of interest in their bound state, others are proteolytically cleaved and present in
blood and other body fluids after release (Fig 15B).
Released Surface Receptor Markers: A soluble form of CD14, named sCD14 or pre-
sepsin is generated during inflammation and serum levels increase in response to bacterial
pathogens [187]. In recent studies, presepsin was suggested as both, diagnostic and
prognostic marker, but the most promising results concern the differentiation between
SIRS and sepsis and bacterial and non-bacterial infection, respectively [188,195,196].
Another molecule expressed on innate immune cells and subsequently released into
body fluids is the triggering receptor expressed on myeloid cells-1 (TREM-1). Different
studies revealed potential suitability of soluble TREM-1 (sTREM-1) in diagnosis and
prognosis. However, due to small study sizes and contradicting results, the utility of
sTREM-1 as a sepsis biomarker remains ambiguous [179,187,188].
Surface-bound Receptors: In contrast to sCD14 and sTREM-1, CD64, an Fc-gamma
receptor on neutrophils and other leukocytes, is not released into body fluids. Several
studies therefore investigated CD64 expression on neutrophils, revealing high expression
in septic patients and lower expression in patients without infection [179]. Furthermore,
CD64 levels seem not affected by auto-immune diseases, making this receptor a promising
biomarker for the presence of infection [188].
Similar to CD64, B- and T-lymphocyte attenuator (BTLA) is expressed on a variety of
immune cells. An increased BTLA+/ CD4+ lymphocyte frequency was associated with
infections as compared to non-septic, but critically ill patients. Furthermore, patients
with a high amount of BTLA+ cells were more susceptible for nosocomial infections [197].
Another negative regulator of T-cell responses, cytotoxic T-lymphocyte antigen-4
(CTLA-4), is also found with increased frequency in sepsis and an antibody against
CTLA-4 improved survival in a murine model [198].
However, for both, BTLA and CTLA-4, further clinical studies are needed to validate
the potential of those molecules as biomarkers [179]. Apart from the single molecules,
cytokine and chemokine signaling as well as different cell types, e.g. DCs and regulatory
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T cells, are analyzed for their diagnostic and prognostic values.
In summary, only two of the presented molecules, CRP and PCT, are utilized in clinical
routines, and even those two are outperformed by the prognostic power of scoring systems
if used stand-alone. One feasible way to overcome this problem might be to combine
several biomarkers to enhance sensitivity and specificity of the prediction [179,180,187].
Another approach is the systematic analysis of patient samples, e.g. body fluids or cells,
by means of the Omics technologies to uncover groups of molecules that are utilizable as
combined biomarker sets either for diagnostic or prognostic purposes.
1.5.2.2 Omics Technologies in Sepsis-related Biomarker Discovery
DNA and RNA Level Omics: Omics methods allow the analysis of cellular compo-
nents at different levels, starting from genetic information (Figure 16(1)). On this
first level of genetic information, especially epigenetics and the genome-wide analysis
of single-nucleotide polymorphisms (SNPs) offer clinical usefulness [178]. SNPs reveal
patient-individual susceptibility and risk of death, and thus are a promising tool for risk
stratification [178,199].
In contrast, epigenetic analyses could yield biomarkers for the early diagnosis and
progression of sepsis alike, provided that DNA modifications are aﬄicted [178]. However,
until now, only few studies utilizing epigenetics for sepsis diagnosis were performed,
including an analysis of histone modifications and the investigation of methylation
patterns in septic newborns [200,201].
The second target of sepsis-related biomarker-research is the ribonucleic acid (RNA)
level (Fig 16(2)). Of particular interest at this level are messenger RNA (mRNA) and
microRNA (miRNA) expression profilings. While mRNAs represent the entirety of all
expressed protein-coding genes and thus proteins and protein isoforms, miRNAs are
post-transcriptional regulators of gene expression. For both, mRNA and miRNA, first
studies are promising in identifying of sets of markers and single entities with diagnostic
and prognostic value. However, further evaluation in larger studies is needed to validate
the clinical suitability [178,199].
Proteomics: In contrast to the previously described Omics approaches, proteomics
maps the functional repertoire of cells at a certain time point in form of actually expressed
proteins (Fig 16(3)).
Recent studies targeted either distinct cell types or body fluids in clinical settings or
used animal or cell-line models (reviewed in [202]). Many of the studies were able to
confirm regulation of known and proposed biomarkers and added novel candidates to
the lists. For example, Kalenka and colleagues reported differences in serum-protein
composition between patients with sepsis and septic shock for the first time and utilized
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those proteins for survival prediction successfully. Thereby, they proved the idea of
prognostic markers found by proteomics [203]. A similar pilot study by Su and colleagues
also confirmed the suitability of urine for the detection of prognostic markers [171]. Most
recently, platelets from septic patient sera were characterized proteomically in comparison
to platelets from healthy persons [172]. This study by Liu and colleagues also identified
five differentially expressed proteins.
In addition to protein content and regulation, proteomic techniques allow monitoring
of post-translational modifications, which are crucial regulators of protein activity. For
example, Cuello and colleagues identified the redox status of long pentraxin 3, leading to
differential oligomerization, as a reliable predictor for disease outcome in a murine sepsis
model [204].
However, the diagnostic and prognostic values of identified potential markers need to
be verified in large-scale studies and furthermore, the challenge of identification of low
expression proteins needs to be tackled for future research [178,199,202].
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Figure 16. Omics approaches to detect novel biomarkers for sepsis at different cellular
levels. 1: Epigenetics & SNPs, 2: Transcriptomics, 3: Proteomics, 4: Metabolomics.
Adapted from Skibsted et al. [178]. DNA: deoxyribonucleic acid, RNA: ribonucleic acid,
mRNA: messenger RNA, miRNA: microRNA.
Metabolomics: Metabolite analysis is the Omics approach furthest downstream from
genomics and simultaneously the most recent addition to Omics technologies in sepsis-
related research [178]. Until now, only one study utilizing patient samples supports
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the idea of changing metabolites in plasma samples as diagnostic or prognostic biomar-
kers [205]. However, model studies using rats could build a foundation for outcome
predictions with high specificity and sensitivity [199].
Even though Omics technologies uncovered several new candidates for diagnostic or
prognostic biomarkers in sepsis, validation studies and proposals for clinical use are
largely missing. Because of that, the practical utility as well as sensitivity and specificity
of the candidate panels are still uncertain. Additionally, it must be assumed that in the
process of validation some of markers will be proven false, leaving behind the need for
further biomarker studies.
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Ubiquitin and Ubiquitin-like modifiers (UBLs) are small proteins that serve as post-
translational modifications in many cellular processes including immunity. The high
complexity created by manifold chain formation of UBLs is under tight control of about
100 deconjugating enzymes, which shape and remove UBL-modifications.
Deubiquitinating Enzymes (DUBs), which remove ubiquitin, are the largest and best
described group of deconjugating enzymes. Some DUBs are crucial regulators of innate
and adaptive immune responses and are implicated in diseases and infections. Viral as
well as bacterial pathogens influence DUB activities and furthermore acquired or evolved
enzymes with deubiquitinating activity themselves.
Listeria monocytogenes (Lm) is one widely used model-organism for bacterial infection
and intracellular lifestyle of pathogens. Moreover, listeriosis is also a major health concern
and a re-emerging disease which can cause life-threatening symptoms in risk patients.
The most frequent severe symptom occurring is sepsis, which is characterized by a
rapid progression and high mortality even in intensive care units. The major challenge in
sepsis-related research at the moment is the identification of molecular markers to allow
correct diagnosis of sepsis as well as an early prognosis of progression.
Listeria invades cells by utilizing the receptor-tyrosine kinase c-Met as well as the adhesin
E-cadherin, which are activated by the listerial factors Internalin B and Internalin A,
respectively. While the invasion route via E-cadherin and InlA is dependent on receptor-
ubiquitination by the Ub-ligase Hakai, the role of c-Cbl-mediated ubiquitination of c-Met
is contentiously discussed. At the moment, it is not clear which DUBs and Ub-sites are
involved in activation by InlB and whether Lm interferes with (de)ubiquitination of the
receptor. Even though some DUBs, e.g. CYLD, are described to be involved in systemic
Listeria infection, an overview of the entirety of DUB-activities is also missing. Chemical
proteomics can provide small, covalently binding, activity-based probes (ABPs) based on
ubiquitin and UBLs to tackle this gap. These tools enable systematic detection and even
enrichment of active DUBs as compared to the other ubiquitin-processing enzyme families.
This study aims at the detection and description of active DUBs as an enzyme class in-
volved in Listeria monocytogenes infection and subsequently emerging disease symptoms.
Furthermore, this study attempts to tackle technical limitations of DUB detection by
improvement of currently available DUB activity-based probe concepts. For this purpose,
the following main research questions are to be answered.
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Firstly, are ubiquitination and DUB-activities involved in InlB/c-Met mediated cell
invasion of Listeria? To answer this question on a cellular level, the role of c-Met ubi-
quitination in receptor internalization after activation with the listerial virulence-factor
InlB should be examined utilizing “ubiquitination-resistant” c-Met mutants. Moreover,
DUB candidates, that are able to directly deubiquitinate c-Met are to be defined and cha-
racterized regarding their localization. To achieve this, novel sequence-specific tools are
to be designed, which are able to covalently bind DUBs capable of c-Met deubiquitination.
Secondly, does Lm infection deregulate Ub-mediated processes and DUB-activities
in vivo? To elucidate this question, the global protein regulation during Lm infection
as well as DUB-activities should be analyzed in a sub-lethal Lm infection model. Special
attention should be payed to Ub and UBL-system regulating components and their
role in the pathophysiology of Lm infection and bacterial clearance. A workflow for
the systematic detection of physiological DUB-activities should be established utilizing
suitable activity-based probes. As it is not clear whether the available ABPs assess the
actual activity of DUBs, a promising ABP-candidate is to be evaluated regarding its
selectivity.
Thirdly, can DUB-activities serve as molecular biomarkers for the diagnosis or prog-
nosis of sepsis? To examine this question, blood lymphocytes from ICU patients are
to be collected from patients with sepsis as well as controls and DUB-activity patterns
are to be obtained. To utilize DUB-activity patterns for such an application, a workflow
for the analysis as well as a statistical approach for the comparison of patterns are to be
conceptualized.
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3.1 Antibodies and Recombinant Proteins
3.1.1 Antibodies
All antibodies, primary and secondary, used in this thesis are summarized in Tables 3
and 4. For primary antibodies, the antigen, host and clone, if monoclonal, are given as
well as the manufacturer and the dilution the antibody was used in. The abbreviations in
brackets state the use of the antibody, WB = western blot and IF = immunofluorescence.
For secondary antibodies, name, manufacturer, antigen species, host species, dilution and
the conjugate are given. Conjugates are either horseradish peroxide (HRP), cyanines
(Cy) or Alexa Fluor fluorochromes (AF).
Table 3. Secondary antibodies utilized for western blot analytics and immunofluores-
cence. JIR = Jackson ImmunoResearch, MP = Molecular Probes, AF = Alexa Fluor,
Cy = cyanine.
name manufacturer antigen species host conjugate dilution
A4a JIR mouse goat HRP 1:3000 (WB)
B4c JIR rabbit goat HRP 1:3000 (WB)
G4c JIR goat donkey HRP 1:3000 (WB)
A7c JIR mouse goat Cy3 1:250 (IF)
B7c JIR rabbit goat Cy3 1:250 (IF)
X7c JIR rabbit donkey Cy3 1:250 (IF)
G9c JIR goat donkey Cy2 1:250 (IF)
A12c MP mouse goat AF 488 1:250 (IF)
B12c MP rabbit goat AF 488 1:250 (IF)
B13c MP rabbit goat AF 594 1:250 (IF)
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Table 4. Primary antibodies utilized for western blot analytics and immunofluores-
cence. WB = Western Blot, IF = immunofluorescence, CST = Cell Signaling Technolo-
gies, SySy = Synaptic Systems
antigen manufacturer clone host dilution
actin Sigma polyclonal rabbit 1:10,000 (WB)
β-actin Sigma AC-15 mouse 1:10,000 (WB)
phospho-Akt CST 587F11 mouse 1:500 (WB)
phospho-Erk 1/2 CST D13.14.4E rabbit 1:8000 (WB)
GFP SySy polyclonal rabbit 1:1000 (WB)
c-Met CST D1C2 rabbit 1:3000 (IF)
1:2000 (WB)
c-Met CST L6E7 mouse 1:200 (IF)
phospho c-Met CST D26 rabbit 1:2000 (WB)
CYLD CST rabbit 1:200 (IF)
GAPDH CST 14C10 rabbit 1:10,000 (WB)
GAPDH ABD SeroTec 4G5 mouse 1:10,000 (WB)
HA-peptide Roche 12CA5 mouse 1:1000 (WB)
HIS-Tag Novagen mouse 1:1000 (WB)
HSP90 R&D Systems polyclonal goat 1:500 (WB)
UCHL3 CST polyclonal rabbit 1:1000 (WB)
USP2 Santa Cruz C-20 mouse 1:200 (IF)
USP21 Sigma polyclonal rabbit 1:200 (IF)
USP8 Santa Cruz F-3 rabbit 1:100 (IF)
VCPIP1 OriGene polyclonal rabbit 1:2000 (IF)
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3.1.2 Hepatocyte Growth Factor (HGF)
Full-length HGF was provided by Dr. Joop van den Heuvel and prepared by Nadine
Konisch & Daniela Gebauer (all PREX/SFPR, Helmholtz Center for Infection Research,
Braunschweig).
CHO lec3.2.8.1 EGT 92/A50.373 cells were cultivated in a 5 L-Batch-reactor in
ProCHO5 medium supplemented with 7.5 mM glutamine (both Sartorius). As the protein
was secreted during cell cultivation, the supernatant was harvested by centrifugation
with a Sorvall™ RC 12BP Plus Large Capacity Centrifuge (Thermo Scientific) at 7332×g
for 30 min while cooling to 4°C. Then, 0.1 % (v/v) sodium azide was added and the
supernatant was concentrated using two Pellicon 2 ultra-filtration cassettes (Merck
Millipore) until a final volume of 1 L was reached. After sterilization by filtration using
Sartobran 300 capsules with 0.45µm and 0.2µm pore size (Sartorius), the protein was
applied onto a 5 mL HiTrap Heparin column (GE Healthcare), eluted utilizing a salt-
gradient from 0 to 100 % HiTrap buffer B (50 mM Tris/HCl, 2 M NaCl, pH 8.0.) and
collected in 2 mL fractions were. After inspection via SDS-PAGE, fractions were pooled
and activated utilizing HGF-A leading to incomplete conversion of single-chain HGF
(scHGF) to two-chain HGF (tcHGF). Subsequently, the protein was dialyzed against
50 mM Tris/HCl, 250 mM NaCl, pH 8,0 and the chromatography was repeated another
three times. Each time, the fractions were inspected by SDS-PAGE and the desired
fractions were then dialyzed against 50 mM HEPES, 250 mM NaCl, pH 7,4 until no
scHGF could be detected. For the final clean up, a 1 mL MonoS GL column (GE
Healthcare) coupled to an Äkta Purifier System was utilized. A gradient from 250 mM to
1 M NaCl utilizing MonoQ buffers A and B (50 mM HEPES and 1 M NaCl (B), pH 7.4,
degassed) yielded the final fractions of pure tcHGF, which were, after pooling, dialyzed
against 50 mM HEPES, 600 mM NaCl, pH 7,4. The protein content of the fractions was
measured by Nanodrop 2000 (Peglab, Germany) in the 1 Abs = 1 mg/mL mode and then
corrected using the extinction coefficient of 1.8. Finally, tcHFG was aliquoted and stored
at -80 °C. For each experiment series, tcHGF was checked for activity by cell-scattering
and activation of c-Met signaling cascade (p-Erk1/2 & p-Akt). The control buffer used
for stimulation experiments was obtained from the final dialysis step.
3.1.3 Internalin B (InlB)
The recombinant InlB full-length protein used in this study was kindly provided by
Dr. Jörn Krause and produced by Claudia Hanko (both SFPR, Helmholtz Center for
Infection Research, Braunschweig).
Escherichia coli (E.coli, Rosetta/Rosetta 2) cells from glycerol stocks were cultivated
at 37°C over night (o/N), with shaking in Lysogeni broth (LB; 15 g/L yeast extract,
10 g/L tryptone, 7 g/L sodium chloride, autoclaved) using chloramphenicol and ampicilin
as selective antibiotics (1µg/mL each). The next day, starter culture was diluted 1:100
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into fresh flasks and the inoculated cultures were grown to an optical density (OD ) of
0.5-0.8 at 37°C and 110 rpm. Subsequently, expression of InlB was induced by reduction
of temperature to 20°C, addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG) and
incubation o/N. Cells were harvested by centrifugation and lysed by addition of ice-cold
E.coli Lysis-buffer (1x PBS, 1 / 25 mL Complete Protease Inhibitor (Roche), 1.6 µg/mL
DNAse, 0.8 M MgCl2) and cell disruption using a French Press or sonicator. After
centrifugation to remove insoluble protein and cell debris at 16.000 rpm for 1 h at
4°C (Sorvall Centrifuge, Rotor: SS-34), the lysate was incubated with pre-conditioned
glutathione sepharose (GSH) in a 50 mL glass column with glass filter for 1 h at 4°C
and gentle shaking, to allow the binding of the InlB glutathione S-transferase (GST)-tag
to the beads. Subsequently, unbound protein was discarded and GSH was washed with
ice-cold PBS twice and re-equilibrated in ice-cold PreS-Cleavage Buffer (50 mM MES,
pH 6.0). Thereafter, the beads were incubated with PreScission Protease (#27-0843-
01, GE Healthcare) in PreS-cleavage buffer o/N while shaking at room temperature
(RT). The next day, the cleaved InlB was collected, remaining GSH particles were
sedimented by centrifugation and InlB was dialyzed against SourceQ-buffer A (50 mM
MES, 300 mM NaCl, pH 6.0 (NaOH), degassed). Thereafter, InlB was purified utilizing
an Äkta purifier system (GE Healthcare) equipped with a MonoQ column (SourceQ
15, GE Healthcare). A gradient from 0 % to 100 % SourceQ Buffer B (50 mM MES
and 1 M NaCl, pH 6.0 (NaOH), degassed) was used to separate InlB from contaminants
via ion exchange chromatography. The resulting 1 mL fractions were then analyzed via
SDS-PAGE and according to the apparent purity, the fractions were selected for use in
stimulation experiments. The protein content of the fractions was measured by Nanodrop
2000 (Peglab, Germany) in the 1 Abs = 1 mg/mL mode and then corrected using the
extinction coefficient of 0.69. The resulting molecular weight of InlB was 67606 kDa.
InlB full-length was stored at -80°C until use and for each experiment series checked for
activity by cell-scattering and activation of c-Met signaling cascade (p-Erk1/2 & p-Akt).
The control buffer used contained an estimated sodium chloride concentration (500 mM)
and 50 mM MES corresponding to the salt-gradient of the MonoQ column.
3.1.4 Recombinant Deubiquitinating Enzymes
All recombinant deubiquitinating enzymes used are listed in Table 5. Except for BRCC3,
which carries a GST-Tag, all enzymes posses a poly-histidin tag (HIS6-Tag) utilized for
western blot detection. For non-full length DUBs, the name is tagged with XXXCD
marking the enzyme as short form with only the active center recombinantly produced.
The enzymes were purchased either from Enzo Life Sciences (Lörrach, Germany), Life
Sensors (Malvern, UK), Boston Biochem (Cambridge, UK) or Abnova (Taipei City,
Taiwan), as stated in Table 5.
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Table 5. Recombinant deubiquitinating enzymes used in this study. XXXCD denotes
DUBs of which only the active domain was recombinantly produced.
Name product code manufacturer conc. [mg/mL] assay [µg] MW [kDa]
USP2CD E-506 Boston Bio 1.58 0.5 42
USP5 DB516 Life Sensors 0.6862 1 94
USP7 E-518 Boston Bio 2.1 1 42
USP8 E-520 Boston Bio 0.953 0.5 131
USP9x E-552 Boston Bio 0.4 1 292
USP10 DB514 Life Sensors 0.0495 0.5 99
USP14 DB505 Life Sensors 1.36 0.5 68
USP15 UW9845 Enzo 1 1 109.2
USP20 DB520 Life Sensors 1.05 0.5 105
USP21 DB509 Life Sensors 0.189 0.5 73
USP25 E-546 Boston Bio 1.25 0.5 123
USP28 DB525 Life Sensors 0.7 0.5 123
USP47 DB510 Life Sensors 1.57 1 157
CYLD E-556 Boston Bio 1.18 1 108
UCHL1 DB104 Life Sensors 1.25 1 25
UCHL3 UW9745 Enzo 1 0.3 29
UCHL5 DB102 Life Sensors 0.98 0.25 49
BAP1 E-345 Boston Bio 0.405 2 81
OTUB1 E-522 Boston Bio 1.66 0.5 33.2
OTUB2 E-554 Boston Bio 1.4 0.5 28
A20CD E-344 Boston Bio 2.26 0.5 46
ATXN3 E-341 Boston Bio 1.05 0.5 42
ATXN3L DB402 Life Sensors 4.1 0.5 41
JosD1 DB403 Life Sensors 1.1 0.5 22
Yod1 DB202 Life Sensors 0.6232 0.5 38
AMSH DB301 Life Sensors 0.49 0.5 49
BRCC3-GST H00079184-P01 Abnova 0.2 0.5 62.5
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3.2 Cell-biological Methods
3.2.1 Media and Supplements
All media and supplements were purchased from Life Technologies (Gibco / Invitrogen,
Paisley, UK) unless otherwise stated. Fetal bovine serum (FCS) was purchased either
from PAA Laboratories (Fetal Bovine Serum GOLD) or Sigma Aldrich, St. Louis, USA.
All media and PBS were sterilized by filtration utilizing Steritop Filter Units (Merck
Millipore, Billerica, USA). All media used are shown in Table 6.
3.2.2 Cell Lines and Cells
Utilized cell lines are listed and described in Table 7. Peripheral blood mononuclear cells
(PBMCs) were isolated either from Buffy coats of healthy donors or sterile blood samples
of sepsis patients. Buffy coats were kindly provided by the Deutsches Rotes Kreuz
(NSTOB Springe), blood samples of sepsis patients were collected in the surgical ICU
(OVGU Magdeburg, Dr. Lodes) and prepared by the work group medical microbiology
(OVGU Magdeburg, Prof. Dr. Schlüter).
3.2.3 Cell Culture and Harvesting
All cell lines referred to in Table 7 were cultured in treated culture dishes or 24, 12-well
plates (all NuncTM, Thermo Scientific) utilizing Innova incubators (New Brunswick Scien-
tific). Culture conditions were 37°C and 7.5 % carbon dioxide (CO2). The culture media
and supplements used for particular cell lines are listed in Table 6.
At 80-90 % confluence or twice a week, cells were passaged. Therefore, the adherent
cells were washed with PBS once and trypsinized (0.05 % Trypsin with 5 mM EDTA) for
5 min at 37°C. Afterwards, full medium or FACS-buffer (1xPBS, 2 % FBS, 1 mM EDTA)
was added to stop the proteolytic cleavage and cells were spun down at 170×g for 5 - 10
minutes at RT utilizing a Multifuge 1 S-R (Heraeus). Subsequently, the supernatant
was discarded and cells were resuspended in fresh medium for further cultivation or
FACS-buffer for measurement at the Accuri flow cytometer (Accuri Cytometers Inc.).
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Table 6. Cell media used for maintenance of cell lines and cultivation of cells.
Medium Base Supplements Cell line /
Cell type
DMEMfull Dulbecco’s modified
Eagle’s Medium
(DMEM)
1 g/l glucose
10 % FBS
2 mM glutamine
50 mg/l streptomycin
50,000 units/mL
penicillin
HeLa S3
EL-4
DMEM-pen/strep Dulbecco’s modified
Eagle’s Medium
(DMEM)
1 g/l glucose
10 % FBS
2 mM glutamine
HeLa S3
(microscopy
and
transfection)
DMEMMM Dulbecco’s modified
Eagle’s Medium
(DMEM)
1 g/l glucose
none HeLa S3
(starvation)
RPMI-1640full Roswell Park
Memorial Institute
Medium
(RPMI-1640)
10 % FBS
2 mM glutamine
50 mg/l streptomycin
50,000 units/mL
penicillin
peripheral
blood
mononuclear
cells
(PBMCs)
Table 7. Properties of used cell lines.
Cell line Description (organism,
tissue/cell type, disease,
ref. name)
Morphology & growth
properties
Medium
EL-4 mouse, T lymphocyte,
lymphoma,
ATCC® TIB-39™
lymphoblast,
suspension cells,
adherent (treated
culture dishes)
DMEMfull
HeLa S3 human, cervix,
adenocarcinoma,
ATCC® CCL-2.2™
epithelial, adherent DMEMfull
DMEM-pen/strep
DMEMMM
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3.2.4 Transient Transfection of HeLa S3 Cells
HeLa S3 cells were seeded either in 24-well plates, for microscopy and transfection
controls, or 12-well plates for western blot analysis at a cell density of 1.3×104/cm in
DMEM-pen/strep to avoid interference of antibiotics with the transfection and microscopy.
Additionally, wells for microscopy contained sterile glass cover slips with 12 mm in
diameter (Hecht Assistent, Germany) and were grounded with a damp tissue to ensure
even distribution of cells.
After seeding, cells were incubated for 24 h at 37°C and medium was substituted by
fresh medium shortly before transfection. In parallel, the transfection mix was prepared
in a 96-well plate with v-bottom. For 24-well plates, 50 µL of DMEMMM mixed with
0.7 µg of DNA per well and Fugene transfection reagent (Promega, Fitchburg, USA)
in a ratio of 1:3 and then incubated for 15 minutes at RT (see 3.5.2 for a list of used
constructs). For 12-well plates all volumes were scaled up by a factor of 1.84 to account
for the increased area of the wells. After incubation, the transfection mix was added
drop-wise to the wells and cells were cultivated for another 24 h.
The next day, cells for control of transfection efficiency (3.2.5) were trypsinized as
described in 3.2.3 and for all other cells destined for stimulation experiments, medium
was changed to DMEMMM except for control samples which are labeled as non-starved.
In that case, medium was exchanged against fresh DMEM-pen/strep to remove excessive
transfection complex.
3.2.5 Flow-cytometric Analysis of Transfection Efficiency of HeLa S3 Cells
Initial transfection stability as well as transfection efficiency for the stimulation expe-
riments was checked by flow cytometry as all used constructs contained an eGFP-tag
allowing to test for green fluorescence as a transfection marker. Therefore, cells were
trypsinized after 24 and 48 h and following centrifugation (5 min, 410×g) resuspended in
300 µL of FACS-buffer. To examine the cell viability after transfection and ensure that
eGFP-positive cells were alive, propidium iodide (PI, Sigma-Aldrich) was added to all
samples up to a final concentration of 0.75 µg/mL. As negative controls, cells which were
also grown in 24-well plates without further treatment were used. For the positive control,
cells were incubated in 0.25 % Triton X-100 in PBS on ice for 5 min to permeabilize the
cells and stained with PI in parallel.
All samples were then transferred to 5 mL FACS-tubes and measured immediately
at the BD Accuri C6 Flow Cytometer operated via BD Accuri C6 Analysis Software
(1.0.264.21, BD Biosciences, USA). EGFP and PI both were excited with the 488 mm
laser and analyzed in channel 1 (533 nm, 30 nm window) and channel 3 (630 nm; long
pass filter), respectively. The evaluation strategy is shown in Figure 17. The samples
were first gated for cells in general, then for live/dead utilizing PI staining and unstained
control cells and finally for eGFP-fluorescence in living cells. Furthermore, all cells were
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monitored for the proportions of living and dead cells among the non-transfected and
transfected cells.
Figure 17. Evaluation strategy of transfection efficiency by flow cytometry. In Plot 1 a
rectangular gate (R1) was set to select all cells. The rectangular shape is due to the
need of the PI positive control to fall at least partly into the gate. Then, in Plot 2 the
samples are divided into a PIneg (alive) and a PIpos (dead) population. To determine
the amount of eGFP+ cells, two parallel approaches were pursued. On the one hand,
as shown in Plot 3, all cells were divided into 4 populations, PIpos and eGFP- (UL),
PIpos and eGFP+ (UR), PIneg and eGFP- (LL) and PIneg and eGFP- (LR). The second
approach is shown in Plot 4, which determines the eGFP+ cells among the living cells
and utilizes the live/dead-gate from Plot 2.
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3.2.6 Stimulation of Cells with HGF and InlB
Both HGF and InlB were produced in-house as described in 3.1.2 and 3.1.3 and stored
as a high concentration stock at -80°C.
Before stimulation experiments were carried out, HGF and InlB were tested for protein
integrity and ability towards HeLa S3 cells to activate the c-Met signaling cascade, namely
p-Erk 1/2 and p-Akt (5 min) and to induce cell scattering (24 h). Therefore, different
concentrations of both proteins, ranging from 0.02 nM to 20 nM, were applied to the
cells and subsequently signaling activity was verified by western blotting using antibodies
against phosphorylated Erk1/2 and phosphorylated Akt (see Table 4). Scattering was
examined via life-cell microscopy.
Prior to stimulation, cells were starved with DMEMMM for 24 h including three changes
of medium at 0 h, 2 h and 20-22 h starvation time to remove the excess supplements.
For stimulation, the cell medium was aspirated and fresh minimal medium with a final
concentration of 10 nM HGF or InlB was added. Cells were then incubated for a given
time with the proteins and afterwards the stimulation was stopped either by PFA-fixation
or addition sample buffer. For microscopy images, cover slips with cells on it were washed
2 min before end of stimulation and then fixed with 4 % PFA. For western blot analysis,
cells were also washed with PBS and the stimulation was stopped by addition and rapid
dispersion of reducing 4-time concentrated sample buffer and 1 % (v/v) Benzonase
(EMPROVE® bio: Merck Millipore, Billerica, USA) using cell scrapers.
The control buffers used contained an 500 mM NaCl and 50 mM MES for InlB and
50 mM HEPES, 600 mM NaCl, pH 7.4, for HGF. For the transfection experiments both
control buffers were added to the stimulation solution of the other protein and to the
control solution to eliminate differences in buffer composition.
3.2.7 Immunofluorescence Analysis of HeLa S3 Cells
All used antibodies and respective dilutions used can be found in Tables 4 and 3 in
chapter 3.1.1.
For immunofluorescence analysis cells were cultured in 24-well plates with 12 mm glass
cover slips (Hecht Assistent, Germany) on the bottom of the cavity which were grounded
with a damp tissue to ensure even distribution of cells. Depending on the experiments,
cells were transfected and stimulated as described in 3.2.4 and 3.2.6.
At first, cells were fixed with fixation solution (1x PBS, 4 % paraformaldehyde (PFA))
for 20 min at RT, washed with PBS and permeabilized with cold IF permeabilization
solution (1x PBS, 0.15 % Triton-X100) for 5 min. Subsequently, cells were blocked with
blocking solution (1x PBS, 1 % bovine serum albumin (BSA), 0.1 % Tween-20), for
30 min at RT and incubated with the desired primary antibodies diluted in blocking
solution in a humid dark chamber at 4°C o/N. On the next day, the cover slips were rinsed
with washing solution (1x PBS, 0.1 % Tween-20) thrice and the incubated with secondary
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antibodies and the DNA counter-stain DAPI (Sigma-Aldrich, St.Louis, USA) at a final
concentration of 1 ng/mL staining mix. Thereafter, cover slips were again washed with
washing solution (2x), PBS (1x), dehydrated in 70 and 96 % ethanol for 1 min each and
dried on filter paper for a short time. Finally, cover slips were embedded in pre-warmed
Mowiol® 4-88 Embedding solution (Sigma-Aldrich) onto Superfrost Microscope slides
(Thermo Scientific) and dried at RT in the dark o/N.
Microscopic analysis was carried out at an inverted microscope (Ti-Eclipse, Nikon) using
a Plan-Apochromat 100x/1.45 immersion oil objective and epifluorescence illumination
from IntensiLight (Nikon) light source. The microscope and camera were operated with
the NIS-Elements AR software (7.30.02, Nikon) and images were acquired utilizing a
cooled, charge-coupled device camera with back-illumination (CoolSnap MYO, Roper
Scientific).
For image evaluation and processing NIS-Elements and Fiji (ImageJ) image processing
package were utilized [206,207].
3.2.8 Isolation of Cell Populations from Blood of Healthy Donors
Buffy coats of healthy human donors for cell isolation were provided by Deutsches Rotes
Kreuz (NSTOB, Springe) and tested negatively for the presence of HI-, HB- and HC-
virus particles. The protocol used was adapted from Böyum A. (1968) as follows [208].
The content of each Buffy coat was equally distributed to two 50 mL reaction tubes
pre-filled with 7.5 mL buffy buffer (PBS supplemented with 4 % FBS) and gently mixed.
Subsequently, the mixture was slowly pipetted onto an cushion of 14 mL Ficoll-Paque
(1.0077±0.001 g/mL at 20°C, GE Healthcare, Chalfont St Giles, UK) and the gradient
centrifugation was carried out at 840×g for 25 min with disabled breaks. Subsequently,
PBMCs were extracted from the interphase of the gradient and washed twice with
50 mL of buffy buffer by centrifugation at 410×g for 10 min to remove the Ficoll. To
isolate granulocytes and erythrocytes after PBMCs were extracted, the gradient was
carefully aspirated and the white layer directly above the erythrocytes (granulocytes)
and a portion of the erythrocytes were extracted and also twice washed with buffy buffer.
After resuspension, PBMCs and granulocytes, if collected, were filtered through a 40 µm
pore-size cell strainer (Falcon), diluted to a total volume of 50 mL and counted using
trypan blue and a hemocytometer. In case of clearly visible erythrocyte contamination,
i.e. a red pellet, erythrocytes were destroyed by lysis using ACK-buffer (0.15 M NH4Cl,
10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2-7.4 (HCl), sterile filtered). Therefore, cells
were resuspended in 10 mL of ACK-buffer by inversion of tube, incubated, filled to 50 mL
with buffy buffer and centrifuged at 410×g for 10 min .Finally, the cells were portioned
to 1x108 cells, pelleted again at 410×g for 10 minutes for PBMCs and granulocytes and
at 1100×g for erythrocytes and stored free of supernatant at -80°C until use.
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3.2.9 Isolation of PBMCs from Blood of Sepsis Patients
All blood samples were collected in the surgical intensive care unit (ICU) of the university
hospital of the OVGU Magdeburg (Dr. Lodes) and prepared by the work group medical
microbiology (OVGU Magdeburg, Prof. Dr. Schlüter).
To acquire PBMCs from sepsis patients, 7 mL of RPMI were sterilely pipetted into
a 15 mL reaction tube in advance and approximately 7 mL of patient blood was then
added to the tube. After collection, the samples were send to medical microbiology work
group and PBMCs were isolated there.
Therefore, 15 mL of Ficoll were pipetted into a 50 mL reaction tube and the blood-
medium mixture was pipetted slowly on top of the ficoll to prevent mixing of the phases.
Then, the tube was centrifuged at 2340 rpm for 20 min w/o break in a Rotanta 460 R
centrifuge (Hettich, Tuttlingen, Germany). After removing of the upper layer (plasma),
PBMCs were taken from the gradient, transferred into a new 50 mL tube and washed with
3-times the transferred volume of PBS. If the cell pellet was reddish after centrifugation,
an erythrocyte lysis was carried out using AKR-buffer (0.15 M NH4Cl, 10 mM KHCO3,
0.1 mM Na2EDTA). Cells were incubated for 5 min in 10 mL of AKR-buffer, washed
with PBS and centrifuged again. After cell counting, cells were transferred into a 1.5 mL
reaction tube and the pellet was stored at -80°C until it was transported to Braunschweig
on dry ice.
After thawing on ice, cells were subjected to glass-bead lysis (see subsection 3.4.1).
3.2.10 Flow-cytometric Analysis of Mouse Liver Leukocytes
For L.m. infected mice (subsection 3.6.1), the leukocytes contained in the liver were
analyzed at day 1, 3, and 9 p.i. as well as in uninfected controls. Therefore, animals were
anesthetized with isoflurane. Thereafter, mice were intracardially perfused with 0.9%
PBS to remove contaminating intravascular leukocytes. The livers were dissected, the
tissue was minced through a 100 µm cell strainer and leukocytes were separated by Percoll
gradient centrifugation (GE Healthcare) as described before [209]. The leukocytes were
re-suspended in cell culture medium and the cell numbers were determined. The isolated
leukocytes were then analyzed by flow cytometry on a FACS Canto with FACS Diva
software (both from BD Biosciences). Cells were stained with anti-CD45 in combination
with anti-CD4 and CD3 for CD4 T cells, anti-CD8 and CD3 for CD8 T cells, anti-NK1.1
and CD3 for natural killer (NK) cells, F4/80 and CD11b for macrophages, CD11c and
CD11b for dendritic cells (DCs), CD11b, Ly6G and Ly6C for inflammatory monocytes,
and neutrophils (see Table 8). All antibodies were obtained from BD Biosciences.
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Table 8. Marker combinations used to determine populations of liver leukocytes in
L.m. infected mice. To determine the leukocyte population, cells were stained for
CD45. If cells were CD45+, they were regarded as leukocytes and gated according to the
markers listed. CD = cluster of differentiation
marker combination cell type
CD3+, CD4+ CD4+ T cells
CD3+, CD8+ CD8+ T cells
CD19+, CD45RB200+ B cells
CD3-, NK1.1+ natural killer (NK) cells
CDIIc+ dendritic cells (DCs)
CD11b+, F4/80+ macrophages (MΦ)
CD11b+, Ly-6Chigh, Ly-6G- inflammatory monocytes
CD11b+, Ly-6Cmedium, Ly-6G+ neutrophils
3.3 Synthesis and Ligation of Activity-based Probes
The basic protocol for the synthesis and ligation of activity-based C-terminal probes
was adapted from literature [88] and used as described earlier [96, 210]. For Ubiquitin
Isopeptide Probes (UIPPs), the protocol was adapted from Iphöfer et al.(2012) [95]. All
reactive groups and warhead-constructs were produced and provided by Antje Ritter,
Tatjana Arnold and Dr. Raimo Franke (all CBIO, Helmholtz Center for Infection
Research, Braunschweig). Two types of warheads were utilized in this study, classical
C-terminal electrophiles (3.3.1.1) and isopeptide warheads (3.3.1.2), and the synthesis of
both is described briefly below.
3.3.1 Warhead Synthesis
All solvents used were low moisture and HPLC-grade, all chemicals (reagent grade) were
used as supplied. Analytical thin-layer chromatography was performed on E. Merck silica
gel 60 F254 plates (0.25 mm). Isotopic composition of the compounds was confirmed
using ultra-high resolution and high accuracy mass spectrometry (Thermo Scientific LTQ
Orbitrap Velos).
3.3.1.1 C-terminal Electrophiles
The electrophiles VA and VME were synthesized as described earlier [95]. Starting from
50 mg of dried N-tert-butyloxycarbonyl-(E)-4-amino-2-butenoic acid (VA), which was
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dissolved in absolute DMF, and activated with DIPEA (0.745 mM). Subsequently, EDC
(0.375 mM), HOBt and 2- fluoroethylamine hydrochloride (0.375 mM) were added and
the solution was stirred o/N at RT. The next day, the reaction was stopped by adding
phosphate buffer (pH 7) and after addition of saturated NH4Cl extracted with ethyl
acetate. The combined ethyl acetate layer were washed with saturated NaCl solution and
subsequently dried (anhydrous MgSO4), filtered and concentrated. The produced N-tert-
butyloxycarbonyl-(E)-4-amino-2-butenoic acid fluoroethylester (VFEA) was then purified
using silica gel chromatography and eluted with 50 % ethyl acetate in dichloromethane
to yield the purified compound. All C-terminal electrophiles used in this study are shown
in Table 9.
Table 9. C-terminal electrophilic warheads prepared for and used in this study.
short name full name MW of warhead [Da] source / literature
VME vinylmethylester 115.06 in-house [88]
VA vinylformicacid 202.11 in-house [95]
VFEA vinylmonofluoroethylamide 145.08 in-house
3.3.1.2 Isopeptide Warheads
In short, peptides were synthesized as C-terminal amides on polyoxyethxlene-grafted
polystyrene residues utilizing an automated multiple peptide synthesizer (Syro I, Mul-
tisynTech, Witten, Germany) at a 25 µM scale. For each amino acid coupling cycle, 5
equivalents of Fluorenylmethyloxycarbonyl-protected amino acids, DIC and HOBt in
DMF were coupled for two times 1 h plus additional time for capping with acetic an-
hydride/pyridine in DMF. Lysine, the amino acid used in ligation to attach the warhead,
was incorporated carrying an Mtt-protecting group on the ε-amino group. Finally, the N-
terminus was acetylated for 30 min using acetic anhydride/pyridine in DMF. Subsequently,
the Mtt-group was cleaved of and N-tertbutyloxycarbonyl-(E)-4-amino-2-buteinoic acid
was added in a relative ratio (125 µM, 25.2 mg) to the resin after pre-activation with
DIC and HOBt in DMF. After 5 days of shaking, peptides were cleaved from the resin as
C-terminal amides using TFA, DCM, water and triisopropylsilane in a ratio of 70:20:5:5
for 4 h, precipitated (ter-butylmethyl ether/cyclohexane), extracted with water and
lyophilized. For more details see Iphöfer et al. (2012) [95]. An overview of all produced
isopeptide warheads is given in Table 10.
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Table 10. Isopeptide warheads produced for and utilized in this study. All marked lysines
(K) were modified with the VA reactive group as described in 3.3.1.2. Adjacent lysines
were replaced by alanine (A) and are marked in italics in the respective peptide sequences.
name peptide sequence MW of warhead [Da]
Ub20-28-K27(VA) SDTIENVKA 976.0
Ub28-36,K33A-K29(VA) ADKIQDAEG 954.5
Ub30-39-K33(VA) IQDKEGIPPD 1111.2
Ub42-54-K48(VA) RLIFAGKQLEDGR 1502.7
Ub54-73-K63(VA) RTLSDYNIQKESTLHLVLR 2286.6
c-Met958-70,K959A-K962(VA) RAQIKDLGSELVR 1607.97
c-Met1098-109,K1104A-K1103(VA) LDNDGKAIHCAV 1377.38
c-Met1098-109,K1103A-K1104(VA) LDNDGAKIHCAV 1377.38
c-Met1156-66-K1161(VA) VLPYMKHGDLR 1451.49
c-Met1254-64,K1263A-K1259(VA) SLQTQKFTTAS 1334.75
3.3.2 Production of HA-Ub75
The first step for probe synthesis was to produce hemagglutinin (HA) tagged ubiquitin
(Ub). Therefore, 400 mL of TB (12 g/l tryptone, 24 g/l yeast extract, 4 % (v/v) glycerol,
100 mL/l TB-salt stock (0.17 M KH2HPO4, 0.72 M K2HPO4) autoclaved) supplemented
with 0.1 % (v/v) ampicilin and kanamycin were inoculated with E.coli BL21+cells
containing a pTYB2-vector (NEB) comprised of HA-Ub fused to a chitin binding domain
(CBD) and an intein domain as well as antibiotic resistance to ampicilin. After over
night incubation at 37°C and 130 rpm in a Multitron incubator (Infors HT, Einsbach,
Germany), the pre-culture was used to inoculate an Labfors 5 L fermenter (Infors) for
protein production. Production was induced by 0.5M IPTG and carried out at 20°C
o/N. The next morning, cells were harvested by centrifugation at 3000×g for 30 min,
resuspended in PBS and aliquoted into 50 mL Falcons containing pellets of 10-15 mL
volume and stored at -80°C until further use. The fermenter was run by Daniela Gebauer
(RPEX, Helmholtz Center for Infection Research, Braunschweig).
For protein extraction, cell pellets were resuspended in HA-Ub lysis buffer (50 mM
HEPES, 100 mM NaOAc, 1/50 mL Complete Protease Inhibitor (Roche) w/o EDTA,
1 µL/10 mL DNAse, pH 6.5 (acetic acid)) at 4°C with stirring and subsequently ho-
mogenized in two cycles in a homogenizer at 16,000 - 20,000 psi. After centrifugation
at 36,000×g for 30 min at 4°C (SorvallTM RC6 centrifuge, Thermo Scientific, USA)
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and filtration through a 0.45 µm nylon (NY) membrane, the lysate was applied onto a
pre-conditioned glass column containing a 10 mL chitin-bead bed (Ref: S6651L, New
England Biolabs, Ipswich, USA). Subsequently, the column was filled with lysis buffer to
prevent adsorption of the beads to the column wall and incubated for 5 h at 4°C with
gentle shaking to allow binding of the CBD to the beads. Following incubation, unbound
proteins were washed off by filling the column twice and the column was transferred to
RT. To prepare for HA-Ub cleavage, the bead-bed was rinsed with 50 mM MesNa (Fluka
(now Sigma-Aldrich)) in lysis buffer, re-filled again to 1 mL above the bed, sealed and
incubated o/N at 37°C.
The next day, cleaved HA-Ub was collected and the column was rinsed with an
additional bed-height of lysis-buffer. After filtering through a 0.32 µm NY syringe filter
and buffer exchange to ABP-buffer A (50 mM NaOAc, pH 4.5 (acetic acid), degassed)
using a VivaSpin membrane concentrator (Hybond membrane, cutoff: 5000 Da, Sartorius
Stedim, Germany) centrifuging at 3000×g, HA-Ub was applied to cation exchange
chromatography (CIEX). Therefore, a gradient of 0 to 100% ABP-buffer B (50 mM
NaOAc, 1 M NaCl (B), pH 4.5 (acetic acid), degassed) on a MonoS column (10/100
(400mg), GE Healthcare) coupled to an Äkta purifier system 900 coupled to Fraction
Collector Frac-950 (GE Healthcare) was utilized to separate reactive HA-Ub75 from the co-
occurring non-reactive form. The resulting fractions were analyzed by MALDI-TOF/TOF
(3.3.4) and HA-Ub-containing fractions were pooled and the buffer was again changed
to ABP-buffer A. Finally, the HA-Ub solution was concentrated until the volume was
below 500 µL and stored at 4°C until the reactive group was ready for ligation. Protein
concentration was determined by NanoDrop 2000 (Peglab) measurement in triplicates.
3.3.3 Ligation and Clean-up of ABPs
The respective warheads (see Tables 9 and 10) were dissolved in ligation buffer (100 mM
HEPES, pH 7.5, sterile filtered through syringe filter (0.2 µm)) and was adjusted to pH 8
using 0.1 M ammonium bicarbonate. Then, 50 µL of 2 M N-hydroxysulfosuccinimide
(S-NHS) and the reactive HA-Ub were added. After adjusting to pH 8 again if necessary,
the ligation solution was incubated o/N at 37°C. On the next day, the solution containing
the ligated ABP was again filtered through an NY syringe filter (0.22 µm) and subjected
to a buffer exchange to ABP-buffer A. To further purify the ABP, the solution was
again fractionated by cation exchange chromatography as described before and fractions
were analyzed by MALDI-TOF. If the desired fractions containing the ABP were not
clearly separable from the residual HA-Ub, a second round of CIEX using CIM® SO3
(0.34 mL) disk or tube (1 mL) monolithic column (Bia Separations, Villach, Austria)
was conducted. Finally, the ABP-containing fractions were combined and the buffer was
exchanged against probe-buffer (50 mM HEPES, pH 7.4). After validation via ESI-MS,
the probe was aliquoted and stored at -80°C.
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3.3.4 MALDI-TOF and ESI-MS Analysis of HA-Ub and ABP-ligation
Products
To determine and select ABP- and HA-Ub-containing fractions during ligation steps,
MALDI-TOF/TOF was used. Therefore, 1 µL of fractions distributed throughout the
chromatography peak was mixed with 1µL of 0.1 M sinapinic acid dissolved in 60 %
acetonitrile (AcN), 0.1% trifluoroacetic acid (TFA) as matrix on an MTP 384 ground
steel target (Bruker Daltonics) and dried for a few minutes. Subsequently, the Ultraflex-
TOF/TOF was utilized using matrix-assisted laser desorption/ionization to determine
the components of the applied fractions. As calibration solution, the protein calibration
standard I (Bruker Daltonics, Billerica, USA) was used allowing measurements in a mass
range between 3000 and 25,000 Da. The maximal allowed error for measurements were
100 ppm. All samples were then monitored for the distinct masses of possible HA-Ub
populations and for the respective probe masses, which were derived from the masses
of HA-Ub and the respective warheads (see Tables11 as well as 9 and 10) subtracting
the mass of a water molecule eliminated in the ligation step. Only fractions mainly
containing the desired masses were further processed, other fractions were discarded.
Additionally, final ABP-product was measured by electrospray ionization needle in-
jection to confirm the product and to assess the purity of the product used. Therefore,
a small portion of the final ABP-solution (3-4 ng/µL, 10 µL) was acidified using 20 %
(v/v) formic acid and cleaned by pipetting through C4 ZipTip® pipette tips, binding all
protein components, and subsequent elution in 65 % MeOH in 0.1 % FA. After drying in
a speedvac centrifuge (RC10101, Sorvall), the sample was resuspended in 10 µL of 0.1 %
FA and subjected directly to the needle measurement.
Table 11. Main HA-Ub populations monitored by MALD-TOF/TOF for determina-
tion of purity in probe ligation. For ligation, only HA-UbMesNa and HA-UbMes (*)
were of interest. The other masses were treated as contaminants.
product description MW [Da]
HA-Ub non-reactive HA-Ub 10159.6
HA-UbMesNa* reactive form 10323.8
HA-UbMes* reactive form w/o sodium 10282.9
HA-UbMesNa∆M1 reactive form, methionine 1 cleaved 10192.7
HA-UbMes∆M1 reactive form, methionine 1 cleaved 10151.8
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3.4 Biochemical Methods
3.4.1 Glass-bead Cell Lysis
Cells and tissues either subjected to western blotting (section 3.4.6) or prepared for
proteomics (section 3.7) were lysed by glass-bead lysis. Therefore, glass beads were
added to cell pellets or tissue powders in a 1:1 ratio. Then, the same amount of ice-cold
glass-bead lysis buffer (50 mM HEPES, 250 mM sucrose, 5 mM MgCl2, 1 % (v/v)
IGEPAL (Sigma-Aldrich, St.Louis, USA), 1 µL/10 mL Benzonase (freshly added)) was
added and samples were vigorously vortexed for 30-45 min at 4°C, using a shaker (IKA
Vibrax) at 2200 rpm and subsequently sonicated for additional 10-15 min in an ice-cold
ultra-sonic bath (Sonorex TK52, Bandelin). Afterwards, crude lysates were transferred
into new reaction tubes and centrifuged for 20 min at 4°C and 14,000×g to remove cell
debris. If necessary, centrifugation was repeated up to three times. Samples were then
stored on ice until further use.
3.4.2 Labeling of Cell Lysates with ABPs
After glass-bead lysis, protein concentration was determined using BradfordRed assay.
The assay was measured at 660 nm in an Infinite M200 Elisa plate reader (Tecan) using
BSA dilutions from 0.1 - 1 mg/mL as standard curve. Subsequently, the lysates were
diluted in 50 mM HEPES, pH 8.0 (NaOH) to distinct concentrations (e.g. 20 µg for
10-well gels, 10 µg for 17-well gels) for western blot applications and with NET-buffer
(50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5 % (v/v) IGEPAL, pH 7.5 (NaOH)) for
proteomic work flows. Then, the pH was checked again and if necessary, adjusted to 8.0
with NaHCO3 and defined amounts of ABPs were added and the samples incubated for
1 h at 37°C. Control samples were treated the same way, but HEPES was added instead
of an ABP. To arrest the reaction for western blot samples, reducing 4×sample buffer was
added. For proteomic samples, reaction was stopped by addition of 10 % SDS-solution
to a final concentration of 0.3 % and incubation at RT for 15 min.
3.4.3 Shift-Assay
To evaluate the binding capability of DUBs and ABPs, so called shift-assays were carried
out. This method is based on the covalent binding between ABP and deubiquitinase,
resulting in a 10 kDa shift of protein mass, clearly visible on SDS-PAGE.
Given amounts of recombinant HIS6-tagged DUBs (see Table 5) were pre-incubated
in ABP-reaction buffer (50 mM TRIS, 50 mM NaCl, 1 mM DTT and 1 mM ATP
freshly added, pH 8.0) at RT for 15 min. Afterwards, 0.1 - 0.3 µg of the respective
ABPs were added and the samples incubated for 1-2 h at 37°C. To stop the reaction, 4x
reducing probe buffer was added to the samples. Finally, samples were either subjected
60
3 Materials and Methods
to SDS-PAGE or stored at -20°C. To evaluate the shift-assays, an α-HIS antibody was
used in western blotting (Table 4) at a dilution of 1:1000, yielding specific signals for the
reactive DUB population.
3.4.4 Deubiquitination Assay
Recombinant DUBs (2 µg) were pre-incubated in 50 mM NaCl, 50 mM TRIS, 1 mM
ATP, 10 mM DTT, pH 8, for 15 min at RT. Subsequently, 3 µg of K63-linked (Ub4)
tetra-ubiquitin chains were added and the samples were taken directly after mixing and
after 10, 30 and 60 min of incubation to assess the ability of the tested DUBs to cleave
K63-linked Ub-tetramers. The respective aliquots were pipetted into 4x probe buffer to
stop the reaction. After incubation, samples were applied to SDS-PAGE, washed with
water, fixed with 10 % EtOH (tech.) and 10 % acetic acid and stained with colloidal
coomassie according to Kang (0.02 % CBB-G250, 5 % aluminum-sulfate(14,18)hydrate,
10 % EtOH, 2 % orthophosphoric acid) [211]. Therefore, gels were washed with MQ for
15 min, incubated in coomassie solution over night and then destained using 10 % EtOH
(tech.) and 2 % phosphoric acid.
3.4.5 Gel Electrophoresis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out based on a protocol
adapted from Laemmli [212].
To separate proteins for subsequent western blotting, precast NuPAGE® Bis-Tris
gradient (4-12%) gels were run with diluted MOPS SDS buffer utilizing an XCell Sure-
Lock® Mini-Cell (all Thermo Fisher Scientific, Waltham, USA). Before loading, samples
were diluted in Roti-Load 1 reducing sample buffer (Carl Roth, Karlsruhe, Germany),
heated for 3 min at 95°C and centrifuged for 2 min at RT. Subsequently, gels were run
for 50 - 55 min at 180 V. For protein size estimation Page Ruler Plus or Page Ruler
prestained protein ladder were used (Thermo Fisher Scientific).
3.4.6 Western Blotting
After gel electrophoresis, gels were equilibrated in blotting buffer (25 mM Tris Base,
0.192 M glycine, 0.02% SDS, 20 % MeOH (p.a.)) and then transferred onto a polyvinyli-
dene fluoride (PVDF) membrane for western blot analysis [213]. Therefore, the PVDF
membrane was activated in MeOH (p.a.) for 20 sec and also equilibrated in blotting
buffer. For wet-blotting an XCell II™ Blot Module (Thermo Fisher Scientific) was used
with the enclosed sponge pads soaked in blotting buffer. The blotting sandwich contained
4 sponge pads, 2 Whatman paper sheets, the PVDF-membrane and the gel. In the case of
parallel blotting, two membranes and gels were arranged in the blotting cell. The blotting
chamber was then filled with buffer, the outer chamber with MQ. Blot settings differed
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between the applications. For α-HA blots, transfer was carried out at 100 mA, 25 V for
2 h 10 min, for all other blots, transfer was conducted at 30 V with non-restricted mA
for 50 min to 1 h 15 min. After transfer, the membrane was incubated for 1 h in the
appropriate blocking solution (5 % (w/v) skimmed milk in PBS (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2HPO4, pH 7.4 (HCl)) forα-HA blots, 5 % (w/v) BSA
in TBS-T for phospho-Ab blots, 5 % (w/v) skimmed milk in TBS-T for standard blots)
and then incubated with primary antibody o/N at 4°C in blocking solution. A list of all
used antibodies and their respective dilutions is presented in chapter 3.1.1. The next day,
the PVDF-membrane was washed three times for 10 min using distinct washing solutions
(PBS-T (1x PBS, 0.1 % (v/v) Tween 20), and PBS, TBS-T (1x TBS, 0.1 % (v/v) Tween
20) and TBS) and incubated with matching secondary antibodies (Table 3) for 1 h
15 min at RT using 0.5 % BSA/skimmed milk in washing solution. Subsequently, the
blot was washed again as described before. Finally, the PVDF-membrane was developed
utilizing ECL™ Prime Western Blotting Detection Reagent (GE Healthcare, Chalfont St
Giles, UK). Therefore, an 1:1 mix of the luminol and the peroxide solution was pipetted
directly onto the PVDF-membrane and chemiluminescence was detected by a LAS-3000
CCD-camera (Fujifilm).
For incubation with multiple antibodies, blots were stripped by washing with strip-
buffer A (0.2 M glycine, 0.5 M NaCl, pH 2.0 (HCl)) and B (0.5 M Tris, pH 11.0 (NaOH))
for 10 min and intermediate rinsing with washing solution. Afterwards, the membrane
was treated as described above with addition of 0.1 % (v/v) NaN3 to the primary antibody
solution. All acquired images were evaluated using AIDA Image Analyzer, 4.15, Raytest,
Straubenhardt, Germany.
3.5 Methods of Molecular Biology
3.5.1 Transfection, Amplification and Isolation of pcDNA 3.1 c-Met eGFP
The pcDNA 3.1 c-Met-eGFP vector was designed by Małgorzata Szczodrak (PhD thesis,
2009) and kindly made available by Prof. Klemens Rottner (Molecular Cell Biology,
TU Braunschweig, Braunschweig). The vector contains full-length, human c-Met with a
C-terminal peptide linker (PGIHRPVAT) and eGFP as well as ampicilin and neomycin
resistance cassettes and has a size of 11,362 base pairs.
The vector was transfected into E.coli DH5α cells by heat shock transformation.
Therefore, 500 ng of DNA was pipetted to the cells one ice and incubated for 25 min.
Afterwards, the cells were heated to 42°C for 45 sec, cooled on ice for 2 min, plated on
LB-agar plates containing ampicilin and finally incubated o/N at 37°C.
The next day, single colonies were picked for cryo-stocks (5 mL LB culture) and DNA
preparation. For DNA preparation, a 75 mL culture of the picked clone in LB medium
containing 0.1 µg/mL ampicilin was incubated o/N at 37°C. The following day, the cells
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were harvested by centrifugation and DNA was prepared by following the instructions for
Maxi-Preps of the NucleoBond® PC 100 kit (Macherey-Nagel, Düren, Germany) protocol
for high copy-number plasmids. After drying, DNA was resuspended in MQ water. For
the cryo-culture, 1 mL of the o/N culture was mixed with 200 µL of 87 % glycerol and
frozen at -80°C for long-time storage.
Table 12. Primers used to validate pcDNA 3.1 c-Met eGFP sequence utilizing MWG
biotech sequencing service.
Read Primer name direction Primer sequence
1 c-Met seq1 reverse CAAAGGCATGGACATAC
2 c-Met seq2 forward CAGATCATCCATTGCA
3 c-Met seq3 forward GTCAATTCAGCGAAGTC
4 c-Met seq4 forward GCATTTCAATATGCCA
5 c-Met seq5 forward AGTTATGATCTCAATG
6 c-Met seq6 forward TAGCCTGATTGTGCA
7 EGFP – N1 rev reverse MWG standard primer
Sequencing of all construct was performed by MWG-Biotech / Eurofins genomics.
Therefore, 10 pmol/µL of each primer (Table 12) was pre-mixed with with 50-100 ng/µL
DNA in 15 µL total volume and sent to MWG. Evaluation of sequencing data was carried
out using VectorNTI Suite 8.
3.5.2 Site-directed Mutagenesis of c-Met
To produce ubiquitination-deficient variants of c-Met, a site-directed mutagenesis approach
was conducted. Therefore, the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, USA) was used following the instructions of the manufacturer.
In short, 125 ng of mutagenesis primers (Table S3) and 10 ng of the template DNA
were mixed with 10x reaction buffer, dNTPs, Quick Solution and ddH2O and 1 µL of
PfuUltra HF DNA polymerase was added. Subsequently, a PCR was carried out, using
the following program:
• heating to 95°C for 1 min
• 18 cycles of 95°C for 50 s, 60°C for 50 s, 68°C for 12 min
• 68°C for 7 min
• 4°C on hold.
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After PCR, the samples were digested with DpnI for 1 h at 37°C to get rid of the parental
plasmid and then transfected into E.coli XL-10 cells. Therefore, cells were thawed,
mixed with β-mercaptoethanol, incubated (10 min), mixed with the PCR-products and
incubated for 30 min, all on ice. Following heat shock for 30 sec at 42°C, cells were
cooled 2 min on ice and then mixed with pre-warmed LB-medium and incubated for 1 h.
Finally, the LB-suspension was plated onto LB-Agar plates.
For each mutant, 5 clones were picked and DNA was analyzed after preparation using
the respective sequencing primers listed in Table 12 to validate the mutation. One of the
clones with the correct mutation was then sequenced fully.
3.5.3 RT-PCR of Mouse Liver Cytokines
RT-PCR was carried out in cooperation with the working group Medical Microbiology of
Prof. Dirk Schlüter (University hospital (OVGU), Medical Microbiology, Magdeburg).
As a control for infection experiments (3.6.1), cytokine profiles were determined.
Therefore, mRNA form livers of non-infected and L.m.-infected mice was isolated using
an RNAeasy kit (Qiagen). Subsequently, the SuperScript reverse transcriptase kit with
oligo(dT) primers (Invitrogen) was used to transcribe mRNA into cDNA and the RT-
PCR for HPRT, TNF, IL-6, IL-1ß, IL-12 and IL-18 was conducted utilizing a Taqman
gene expression assay (Applied Biosystems) on a Lightcycler 480 system (Roche). The
quantification was carried out following the ∆∆CT threshold cycle (CT) method using
HPRT as the reference gene [214]. Finally, data was then visualized using GraphPad
Prism (GraphPad software, USA).
3.6 Microbiological Methods
3.6.1 Infection of Mice with Listeria monocytogenes
All infection experiments were conducted in cooperation with the working group Medical
Microbiology of Prof. Dirk Schlüter and carried out by Dr. Nishanth Gopala Krishna
(both University hospital (OVGU), Medical Microbiology, Magdeburg).
For proteomic and DUB analyses, female C57BL/6 wild type (wt) mice were infected
with a sub-lethal dose of Listeria monocytogenes(Lm) for 1, 3 and 9 days and compared
to non-infected mice. EGD strain L.m. was grown in Brain Heart Infusion (BHI) broth
(Sigma) and aliquots of log-phase cultures were stored at –80°C. For intravenous infection,
fresh log-phase cultures were prepared from frozen stocks and 1 x 104 L.m. were diluted
in 200 µL PBS (sterile, pyrogen-free, pH 7.4) and then injected into the caudal vein.
After indicated time-points the mice were directly sacrificed or anesthetized and then
sacrificed and livers were dissected and prepared as stated in the individual subsections
(3.6.2, 3.5.3 and 3.2.10). For the proteome work flow (3.7.1), liver pieces were snap-frozen
in 2-methyl-butane and stored at -80°C.
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3.6.2 Determination of Colony Forming Units
CFU-determination was carried out by Dr. Nishanth Gopala Krishna (University hospital
(OVGU), Medical Microbiology, Magdeburg).
Livers for flow-cytometric analysis were partly used to determine the colony forming
units (CFU). Therefore, homogenized (tissue grinder) liver pieces were diluted 10-fold
and homogenates were plated on BHI agar plates. After incubation at 37°C for 24 h,
bacterial colonies were counted microscopically.
3.7 Proteomic Methods
3.7.1 Preparation of Mouse Liver Samples
After infection with L.m. (see section 3.6.1), mice were sacrificed on day 1, 3 and 9 post
inoculation (p.i.) and the livers were snap-frozen in 2-methyl-butane and stored at -80°C.
Upon completion of sampling, the liver pieces were ground using liquid-nitrogen cooled
mortar and pestle, transferred to 2 mL reaction tubes and stored on ice. Subsequently,
the liver powder was subjected to glass-bead lysis as described in subsection 3.4.1.
3.7.2 Peptide Generation for Liver Proteome Studies
After glass-bead lysis (3.4.1) protein lysate accounting for 70 µg protein was diluted
using MQ and precipitated by addition of 100 % EtOH (p.a.) and 88 mM NaOAc, pH
5.0, and incubation o/N at RT. The next day, samples were centrifuged at 14,000×g
for 1 h and air-dried after removing the EtOH/NaOAc mixture. Subsequently, the
pellet was dissolved in iTRAQ® dissolution buffer (0.5 M triethyammonium bicarbonate
(TEAB) and, after addition of reducing agent (1/10 of dissolution buffer volume, 50
mM tris-(2-carboxyethyl)phosphine (TCEP)), incubated for 1 h at 60°C. Next, cysteine
blocking reagent (200 mM methyl methanethiosulfonate (MMTS) in isopropanol) was
added and the sample was incubated for 15 min at RT. After reduction and alkylation,
samples were subjected to tryptic digestion o/N. Therefore, activated (50 mM acetic
acid) sequencing modified trypsin (Promega, Madison, USA) was added to the sample at
a ratio of 1:100 (trypsin:protein) and the sample was incubated at 37°C o/N. The next
day, a small aliquot of the sample was subjected to digestion control via LC-MS/MS
and RawMeat. If digestion control was successful, peptides were subjected to iTRAQ®
labeling (subsection 3.7.3).
3.7.3 ITRAQ-labeling of Peptides
For relative quantification of peptides and proteins, isobaric tags for relative and absolute
quantification (iTRAQ)® were used (SCIEX, Framingham, USA). The labeling allows
mixing of sample and evaluation of the distinct reporters (114, 115, 116 and 117) in the
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LC-MS/MS analyses. All labels are reactive to primary amines and add an isobaric mass
tag of 145 Da to peptides, that will fragment in LC-MS/MS measurements to reveal the
individual reporter groups [215].
To label samples for DUB-enrichment or proteome sample-sets, samples were spun down
for 20 min at 14,000×g and iTRAQ reagents were added to peptides generated either on-
bead and subsequently cleaned (subsections 3.7.7 and 3.7.4) or directly following digestion
(3.7.2), respectively. Samples had to be prepared in dissolution buffer. Subsequently,
ethanol (p.a.) was added to reach a solvent concentration of about 70 %, taking into
account that the reagents are solved in AcN and samples were incubated 3 h at slightly
elevated temperature (25°C) with shaking. After labeling, samples were dried in a
speedvac and in parallel, labeling-efficiency was evaluated via LC-MS/MS analysis. If
the efficiency was greater then 95 % based on the area of the labeled peptides’ MS peaks,
sample preparation was resumed and all samples were subjected to solid-phase extraction
to remove the TEAB-buffer (3.7.4).
3.7.4 Desalting and Clean-up of Peptides
Desalting and clean-up of peptides was carried out using reverse phase (RP) solid-phase
extraction (SPE) cartridges from Waters choosing either 1cc HLB or 3cc HLB columns
(Waters, Milford, USA) guided by the peptide-amount of the samples. Columns were
equilibrated using 100 % MeOH (p.a.), 100 % AcN (p.a.), SPE-buffer B and SPE-buffer
A (0.2 % FA, 0.5 % AcN (A), 60 % AcN (B) in MQ), consecutively. After preparation,
samples were applied onto the column and the flow-through was collected in reaction
tubes. Subsequently, the bound peptides were washed twice with SPE-buffer A and
eluted with SPE-buffer B, utilizing an appropriate pipette to remove all liquid from the
column by pressure. To increase the yield, the flow-through and first wash fraction of the
previous run were applied onto the re-equilibrated column and treated as before. Both
elutions were pooled and dried using a speedvac.
3.7.5 De-complexation of Peptide Samples by SCX
To reduce the sample complexity, peptides were fractionated utilizing strong cation
exchange chromatography (SCX). After peptide clean up (3.7.4 or 3.7.8) previously
dried samples were dissolved in SCX buffer A (25 % AcN, 0.065 % FA) and centrifu-
ged for 20 min 109,000xg to remove impurities. Fractionation was then carried out
using a MonoS-PC1.6/5 column coupled to an Ettan microLC system (Amersham Bios-
ciences (GE Healthcare)) with a SunCollect micro-fraction collector (MALDI spotter,
Sunchrom). The system was operated at a constant flow-rate of 150 µL/min running
a 15 min gradient from 0 % to 35 % SCX buffer B (25 % AcN, 0.065 % FA, 500 mM
potassium chloride) followed by a gradient to 100 % buffer B in 7 min and collecting
fractions continuously minute-wise. For samples with an estimated peptide amount above
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80 µg, two consecutive runs were conducted. Finally, fractions were pooled according to
the approximate peptide concentration to yield 15 final fractions for LC-MS/MS analyses.
After SCX, all fractions were desalted as described in subsection 3.7.4.
3.7.6 HA-immunoprecipitation
After glass-bead lysis and incubation with ABPs as described in subsections 3.4.1 and
3.4.2, samples were further diluted with NET-buffer to reach a final SDS-concentration of
0.1 %. Subsequently, the labeled lysates were filled onto 5 mL spin columns with a 30 µm
pore-size frit (Thermo Scientific, USA) containing 100 µL of pre-washed monoclonal a-HA
agarose beads (Sigma, clone HA-7). The columns were then sealed with PARAFILM®
M (Brand, Germany) on both ends and incubated for 5 h at 4°C constantly rotating at
6 rpm. Hereafter, unbound protein was discarded and the DUB-containing beads were
washed twice with NET-buffer and 100 mM NH4HCO3 by short centrifugation at 200×g.
Control samples for unspecific protein binding were generated using the same work flow
while omitting addition of ABPs in the labeling step. Finally, samples were subjected to
on-bead digestion (subsection 3.7.7).
3.7.7 On-bead Peptide Generation for DUB-enrichment
After DUB-enrichment by HA-IP (3.7.6), samples were digested directly on the HA-
agarose beads. Therefore, a carbamidomethylation utilizing chloroacteamide (CAA) and
dithiothreitol (DTT) was carried out. 20 mM DTT in 0.1 M NH4HCO3 was added
until the buffer level reached twice the height of the bead-bed. Then, the samples were
incubated for 30 min at 56°C, the solution was removed by spinning down and 55 mM
CAA in 0.1 M NH4HCO3 was added. The s18amples were then again incubated for
30 min, this time at RT in the dark, and washed twice with NH4HCO3. Subsequently,
activated trypsin was added to the sample at a ratio of 1:100 (trypsin:protein) and the
sample was incubated at 37°C o/N. The next day, the peptides were eluted twice using
0.1 % FA and a small part of the sample was subjected to digestion-control via LC-MS/MS
and RawMeat. The remaining samples were cleaned as described in subsection 3.7.4
and then subjected to iTRAQ labeling (3.7.3) if digestion had been successful. For the
non-quantitative measurements, samples were directly applied to On-line reverse phase
(RP)-C18 peptide clean-up (3.7.8).
3.7.8 On-line Reverse Phase (RP)-C18 Peptide Clean-up
Directly after combination of the iTRAQ-labeled samples from HA-IP an on-line RP-C18
chromatography was carried out to remove unbound iTRAQ reagents, salt and detergents
from the sample. Therefore, a self-packed PR-C18 column coupled to an Äkta purifier
system with fraction collector Frac-950 was utilized. The column was equilibrated by
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consecutive washing with PR buffer B and A. Subsequently, the sample was injected into
a 2 mL loop by a syringe and flushed onto the column, followed by further washing with
buffer A. For elution, a column volume step gradient from 0 - 100 % RP buffer B (0.1 %
TFA, 60 % AcN, filtered, degassed) was used. Finally, acquired fractions were pooled
according to the UV-spectrum, excluding the detergents, which were eluted as a single
peak after the peptide containing fractions. The desired fractions were then dried for
storage.
3.7.9 Mass Spectrometric Data Acquisition and Protein Identification
Directly before measurement, dried samples were dissolved in 6 % AcN in 0.1 % FA,
sonicated for 5 min at RT and 0.1 % FA was added to a final concentration of 3 % AcN.
Finally, samples were centrifuged at 109,000×g and 4°C for 20 min (SorvallTM Disco-
very MS120SE ultra centrifuge, Hitachi) and transferred into glass vials with screw neck
(Waters) and subjected to mass spectrometry.
Three different mass spectrometry set-ups were used in this study.
1. LTQ Orbitrap Velos (Pro) with
a) Liquid chromatography (LC): UltiMate 3000 RSLC nano LC system
b) pre-column: Acclaim PepMap 100 (75 μm x 2 cm, C 18, 3 µm)
c) analytical column: Acclaim PepMap RSLC (75 μm x 25 cm, C18, 2 µm)
d) software: Chromeleon (version 6.8), Xcalibur (version 2.1)
2. LTQ Orbitrap Velos Pro with
a) LC: Nano Acquity LC system
b) analytical column: Nano Acquity UPLC column (75 μm x 25 cm, C18 ,1.7 µm
BEH130; Waters)
c) software: Xcalibur (version 2.1)
3. an Orbitrap FusionTM TribridTM with
a) UltiMate 3000 RSLC nano LC system
b) pre-column: Acclaim PepMap 100 (75 μm x 2 cm, C 18, 3 µm)
c) analytical column: Acclaim PepMap RSLC (75 μm x 25 cm, C18, 3 µm)
d) software: Chromeleon (version 6.8), Xcalibur (version 3.0.63)
The samples were applied onto the pre-column and washed for 3 min or applied directly
onto the analytical column. Subsequently, the peptides were separated via a gradient from
3.7 - 31.3 % of solvent B (0.1% FA, 80 % AcN) and then electro-sprayed by a stainless steel
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emitter. The mass spectrometer was operated with the parameters described in Table S2
and controlled by Xcalibur and Chromeleon. After detection, raw-files of each experiment
were uploaded to Proteome Discoverer (PD, version 1.4.1.14, Thermo Scientific) or Mascot
Server (2.4.1, Matrix Sciences) [216,217]. If SCX-fractions were measured, all fractions
were merged in one run. Subsequently a database search was carried out by the Mascot
search-engine, either standalone or integrated into PD. The search parameters are listed
in Table 13. After successful DB search and protein identification, datasets were either
analyzed directly in PD or, if the search was conducted with Mascot, loaded into Scaffold
3.6.5 (Proteome Software, USA).
Table 13. Mascot parameters used for protein identification. In the modification rows, let-
ters in brackets state the modified amino acids: K = lysine, C = cysteine, M = methionine.
Letters in brackets behind value denote the analysis setting used in d = DUB-enrichment
(Lm-liver), p = proteome, s = Dub-enrichment from PBMCs m = DUB-enrichment in
method development.
parameter value (p/d) value (s) value (m)
database Swissprot Swissprot Swissprot
release 2014_01 2015_01 2013_01
taxonomy mus musculus
(house mouse)
homo sapiens mus musculus
(house mouse)
enzyme trypsin trypsin trypsin
max. missed cleavage 1 1 1
fixed modifications iTRAQ 4-plex (K)
iTRAQ (N-term)
Methylthio (C)
Carbamidomethyl
(C)
Carbamidomethyl
(C)
variable modifications Oxidation (M) Oxidation (M) Oxidation (M)
precursor mass
tolerance
10 ppm 10 ppm 10 ppm
MS/MS tolerance 0.4 Da 0.4 Da 0.4 Da
3.7.10 Protein Quantification
Protein quantification was carried out for those DUB-enrichment and proteome samples
that were iTRAQ labeled (3.7.3). Regulation factors for the proteins were calculated
by PD using only peptides that met the parameters described in Table 14. PD gene-
rated ratios based on peptide-specific iTRAQ reporter-ion intensities of all 4 channels
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Table 14. Proteome Discoverer (PD) parameters used to filter the datasets and to
validate the reliability of the data. d = setting used exclusively in DUB-enrichment
datasets, p = parameter exclusively used in proteome datasets. If not stated, parameters
were identical in all experiments. FDR = false discovery rate.
parameter PD 1.4.1.14 value parameter Scaffold 3.6.5 value
Peptide confidence high identification probability (idp) 99 %
Peptide rank 1 min. peptide idp 95 %
Peptide score 30 min. spectral count 2
No. of peptides 1 (d/s), 2 (p) No. of peptides (unique) 1
FDR 1 %
Mascot significance threshold 0.02
protein grouping disabled
using channel 115 (non-infected control sample) as standard. The intensities of the
other channels were divided by the standard yielding the following regulation factors:
day 1/day 0: 117/115; day 3/day 0: 114/115 and day 9/day 0: 116/115. The complete
dataset was then exported to Microsoft Excel and the protein regulation factors were
transformed to log2 values, median-normalized and finally analyzed for significantly
regulated proteins.
3.8 Determination of Significantly Regulated Proteins
Significantly regulated proteins were determined in cooperation with Prof. Frank Klawonn
(HZI). Therefore, a “significance test based on a large number of small samples” described
earlier was used [218]. The algorithm is based on the assumptions that regulation
factors of proteins follow a normal distribution and that the random variation of protein
regulation is independent of the true regulation factor. In the first step, a reliable
standard deviation of each samples or time-point was estimated by utilizing the median
absolute deviation from the median (MAD) and aggregating this estimation for all
proteins. Subsequently, a hypothesis test for the identification of significantly regulated
proteins is constructed using the estimated standard deviation σ0. Thereby, the null
hypothesis is that a certain protein is not regulated, having a regulation factor of 0 and
a variance of σ20 [218]. To calculated the p-value for each protein to be significantly
regulated, a threshold (cα) was determined using equation 1 where α = significance level
for the test, k = number of replicates carried out, m = number of replicates in which a
protein is at least found out of k replicates, nm = number of proteins at least found in m
replicates,σ0 = estimated reliable standard deviation utilizing the MAD, varying around
zero. Using the calculated p-values from this test, all proteins with a value smaller than
0.01 were regarded significantly regulated.
cα = σ0 · Φ−1
1− ( α
2 · nm ·
( k
m
)) 1m
 (1)
4 Results
4.1 Detection of Ubiquitination-sites and Deubiquitinating
Enzymes with a Role in InlB-mediated Cell Invasion
The receptor-tyrosine kinase c-Met is the entry-portal of Lm to accomplish cell invasion
of distinct cell types decorated with c-Met. Differentially regulated ubiquitination could
be of crucial importance for this process, however, was not described in the context of
c-Met dependent invasion thus far. For that reason, this study intends to investigate the
role of intracellular ubiquitination sites at c-Met as well as putative DUBs involved in
the deubiquitination of the receptor during activation of c-Met by the Listeria invasin
Internalin B (InlB) in comparison to the physiological ligand hepatocyte growth factor
(HGF). Before ubiquitination-deficient c-Met mutants could be used in the HeLa S3
model system for Lm invasion, the responsiveness to HGF and InlB was tested.
4.1.1 Recombinant HGF and InlB are Suited to Activate c-Met Dependent
Signaling in HeLa S3 Cells
To initially characterize the ability of HeLa S3 cells to be stimulated by either HGF
or InlB as well as to ensure the functionality of the recombinant proteins ahead of
stimulation experiments, a dilution series from 0.02 to 20 nM of both HGF and InlB were
applied to HeLa S3 cells for 5 min and the phosphorylation of c-Met, Erk1/2 and Akt
was monitored. For both stimulants, phosphorylation of c-Met at tyrosine (Y)1235 and
1236 was found to occur at a concentration of 0.2 nM, while activating phosphorylation
at Erk 1/2 was already detected in non-stimulated cells and enhanced at 0.02 nM HGF or
InlB (Figure 18 A). Phosphorylation of a more distal signaling component, Akt, occurred
at a concentration of 0.2 nM HGF and 0.02 nM InlB. Those responses render HeLa S3
cells fully functional for the short-term stimulation with recombinant HGF and InlB
produced in-house and a concentration of 10 nM was chosen for the following experiments.
Responsiveness was examined in the same manner for each new aliquot of HGF and InlB.
Additionally, the intended set-up for transfection experiments of c-Met constructs was
checked regarding the activation of all mentioned components after 5, 10 and 30 min of
stimulation. c-Met as well as Erk 1/2 and Akt were phosphorylated in a time-dependent
manner for both HGF and InlB (Fig 18B). Furthermore, all controls showed diminished
or no signals. The last 4 lanes in Figure 18 B represent a pool of wt samples, either
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non-stimulated [neg(-)], mock-stimulated with cell-medium including protein buffer for
30 min [neg(buffer)], or stimulated for 5 min with HGF or InlB. Those samples were used
to ensure comparability of different blots.
In summary, HeLa S3 cells are readily responding to recombinant, in-house produced
HGF and InlB in a time-dependent manner at a stimulant concentration of 10 nM,
enabling the monitoring of c-Met activation and localization.
Figure 18. Response of c-Met, Erk 1/2 and Akt kinases upon HGF and InlB stimula-
tion in HeLa S3 cells. (A) Stimulation of HeLa S3 cells with a dilution series of HGF
and InlB. (B) Stimulation of HeLa S3 cells with 10 nM HGF and InlB after incubation
with transfection reagent (FUGENE) and subsequent starvation.
4.1.2 Influence of Ubiquitination on Receptor Activation, Signaling and
Localization of c-Met
In total, 13 ubiquitination sites of c-Met are reported in the Phosphosite Plus DB [219]
of which 4 sites are located in extracellular domains of c-Met (Table S1). Of the 9
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remaining sites, 2 are in proximity to the c-Cbl binding site around tyrosine 1003 of
the receptor. To analyze the role of ubiquitination at those sites, i.e K962 and K1103,
ubiquitination-deficient mutants of those sites were produced by replacing the lysine (K)
with an arginine (R). Additionally, K1104, the lysine adjacent to K1103, and K1259,
which was identified in HGF-stimulated HeLa S3 cells (Fig S1) and recently also detected
in mouse tissues [220], was mutagenized.
For mutagenesis, a pcDNA3.1+ c-Met enhanced green fluorescent protein (eGFP)
fusion plasmid that was introduced and kindly provided by Małgorzata Szczodrak and
Prof. Klemens Rottner (TU Braunschweig) was utilized [221]. Mutants for all Ub-sites
mentioned above, as well as a K1103R/K1104R double mutant and a quadruple mutant
of all sites were successfully prepared.
Despite of the large size of the plasmid, rendering it difficult to handle and transfect,
transfection could be established and the rate ranged between 10 and 30 %. The
transfection rates were determined by FACS measurements, taking advantage of the
intrinsic eGFP-signal (subsection 3.2.5 & Fig 17). To pre-characterize the mutants
regarding their signaling-competence, responses of c-Met, Erk and Akt after HGF and
InlB-stimulation were assessed.
4.1.2.1 Pre-characterization of the Influence of c-Met Ubiquitin-deficiency on the
Auto-activation of c-Met and Erk1/2 and Akt Kinase Phosphorylation
The first question pursued was, whether the autophosphorylation of c-Met and downstream
activation of Erk1/2 and Akt by phosphorylation were influenced after 5, 10 and 30 min
of stimulation by HGF and InlB in the mutants as compared to the wt. To evaluate
those signaling components, total c-Met content, tyrosine (Y)1235,1236 phosphorylated
c-Met, phosphorylated Erk 1/2 (Erk 1: threonine (T)202/204; Erk2: T185/187) and
phosphorylated Akt (serine (S)473) were analyzed by immunoblotting.
Auto-activation of c-Met by Phosphorylation: For the normalization of phosphoryla-
ted c-Met originating from the transfected constructs, total c-Met as well as endogenous
c-Met were determined and the mean signal intensity of endogenous c-Met was subtracted
from each sample to yield the amount of expressed c-Met-eGFP construct. This value
was then used to normalize the phosphorylated c-Met signal for each sample, eliminating
differences in transfection efficiency between the different samples.
The non-transfected control cells [control(wt)] as well as the cells only transfected with
a GFP-containing vector [GFP(wt)] showed nearly no phosphorylated c-Met as compared
to the non-stimulated internal control in a resting state (Fig 19A). In contrast to that, wt
c-Met-eGFP [wt(trans)] and all mutant constructs were already highly phosphorylated in
a rested and non-stimulated state. While wt c-Met-eGFP as well as the K1104R, K1259R
and K4xR mutants showed a 20 to 50 fold enhanced activation, K962R phospho-levels
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Figure 19. Activity of transfected and endogenous c-Met in rested cells and after sti-
mulation with HGF and InlB. To asses activation of c-Met, phosphorylation at
Y1235/1236 was monitored after 5, 10 and 30 min of HGF- or InlB stimulation in
comparison to non-stimulated and non-transfected control cells. In graphs, circles
indicate activation levels of endogenous c-Met, while squares specify single amino acid-
exchange mutants. Triangles were used to mark the double and quadruple mutants. (A)
Pre-activation of c-Met without stimulation. The phosphorylated c-Met levels observed
in the constructs after starvation and mock-stimulation (30 min incubation with buffer)
were compared to a non-stimulated internal control. The resulting fold change in
phosphorylated c-Met intensity between control and the non-stimulated but transfected
samples of the mutants is shown. (B) Corrected fold changes of phosphorylated c-Met
intensities as compared to non-stimulated but transfected control (0’) after stimulation
of the sample with HGF for 5, 10 and 30 min. To analyze the activation of transfected
c-Met only, the samples were normalized to the amount of transfected c-Met determined
in anti-c-Met western blots corrected by the mean signal intensities of endogenous
c-Met. (C) Corrected fold changes of phosphorylated c-Met intensities as compared to
non-stimulated but transfected control (0’) after stimulation of the sample with InlB for
5, 10 and 30 min. For normalization, the same method as described in B was applied.
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were increased about 160 fold, and K1103R and K2xR about 1000 fold. Following HGF
or InlB stimulation (Fig 19B&C), the endogenous wt c-Met (circles) showed increased
phosphorylation as expected. In contrast to that, all transfected constructs revealed
insensitivity towards the stimulus with fold changes of the signal intensity around 1.
This, taken together with the pre-activation, indicates a permanent activation of the
transfected c-Met receptor variants for wt and mutants alike, raising the question whether
localization of the constructs resembles the wt c-Met or is disturbed leading to differential
activation.
Activation of Erk Kinases 1 and 2: Downstream of c-Met, the Erk kinases 1 and 2 are
activated upon stimulation with HGF or InlB. To monitor this activation, phosphorylation
of Erk 1/2 at T202/204 and T185/187 was analyzed by western blotting. The blot results
were normalized against signals of the house-keeper protein HSP90 obtained from the
same blots after stripping. Similar to phosphorylated c-Met, Erk 1/2 pre-activation
was analyzed by comparison of signal intensity of p-Erk in transfected, non-stimulated
samples compared to the internal non-stimulated control signal of endogenous p-Erk.
Pre-activation of Erk was found to be relatively low as compared to the pre-activation
of c-Met for most of the constructs (Fig 20A). Solely, the quadruple mutant K4xR
showed a fold change in intensity of about 100, indicating severe pre-activation. After
stimulation of cells containing transfected wt c-Met-eGFP with HGF (Fig 20B) or InlB
(Fig 20C), p-Erk signal intensities matched those of wt cells (HGF) or were at least
similar (InlB). This might indicate that the transfected c-Met wt protein, although
pre-activated, does not influence the downstream signaling after stimulation. The p-Erk
signal of cells expressing mutant c-Met, except for K1103R and K4xR, also showed similar
behavior as non-transfected cells but revealed a tendency towards a quenched signal after
stimulation. For the K4xR mutant, p-Erk signal intensity showed no additional increase
after HGF (Fig 20B) or InlB stimulation (Fig 20C). Thus, the transfected cells were
rendered insensitive to Erk-activation, which is probably due to the high pre-activation
level of the K4xR transfected cells.
Activation of Akt Kinase: The third signaling component monitored for activation was
Akt, which is phosphorylated at serine 473 when activated by c-Met induced processes.
The phosphorylated form was monitored by western blotting and signal intensities were
normalized to the housekeeper protein HSP90. In contrast to c-Met and Erk, Akt showed
only mild pre-activation (Fig 21A). The highest fold changes in pre-activation were found
for the K2xR and K4xR mutants, with 5 and 3.4 fold, respectively. All other mutants
and the transfected wt showed levels comparable to the increase in p-Erk. Notably, after
stimulation with HGF, the course of the p-Akt signal of the K2xR mutant was similar
to the endogenous signal (Fig 21B, white triangles/circles), although the same mutant
showed the highest pre-activation. Additionally, both the wt and K2xR signals peaked
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Figure 20. Activation of Erk 1/2 following stimulation of endogenous and transfected
c-Met. Phosphorylation of Erk 1/2 at T202/204 and T185/187 was analyzed after
stimulation with HGF or InlB for 5, 10 and 30 min in comparison to non-stimulated
and non-transfected cells. In graphs, circles indicate endogenous c-Met, while squares
specify single amino acid-exchange mutants. Triangles were used to mark the double
and quadruple mutants. (A) Pre-activation of Erk without stimulation by HGF or InlB.
The p-Erk 1/2 levels observed after starvation and mock-stimulation (30 min incubation
with buffer) were compared to a non-stimulated internal control. (B) Fold change of
endogenous p-Erk 1/2 intensities as compared to non-stimulated but transfected control
(0’) after stimulation of the sample with HGF for 5, 10 and 30 min. (C) Fold change
of endogenous p-Erk1/2 intensities as compared to non-stimulated but transfected
controls (0’) after stimulation of the sample with InlB for 5, 10 and 30 min.
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Figure 21. Activation of Akt after stimulation in comparison to non-stimulated and
non-transfected cells. Phosphorylation of Akt at S473 was analyzed after stimulation
with HGF or InlB for 5, 10 and 30 min in comparison to non-stimulated and non-
transfected cells.All values were normalized to the house-keeper protein HSP90, obtained
from the same blots as p-Akt. (B&C) Circles indicate endogenous c-Met, while squares
specify single amino acid-exchange mutants. Triangles were used to mark the double
and quadruple mutants. (A) Pre-activation of p-Akt without stimulation by HGF
or InlB. The p-Akt levels observed after starvation and mock-stimulation (30 min
incubation with buffer) were compared to a non-stimulated internal control. (B) Fold
change of endogenous p-Akt intensities as compared to non-stimulated but transfected
control (0’) after stimulation of the sample with HGF for 5, 10 and 30 min. (C) Fold
change of endogenous p-Akt intensities as compared to non-stimulated but transfected
controls (0’) after stimulation of the sample with InlB for 5, 10 and 30 min.
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at 10 min, while the other samples reached the highest signal intensity at 5 min HGF
stimulation. In InlB-stimulated cells (Fig 21C), the mutant signal was found to be even
higher than the wt with an increase of about 80 fold over the control time point. All
other constructs induced only a quenched phosphorylation of Akt with a peak at 5 min
and a steep decline of the signal afterwards regardless of the stimulant. This behavior was
also found for both samples only containing endogenous c-Met [control(wt) and GFP(wt)].
In summary, the analysis of phosphorylated c-Met, p-Erk and p-Akt indicated that the
down-stream signaling was altered by some of the amino-acid exchanges, especially in
the double and quadruple mutants which showed distinct reactions of p-Erk and p-Akt
after stimulation. For K4xR, the results hint towards a permanent activation of c-Met
and Erk 1/2 with a pre-activation of Akt and thus the signaling cascade downstream of
c-Met. In contrast to that, for K2xR a high pre-activation of c-Met was found, with only
small influence on p-Erk but a seemingly hyper-activated Akt reaction.
The data needs to be substantiated by biological replicates or further experiments in
knock-out cells to make more definite statements regarding the influence of ubiquitin-
deficiency on the activation of the signaling cascade. Additionally, the results indicate a
differential activation of all transfected c-Met constructs, implying the need to analyze
the localization of c-Met in stimulated and non-stimulated cells.
4.1.2.2 Cells Containing Transfected wt c-Met-eGFP Show Differences in
Signal-intensities in HeLa S3
To analyze the localization of the site-specific ubiquitination-deficient mutants of c-
Met, epifluorescence microscopy was utilized, taking advantage of the intrinsic green
fluorescence of the constructs. As a first step, the localization of the wild-type c-Met-eGFP
construct was evaluated. Analysis of the samples revealed more than one population of
c-Met-eGFP positive cells (Fig 22A). Importantly, those populations and control cells
were found in one image and therefore, allowed direct comparison to each other.
Among the cells carrying the transfected wt c-Met-eGFP, the most obvious population
were highly expressing cells (Figure 22). In those cells, both endogenous and transfected
c-Met localized to the surface of the cells. Additionally, a perinuclear green fluorescent
signal, which was described for this vector before [221] and furthermore only incompletely
recognized by the anti-c-Met antibody (red channel), was encountered.
The second population of cells showed an intermediate expression of c-Met-eGFP
(Fig 22C). Cells with this expression level showed a similar surface-localization as the
high-expressing cells with a part of transfected c-Met also localizing to the perinuclear
region. In contrast, in non-transfected HeLa S3 cells, which were neither starved nor
explicitly stimulated, c-Met localized in pit-like structures (Fig 22D).
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Figure 22. Localization-analysis of wild type c-Met-eGFP in high and intermediate
expressing HeLa S3 cells. HeLa S3 cells were transfected with a wild-type c-Met-
eGFP plasmid, fixed after 48 h and finally evaluated by epifluorescence microscopy.
(A-D) The left panel shows the signal of the transfected c-Met-eGFP fusion (green in
merged images). The middle panel shows the signal of total endogenous and transfected
c-Met stained with a monoclonal Ab against c-Met (red in merged images). The
merged images additionally depict the DNA content of the cells stained by DAPI
(blue). (A) Overview of a typical image of transfected HeLa S3 cells. The lettered
white squares represent the approximate clippings of the three following panels. (B)
Highly expressing transfected cell showing c-Met membrane-localization and perinuclear
signal. (C) Cells expressing c-Met-eGFP with an intermediate intensity as compared
to the non-transfected cells. (D) Non-transfected control cells from the same image as
transfected cells show a typical c-Met localization in vesicle-like structures.
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This “unrested” localization of endogenous c-Met is triggered by some components of
the FCS used, which are able to activate c-Met.
In summary, two expression levels of wt c-Met-eGFP were found in transfected cells.
Both of them showed a surface-localization of c-Met, which does not resemble the
observed localization of endogenous c-Met but rather a localization assumed for starved
cells. However, as differences in signaling after stimulation were observed, the localization
of wt c-Met-eGFP after HGF and InlB stimulation will be analyzed.
4.1.2.3 In Cells with Low Expression Levels, Wild-type c-Met-eGFP and
Endogenous c-Met Co-localize
Following stimulation with 10 nM HGF or InlB for 30 min, cell populations were evaluated
regarding localization of the transfected, wt c-Met-eGFP compared to the endogenous
receptor (Figs 23 & 24).
After 30 min of stimulation with HGF, endogenous c-Met showed perinuclear localiza-
tion in pit-like structures (Fig 23A, white arrow). In general, transfected cells exhibited
an extensive co-localization of endogenous and transfected c-Met as seen by the yellow
color in the merged images. The high amount of transfected c-Met is probably influencing
the localization of endogenous c-Met, which would explain the localization deviating from
the endogenous wt in non-transfected cells.
Highly c-Met expressing cells displayed an unchanged surface localization, as highlighted
by the white arrow (Fig 23B), and an additional perinuclear signal for both c-Met variants.
The intermediate-expressing cell population showed a two-part localization of c-Met
(Fig 23C). A fraction of c-Met localized at the cell-tips (white arrows) while the major
part of transfected c-Met was allocated in vesicle-like structures (yellow arrows). During
data evaluation, a third transfected cell population was detected (Fig 23D). Some cells
expressed the transfected c-Met at low levels just above the auto-fluorescence-signal of
HeLa S3 cells. Those cells showed a only slightly enhanced total c-Met content and could
only be observed in stimulated cells after 5 to 10 min stimulation (data not shown),
probably due to the formation of the pit/vesicle-like structures. In HGF stimulated, low
expressing cells, c-Met localized in structures (white arrows) analogous to non-transfected
cells (yellow arrows) (Fig 23D). Again, both c-Met variants co-localized in the vesicles
indicating comparable dynamics.
After InlB-stimulation for 30 min, the non-transfected cells showed a comparable c-Met
localization as the HGF-stimulated cells forming pit-like structures (Fig 24A). Here,
too, the highly expressing cells showed a membrane-localization of c-Met (Fig 24B). In
contrast, the cells with an intermediate c-Met-eGFP expression level showed only a weak
surface-localization (white arrows) and vesicle-like structures (yellow arrows) in which
endogenous and transfected c-Met co-localized as seen in the merged image (Fig 24C).
Not only among HGF-stimulated but also in InlB-stimulated cells, low level-transfected
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Figure 23. Localization of wild-type c-Met-eGFP in HeLa S3 cells after 30 min HGF-
stimulation in high, medium and low-expressing cells. Cells were starved for
24 h and then stimulated with 10 nM HGF for 30 min. After fixation, cells were
stained with anti-c-Met antibody and DAPI. (A) c-Met localization in non-transfected
HeLa S3 cells stimulated with HGF for 30 min. c-Met was confined to vesicle-like
structures as indicated by the white arrow. (B) Typical, highly c-Met-eGFP expressing
cell. Although the cells were HGF-stimulated, they do not show the wt phenotype
presented in A but surface localization of c-Met (white arrow). (C) Representative cells
with a intermediate expression of wt c-Met-eGFP. White arrows indicate localization
at the cell-tip. A part of the c-Met receptors also localized vesicular (yellow arrows).
(D) Cells with a low expression of c-Met-eGFP. Those cells showed a wild-type like
localization of c-Met in vesicular structures (white arrows). Yellow arrows indicate the
same structures in a neighboring non-transfected cell.
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Figure 24. Localization of wild type c-Met-eGFP in HeLa S3 cells after 30 min InlB-
stimulation in high, intermediate and low-expressing cells. (A) Distribution
of wt c-Met in non-transfected control cells after InlB-stimulation. Cells show pit-
like structures with enhanced c-Met signals (white arrow). (B) Representative cell
with a high expression-level of wt c-Met-eGFP. The white arrow indicates the surface-
localization of endogenous and transfected c-Met. (C) c-Met allocation in cells with
an intermediate expression level. Both localizations, surface (white arrow) and in
vesicle-like structures (yellow arrows) were found in those cells. (D) Cells with a low
expression level of c-Met-eGFP after InlB-stimulation. Both, wild-type (yellow arrows)
and transfected cells (white arrow) showed the same localization of c-Met in pit-like
structures after InlB-stimulation.
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cells were identified (Fig 24D). Those cells displayed a c-Met localization in vesicle-like
structures (white arrows) which compared well to c-Met structures in non-transfected
cells (yellow arrows).
In summary, cells transfected with wt c-Met-eGFP formed three distinct populations
regarding the strength of c-Met expression. While the highly and intermediately expressed
c-Met levels were detectable in non-stimulated and stimulated cells, low-expressing cells
could only be monitored after stimulation with HGF or InlB. Stimulated cells with high
or intermediate levels of c-Met-eGFP showed distinct localizations of c-Met, which were
deviating from c-Met localization in non-transfected cells but consistent between HGF
and InlB. For both, physiological and pathogenic effector stimulation, cells with low
levels of c-Met-eGFP showed wt-like receptor localization. Therefore, this population
was analyzed for differences in localization of the ubiquitination-deficient site-directed
mutants of c-Met.
4.1.2.4 Ubiquitination-deficiency Does Not Influence c-Met Localization after HGF
or InlB Stimulation in HeLa S3 Cells
Subsequent to the characterization of the wild-type c-Met-eGFP construct, the localization
of all site-directed mutants of c-Met was investigated to clarify whether the Ub-deficiency
has an influence on the receptor-localization after stimulation. In general, all mutants
showed a strong co-localization between endogenous and transfected c-Met and displayed
expression profiles and localizations described for the wt in the previous subsection (data
not shown).
For localization-analysis, only transfected cells with low level of c-Met-eGFP expression
were utilized, as the localization of c-Met in those cells closely resembled that of wt c-Met.
High and intermediate expressing cells either showed surface or mixed localization as
described before for the wt c-Met-eGFP construct (data not shown).
To evaluate the mutants with a exchange of lysine (K) 962, 1103, 1104 or 1259 to
arginine (R) as well as the double mutant of K1103R and K1104R (K2xR) and the
quadruple mutant (K4xR) for their localization following stimulation, all constructs were
transfected and analyzed after 30 min of 10 nM HGF or InlB-stimulation.
Endogenous c-Met localized in vesicle-like structures in proximity to the nucleus
after stimulation (Fig 23A & 24A) and all HGF-stimulated mutants showed a similar
localization of transfected c-Met in pit-like structures and no additional red signals for
the endogenous c-Met population (Fig 25).
In accordance with the observations for the HGF-stimulated cells, all mutants stimula-
ted with InlB at the same concentration for 30 min showed the same vesicular localization
(Fig 26). Here, too, localization of endogenous and transfected c-Met was the same,
as represented by the yellow color occurring in the merged images. Notably, in most
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Figure 25. Localization of ubiquitination-deficient c-Met mutants in HGF-stimulated
HeLa S3 cells. All cells were stimulated with 10 nM HGF for 30 min and stimulation
was arrested by addition of 4 % PFA. Subsequently, cells were stained for c-Met (red
channel) and DNA content (blue channel). Additionally, all shown cells expressed the
respective mutagenized c-Met receptors at low levels. Yellow color in the merged image
indicates co-localization while red indicates exclusive localization of endogenous c-Met.
Green signals account for either autofluorescence of HeLa S3 cells or perinuclear c-Met
fragments, which were not labeled by the antibody .
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Figure 26. Localization of ubiquitination-deficient c-Met mutants in InlB-stimulated
HeLa S3 cells. All cells were stimulated with 10 nM InlB for 30 min and stimulation
was arrested by addition of 4 % PFA. Subsequently, cells were stained for c-Met (red
channel) and DNA content (blue channel). Additionally, all shown cells expressed the
respective mutagenized c-Met receptors at low levels. Yellow color in the merged image
indicates co-localization while red indicates exclusive localization of endogenous c-Met.
Green signals account for either autofluorescence of HeLa S3 cells or perinuclear c-Met
fragments, which were not labeled by the antibody.
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cells solely green signals were detected. This might either be due to autofluorescence
of the HeLa S3 cells, a degraded c-Met population not detected by the antibody or a
portion of free eGFP. However, those signals were not considered for the analyses of
c-Met localization.
In summary, all mutants analyzed, i.e. K962R, K1103R, K1104R, K1259R, K2xR
and K4xR, showed no obvious differences in localization as compared to wt c-Met when
stimulated with 10 nM HGF or InlB for 30 min. The major signals in vesicular structures
showed clear yellow color in merged images. As no solely red signals were detected in
transfected cells, it is concluded that the receptor internalization of the ubiquitination-
deficient c-Met mutants was comparable to the wt and did not show impaired or shifted
dynamics. Furthermore, no difference was observed between HGF and InlB as a stimulant.
However, attention should be paid to the fact that the experiments were carried out in
cells containing endogenous c-Met. Additionally, the influence of c-Met ubiquitination
onto the recycling or degradation of the receptor requires further discussion.
4.1.3 Regulation of c-Met Receptor Ubiquitination by DUBs
Not only addition of ubiquitin but also its removal by DUBs contributes to the balance
of ubiquitin-mediated processes. For c-Met, no DUB which is directly involved in c-Met
deubiquitination was described so far. However, knock-out of USP8 (UBPY) in mice
produced a phenotype of impaired c-Met recycling [222] and A549 cells from a panel
of DUB knock-outs reacted differentially to HGF stimulation [137]. To tackle this gap
in knowledge, potential candidate DUBs were analyzed regarding their co-localization
with c-Met. In order to do this, HeLa S3 cells were stimulated with HGF or InlB and
subsequently analyzed for c-Met and candidate DUB localization by epifluorescence-
microscopy.
4.1.3.1 Regulated Phosphorylation Sites of VCPIP1 & USP8 Do Not Influence
DUB Localization after HGF- and InlB-stimulation
To obtain a first clue as to which DUBs might be responsible for c-Met deubiquitination, a
phosphoproteome study of HGF-stimulated cells was analyzed for DUBs with significantly
regulated phosphosites [223]. The study revealed a downregulation of S768 on the DUB
VCPIP1 after stimulation, rendering VCPIP1 a potential candidate for further localization
experiments. Additionally, on USP8, S452 was found to be upregulated. Therefore,
VCPIP1 and USP8-localization were analyzed in this study.
VCPIP1: The 0 min (neg) control sample illustrates the cell membrane localization
of c-Met after resting of the cells (Figure 27 ). Controls to assess the influence of the
buffer in which HGF and InlB were solved, were also conducted and showed no difference
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to the negative control (Suppl. Fig S3 & S4). Following stimulation by HGF or InlB,
c-Met clustered in vesicle-like structures after 5 min with a peak at 30 min followed by a
beginning recycling to the cell membrane at 60 min (Fig 27). In contrast, the VCPIP1
signal (red) was found to be distributed evenly throughout the cells with a signal-increase
few bright, dot-like signals in the nuclear compartment.
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Figure 27. VCPIP1 localization during
HGF and InlB stimulation in HeLa
S3 cells. HeLa cells were stimulated with
10 nM HGF or InlB for the indicated time
periods and subsequently stained for c-Met
(green), VCPIP1 (red) and DNA content
(blue). Finally, samples were analyzed by
epifluorescence microscopy. The white bar
represents 10 µm. The negative control
[0 min(neg)] shows cells which were only
starved, but not stimulated. For both, HGF-
and InlB-stimulated cells, the typical c-Met
vesicular structures were observed after
30 min of stimulation. For VCPIP1, no
major changes in localization and no direct
co-localization with c-Met were observed.
Additional time points and controls are
provided in the Appendix (Figures SS3 &
SS4).
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The Human Protein Atlas (HPA) [224,225] denoted a probably cell-membranous loca-
lization for VCPIP1, while UniProt gene-ontology (GO) annotation states a cytoplasmic
and endoplasmic reticulum localization. During the course of stimulation with HGF or
InlB monitored (Fig 27 and Suppl. Figs SS3 & SS4), for VCPIP1 (red channel) neither
a change in its localization nor co-localization with c-Met was observed. Those results
indicate, that VCPIP1 is an unlikely regulator of c-Met receptor ubiquitination.
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Figure 28. USP8 localization during
HGF and InlB stimulation in HeLa
S3 cells. HeLa cells were stimulated with
10 nM HGF or InlB for the indicated time
periods and subsequently stained for c-Met
(green), USP8 (red) and DNA content
(blue). The white bar represents 10 µm.
The negative control (0 min(neg)) shows
cells which were only starved, but not
stimulated. For USP8, no major changes in
localization and no direct co-localization
with c-Met were observed. Additional time
points and controls are provided in the
Appendix (Figs S5 & S6).
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USP8: The second candidate DUB, USP8, was also analyzed for its localization regar-
ding c-Met in the same way as described above for VCPIP1. In general, c-Met showed the
typical reaction to activation with its ligand as described before (Fig 28; Suppl. Figs S5 &
S6). In contrast, USP8 signals were found to be broadly distributed within the cells with
higher intensities in the nuclear compartment, similar to VCPIP1. The HPA specified
a localization in Golgi apparatus and cytoplasm, while UniProt GO annotations for
subcellular localization hint to a more global distribution, including not only cytoplasm,
but also nucleus and various membranes, which matches the localization found in the
HeLa S3 cells. Notably, the localization of USP8 did not change during the stimulation
with HGF or InlB. Additionally, no visible co-localization to c-Met occurred, although
USP8 was described to be involved in RTK-recycling for other receptors.
In summary, neither VCPIP1 nor USP8 displayed a re-localization in response to HGF
or InlB stimulation for up to 1 h. Furthermore, although c-Met showed accumulation in
vesicles up to 30 min and subsequent recycling to the membrane and thereby excessive
reallocation within the cell, no co-localization between the DUBs and c-Met was detected
in this setup.
4.1.3.2 c-Met-specific Ubiquitin-isopeptide Probes Define DUB Candidates for
c-Met Deubiquitination
As the preceding investigations did not detect a DUB directly interacting with c-Met,
a complementary approach to identify further DUB candidates was applied. To this
end, the in-house developed concept of Ubiquitin-Isopeptide probes (UIPPs) was applied.
These probes harbor a reactive group, which links the probe covalently to active DUBs
and uses the peptide sequence of the substrate to generate specificity (Fig S17A) [95]. In
case of c-Met, 4 peptide-warheads containing c-Met sequences surrounding the lysines
also chosen for mutant-generation (K962, K1103, K1104 and K1259) were produced
successfully (Table 10). However, only the c-MetK962-UIPP could be produced in a
sufficient amount for further analyses due to ligation-difficulties accounted for by the
high hydrophobicity of the peptide warheads.
To explore the binding of DUBs towards the c-MetK962-UIPP, the probe was incubated
with a panel of recombinant DUBs and analyzed by immunoblotting. Four USPs, two
UCHs and one OTU-family DUB were able to bind the probe (Fig 29), while all other
DUBs utilized showed no activity towards the c-MetK962-UIPP (Suppl. Fig S17). Of
those, the catalytic domain of USP2 showed the most prominent binding, while CYLD
and USP21 showed only relatively faint shifted bands. (Fig 29B). The same is valid for
BAP1, USP15 and OTUB1, which exhibited only extremely weak activity towards the
c-MetK962-UIPP resulting in a hardly visible shifted band (Fig 29C). Therefore, those
DUBs were assumed to be not specifically reactive towards the sequence surroundings of
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K962 of c-Met. The last binding DUB, UCHL3, showed a good reactivity towards the
UIPP (Fig 29C), but as UCHL3 does not process poly-Ub chains in vitro [56, 226] and is
likely to cleave ubiquitinated peptides [227], it was not considered to be of particular
interest.
However, CYLD, USP2 and USP21 were included for further investigation of their
binding towards the ubiquitinated c-Met RTK by immunofluorescence microscopy, as
the binding to the UIPP suggests a deubiquitinating activity against the c-Met sequence
surroundings.
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Figure 29. Reactivity of recombinant DUBs towards the c-Met K962-UIPP. (A) Scheme
of c-Met-UIPP, presenting the structure of the UIPP as well as surroundings and
assumed PTM-situation of c-Met after activation. (B) DUBs with a clear shift for
c-MetK962-UIPP. (C) DUBs that also showed a shift, but were not included in further
experiments. (B&C) All DUBs were incubated with the c-MetK962-UIPP for 1 h at
37°C. Subsequently, the samples without (control) and with probe were applied to
SDS-Page and western blotting. The DUBs were detected by an α-HIS6 antibody. The
full panel is presented in Figure S17. A second band above the original one (DUB in
control) indicates binding of UIPP and DUB, thus leading to the shift in MW.
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4.1.3.3 Two of the Three Candidate DUBs, USP21 and CYLD Show
Localization-changes during InlB-stimulation
USP21: The first candidate, USP21 showed a mitochondrial localization (Fig 30 and
Suppl. Fig S9). Notably, USP21 was only described as localized in cytoplasm and nucleus
(HPA) as well as microtubule-associated and centrosomal [228] in different cell lines before.
Beginning as early as 5 min after stimulation, USP21-positive structures formed brighter
spots in the perinuclear area of the cell. At 10 to 30 min InlB a relatively small portion
of c-Met is found to be re-localizing to this USP21-intense area as indicated by the white
arrows in Figure 30. Although the merged image showed yellow and orange coloring
in that area, it is not certain whether c-Met and USP21 directly interact with each
other. The interaction would have to be validated either by high-resolution microscopy
or IP-experiments. However, it is interesting to speculate about the role of the small
portion of c-Met which is found in vicinity to USP21 after InlB stimulation.
USP2: For USP2, the observed cytoplasmic localization is in accordance with the
data from Human Protein Atlas and UniProt KB. The DUB showed this localization
throughout all stimulation experiments without any visible re-localization (Suppl. Fig S7).
In contrast, c-Met showed the typical re-localization after stimulation as described before.
However, no co-localization between c-Met and USP2 was observed at the monitored
time points following InlB stimulation in this study.
CYLD: The third candidate, CYLD, also showed a cytoplasmic and additional nuclear
localization within high and lower expressing cells, but no visible co-localization to c-Met
(Fig 31 & Suppl. Fig S8). However, starting at 20-30 min of InlB-stimulation, CYLD
formed dot-like structures of higher fluorescence in the nucleus (white arrows) while at
earlier time points and in the controls, the nuclear CYLD was found to be more evenly
distributed (red arrows) (Fig 31). Following the course of stimulation to 60 min, some
nuclei showed those structures while others (yellow arrows) revealed a lower intensity in
nuclear CYLD signals. In summary, although CYLD does not co-localize with c-Met after
InlB-stimulation, its localization is influenced by the stimulation in an InlB-dependent
manner after c-Met activation. As CYLD is already known to regulate NF-κB activation
in infection and immunity (subsection 1.2.2) and additionally has a severe influence on
Lm infection in vivo (subsection 1.2.2.1) the relocalization could be a manifestation of
a function CYLD exhibits during the early Lm invasion processes. It would be of high
interest to characterize the c-Met dependent invasion of Lm into CYLD-knockout cells.
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Figure 30. Localization
of USP21 at different,
sequential time points of
InlB stimulation in HeLa
S3 cells. All cells were
stimulated with 10 nM InlB
for the indicated time periods.
Subsequently, stimulation was
stopped by fixation of cells.
Finally, the cells were stained
for c-Met (green), USP21(red)
and DNA content (blue) and
USP21-localization was evalua-
ted. The white bar represents
a scale of 10 µm. The 0 min
(neg) sample was only rested
but not stimulated. White
arrows indicate spatial overlap
of c-Met and USP21 signals
resulting in orange/yellow
signals in the merged images.
Additional time points and
controls are provided in the
Appendix (Suppl. Fig S9).
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Figure 31. Localization
of CYLD at distinct time
points of InlB stimulation in
HeLa S3 cells. All cells were
stimulated with 10 nM InlB for
the indicated time periods. Sub-
sequently, stimulation was stop-
ped by fixation of cells. Fi-
nally, the cells were stained for
c-Met (green), CYLD (red) and
DNA content (blue), and CYLD-
localization was evaluated. The
white bar represents a scale of
10 µm. The 0 min (neg) sample
was only rested but not stimu-
lated. Red arrows indicate the
nuclear localization before and
at the beginning of stimulation.
Starting with 30 min of InlB tre-
atment, CYLD accumulates in
dot-like structures in the nucleus
(white arrows). At 60 min after
stimulation, some nuclei show the
same accumulation, while others
(yellow arrows) show weaker sig-
nal intensities. Additional time
points and controls are provided
in the Appendix (Figure S8).
4.2 Systemic Lm Infection - Hepatic Protein Responses in
Murine Listeriosis
Although the infection cycle of Listeria monocytogenes (Lm) is a well known, information
regarding the systemic host responses towards Lm infections is missing. As Lm is able to
cross several tissue barriers and to cause systemic infections, the analysis of a whole organ
is of interest to understand the influence of Lm infection on the host proteome. One of the
main sites of infection following spread of bacteria through the bloodstream is the liver.
All infections and the following experiments to characterize the liver infection (CFUs,
FACS, RT-PCR) were carried out by Dr. Nishanth Gopala Krishna in cooperation
with Prof. Dirk Schlüter (both University hospital (OVGU), Medical Microbiology,
Magdeburg).
This part of the study intends to characterize the hepatic protein response to Lm
infection for the first time, to achieve 3 major goals:
1. to evaluate the suitability of this mouse infection model for a mass spectrometric
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analysis of the hepatic protein response and to pre-characterize the chosen time-
points regarding their immune-cell population and cytokine profiles,
2. to unveil host proteins involved in the pathophysiology of Lm infection and bacterial
clearance,
3. to analyze the influence of Lm infection onto the physiological liver processes,
4. and to reveal Ub and UBL-system components implicated in the regulation of Lm
infection on the side of conjugation and deconjugation.
4.2.1 Sub-lethal Listeriosis Features Immune Cell Infiltration and Dynamic
Cytokine Responses
To reach the first goal, colony-forming units (CFUs), cytokine profiles and immune cell
content of murine liver samples were determined. Therefore, mice were inoculated with
1× 104 bacteria and livers were harvested after 1, 3 or 9 days of infection. In general, the
Listeria amounts in the livers were well-comparable between the different replicates of
each time point. For day 1 p.i., the CFUs resembled the initial Lm amounts accumulating
in the liver after infection. Subsequently, the CFUs rose as bacteria were replicating in
the liver and then diminished between day 3 and 9 as clearance was setting in (Fig 32A).
4.2.1.1 Characteristics of Leukocyte Populations Define Innate and Adaptive
Phases of Infection
During the activation of the host-defenses, immune cells infiltrate the liver tissue. Analysis
of innate immune cells (Fig 32B) revealed that only macrophage (MΦ) numbers showed
dynamics directly congruent with the CFUs peaking at day 3. On the contrary, inflam-
matory monocyte (Mo), neutrophil (Neu), dendritic cell (DC) and natural killer cell (NK)
counts gradually increased throughout the monitored time-points. NK cells represented
the largest set of innate immune cells with about 36 % of all detected innate cells and
displayed an early accumulation. While monocytes and neutrophils also accumulated
directly after inoculation, DC numbers increased mainly between day 3 and 9 p.i.
As it is described for Lm infection, that monocytes differentiate into DCs after encounter
of Lm and prime CD8+ T cells [229], the late cell dynamics of monocytes and DCs are
sensible. Besides the innate cells, major adaptive immune cells were also monitored
as presented in Figure 32C. All three sets of cells, B cells, CD4+ T cells and CD8+ T
cells accumulated rapidly between day 3 and 9, marking the onset of adaptive responses
towards the Lm infection. In general, all of those cell populations presented higher
numbers than the innate cells and showed comparable amounts of about 5× 106 cells per
population.
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Figure 32. Characterization of the course of Lm infection in murine liver samples. (A)
CFUs after inoculation during the course of infection. (B & C) Major immune cell
sets in infected livers after inoculation. Cells were isolated and CD45 positive cell
populations were analyzed by FACS. Bars represent the extreme values with the line
representing the mean of 4 measurements. (B) The liver samples were examined for
macrophages (MΦ), inflammatory monocytes (Mo), neutrophils (Neu), dendritic cells
(DC) and natural killer cells (NK) numbers. MΦ numbers peaked at day 3 and then
decreased towards day 9. In contrast to that, DC numbers increased mainly at the
latest time point. All other innate cell populations increased throughout the stages
of infection and showed the strongest increase at day 1 as compared to uninfected
mice. (C) The liver samples were also monitored for B cells, CD4 positive and CD8
positive T cells. Those adaptive cells also accumulated throughout the infection, with
a saltatory increase between day 3 and day 9 especially for effector T cells and reached
higher amounts than the innate cell populations. (D-I) Cytokine expression patterns
in the liver following Lm infection. The expression was determined by RT-PCR and
is depicted as the increase in the level of mRNA over uninfected controls. All single
measurements are given as well as the mean. (D) IL-6 expression was high at day 1
and 3 p.i. and then decreased as anticipated for a regulator of acute-phase response.
(E-H) The expression of TNFα, IFNγ, IL-1β and IL-12 reached a peak at day 3 p.i.,
representing the typical response towards an infection. (I) IL-18 expression showed
only slight increase of expression at all time points.
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4.2.1.2 Cytokine Profiles of Sub-lethally Infected Livers are Highly Dynamic
Apart from the infiltrating cells, cytokine expression profiles (Fig 32D-I) were utilized to
further characterize the state of the experimental system. As anticipated for a regulator
of the acute-phase response, expression levels of IL-6 were highest at day 1 and 3 p.i.
with a mean increase of about 10 and 11 fold, at day 1 and 3 respectively and dropped
back to the level of uninfected control liver samples at day 9 (Fig 32D). In contrast to
that, TNFα, IFNγ, IL-1β and IL-12 showed a more bell-shaped fold-change of expression,
which was already elevated at day 1, peaked at day 3 and diminished then towards day 9.
The only cytokine in the panel which showed only slight expression changes was IL-18
(Fig 32I). At a more general perspective it became visible, that all cytokine expression
profiles varied considerably, if the individual measurements were considered. Thus, beside
the mean, all single results of the liver samples also used for proteomic analysis are
presented (Fig 32D-I).
In summary, the raised data illustrate the suitability to reproduce a typical Lm infection
in the experimental set-up. Furthermore, the chosen time points could be characterized
regarding influences of cytokines and infiltrating cell populations as well as the amount of
bacteria present in the system (Table 15). The first stage of infection (day 1.p.i.) showed
strongly increased counts of macrophages, monocytes, neutrophils and NK cells together
with a general elevation in cytokine levels with an emphasis on IL-6 expression. The
following stage, day 3 p.i., was defined by the peak of cytokine expression, as well as
further strong increase of innate immune cells as well as beginning B cell accumulation.
In contrast to those, the late stage (day 9 p.i.) was determined by T cell recruitment e.g.
by DCs and therefore, the onset of the adaptive immune response. In addition to the
functional characterization, the cytokine profiles hinted towards variability between the
three conducted replicates, emphasizing the need for a stringent statistical analysis for
proteome experiments.
Table 15. Properties of the analyzed time-points forming distinct stages of Lm in-
fection.
stage day
p.i.
behavior of
bacterial numbers
major immune cell
populations involved
cytokines
early 1 increasing MΦ, Mo, Neu, NKs increase; esp. IL-6,
IL1β
peak 3 peak innate cells, B cells peak in expression
late 9 decreasing DCs, T and B cells decrease
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4.2.2 The Liver Proteome of Mice with Sub-lethal Listeriosis is
Systematically Deregulated
To analyze the protein response to Lm infection in the liver, the proteome of three
stages of infection was studied. Therefore, 12 mice livers were collected to allow three
replicates of a comparative analysis of control and Lm-infected mice. To quantify the
protein responses, an iTRAQ-labeling approach was utilized. Following nHPLC-MS/MS
measurement, proteins were identified by searching against SwissProt database. Finally,
protein significance was determined by utilizing a stringent approach that uses the median
absolute deviation (MAD) from the median to estimate the standard-deviation of the
protein regulation factors and subsequently assign a p-value to each protein [218]. Protein
regulations were considered significant if the p-value was smaller than 0.01 and the
protein was either identified in all 3 or in 2 out of 3 replicates.
To assess quality and properties of the dataset, box and 3D-scatter plots were prepared
utilizing R software (Fig S10A&B). The box plots illustrate the noise inherent to each of
the samples. For all samples, 50 % of all regulation factors ranged between an RF of
-0.5 and 0.5 indicating a decent noise level. The day-wise 3D-scatter plots present the
correlation between the replicates. A perfect correlation would produce a line between
the smallest and the biggest coordinates of the system. For all days, the RF-distribution
followed this diagonal, which indicates a positive correlation in particular for day 3. The
individual Pearson correlation factors are given in Figure S10C. The occurring variations
were taken into account for the analysis of the proteomic dataset.
Overview of the Proteomic Dataset: The dataset yielded 3666 quantified proteins,
of which 67.3 % were identified in all replicates and another 15.1 % in two replicates
(Fig 33A). In total, 82.4 % of all proteins were considered for the determination of
significant regulations while the 644 proteins only identified in one replicate were excluded
from further analyses. Utilizing stringent statistics, 522 significantly regulated proteins
were extracted from the data. Figure 33B reveals a peak of regulation (n=471 proteins) at
day 3 p.i. which was expected from the cytokine profiles and CFUs. In general, up- and
downregulations occurred at a comparable frequency at all stages with a slight emphasis
on upregulation at day 1 (58 %) and downregulation at day 3.p.i. (55 %). Of the 522
significantly regulated proteins, only a small number (n = 15) had a changed abundance
across all time points (Fig 33C). The majority of proteins displayed regulation dynamics
with a significant change only at one or two stages of the monitored infection (73.2 %
and 23.9 %, respectively). Furthermore, Figure 33C underlined the differences between
day 1 and day 9, as no proteins were simultaneously and exclusively regulated at these
two days.
To furthermore validate the iTRAQ-based regulation factors, peptides from proteins
with high regulation factors were reviewed and two examples are presented (Fig 33D&E).
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Figure 33. Protein quantification and regulation dynamics of Lm infected mice liver
samples. (A) Overview of quantified proteins in individual replicates. The Venn-
diagram shows the numbers of proteins quantified and the overlap between the replicates.
In total, 3666 proteins were quantitatively identified. Of them, 2467 (67.3 %) were
found in all three replicates and another 555 in 2 out of 3. Those proteins were then
further investigated for significant regulation. (B) Significant regulations along the
stages of infection. Up- and downregulation occurred at similar frequencies. With
471 proteins, a peak of regulation was observed at day 3. (C) Dynamics of regulated
proteins throughout the time points. Only a small fraction of the proteins (n = 15) was
regulated independently of the infection stages. In contrast, for the majority of proteins,
the abundance only changed at one (73.2 %) or two stages of infection (23.9 %). (D &
E) Exemplary MS/MS-spectra illustrate the determination of regulation by iTRAQ.
(D) The peptide from Serum amyloid A-2 protein (SAA2) was reliably identified by
y- and b-ions. The iTRAQ-reporter ions shown at the enlarged section on the right
indicated a strong upregulation on day 1 and 3 p.i., which is in accordance with the
calculated protein regulation factors. (E) An exemplary peptide from Transthyretin
(TTHY) showed a downregulation at all time points compared to the reference (day 0).
As illustrated, the identification of the peptide sequence was complete.
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The peptide of Serum amyloid A-2 protein (SAA2) was well identified by both b- and y-ion
series and iTRAQ-reporters revealed an upregulation at day 1 and 3 p.i. as compared to
the reference (day 0, uninfected). The illustrated intensities of the reporters matched
the calculated protein regulation factors (RF) of 2.08 (day 1 p.i.) and 2.66 (day 3 p.i.),
respectively. In contrast to that, the peptide of Transthyretin (TTHY), which was also
exhaustively identified, showed a downregulation at all time points compared to the
reference (Fig 33E). The strongest regulation occurred at day 3 p.i. which was also
concurrent to the protein RF of 1.44. Both of the reviewed proteins belonged to the
functional class of acute-phase response proteins (APP).
Proof-of-concept: APPs which are produced in hepatocytes constitute the first organism-
wide inflammatory response [158]. In conjunction with the complement system, which is
an early response to bacterial infection, these proteins are eminently suitable to serve as
proof-of-concept proteins (POC-proteins).
Therefore, the data set was queried for proteins described as APPs in literature and
additionally for proteins which had a functional description in the UniProt KB [230]
implicating a role in acute-phase response or complement activation, e.g. the GO
annotation for a biological process. Of 54 POC-proteins included in that way, 32 were
regulated significantly in the anticipated directions (Table S4).
In summary, it can be stated that the regulation of the APPs is in perfect accordance
with the literature and relatable to the cytokine profiles of IL-1, IL-6, TNFα and IFNγ
(Fig 32), therefore confirming our set-up again as a suitable approach to analyze liver
responses distinct to Lm infection.
4.2.2.1 Protein Regulation Dynamics Correlate to Lm Pathophysiology and
Clearance in Murine Livers
To obtain an insight into the major regulations of each stage of infection, the top 10
regulated proteins were extracted and reviewed regarding their role in infection.
Early Stage of Infection - Pathophysiology: For the first time point, which represented
the early stage in infection, mainly regulation of inflammatory and pathophysiological
processes was expected. Indeed, three APPs ranked among the top regulated proteins;
SAA2, α-1-acid glycoprotein 2 (A1AG2) and Haptoglobin were found heavily upregulated
on day 1 and 3 p.i. (Table 16). Additionally, A1AG2 was also significantly increased at
day 9 and therefore was classified stage-independently regulated proteins. For two of
the tree, SAA2 and A1AG2, it was reported that their heightened presence decreases
Lm CFUs in murine liver [231]. Furthermore, Neutrophil gelatinase-associated lipocalin,
Lactotransferrin, Protein S100-A9 and Interferon-induced guanylate-binding protein
2 were also found to be upregulated both at day 1and day 3. All of these proteins
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were recently described to be increased upon Lm infection [232] and inhibit Lm growth
[233–235].
Of the 10 extracted proteins presented in Table 16 only 2 showed changes in abundance
solely at the early stage of infection. Pancreatic alpha-amylase and Protein disulfide-
isomerase A2 were both highly upregulated with an RF of 2.61 and 1.77, respectively.
Table 16. Top 10 regulated proteins of the early stage of infection (day 1 p.i.). Pro-
teins classified as proof-of-concept data are marked with a hash mark (#) after the
protein name. Direction of regulation is indicated by symbols ( = not significant c=
downregulated, a=upregulated).
Gene
name
ID Protein name d1/d0
mean
RF
d3/d0
mean
RF
d9/d0
mean
RF
Role in Infection
Amy2 AMYP Pancreatic α-amylase a 2.61   Salivary alpha amylase is
endotoxin-
responsive [236]
Saa2 SAA2 Serum amyloid A-2
protein #
a 2.08 a 2.66  decreases Lm CFUs in
murine liver [231]
acute-phase protein [237]
Pdia2 PDIA2 Protein disulfide-
isomerase A2
a 1.77   needed for Chlamydia
entry [238]
Lcn2 NGAL Neutrophil
gelatinase-
associated lipocalin
a 1.70 a 2.15  k.o. increases
susceptibility to
bacterial infections [233]
Ltf TRFL Lactotrans-
ferrin
a 1.63 a 0.89  inhibits Lm growth [234]
Orm2 A1AG2 α-1-acid glycoprotein
2 #
a 1.63 a 3.28 a 1.35 decreases Lm CFUs in
murine liver [231]
acute-phase protein [237]
S100a9 S10A9 Protein S100-A9 a 1.61 a 1.29  antimicrobial peptide to
Lm [235]
Gbp2 GBP2 Interferon-
induced guanylate-
binding protein 2
a 1.53 a 1.34  IFNγ-dependently
upregulated upon Lm
infection
(Gram-pos.) [232]
Hp HPT Haptoglobin # a 1.51 a 2.26  acute-phase protein [237]
Ifit3 IFIT3 Interferon-
induced protein with
tetratrico-
peptide repeats 3
a 1.50 a 1.55  protective role in virus
infection [239]
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While Pancreatic alpha-amylase was not described to play a role in infection so far,
for closely related salivary alpha-amylase, endotoxin-responsiveness was shown [236].
Interestingly, for protein disulfide-isomerases it was demonstrated, that Chlamydia is
dependent on the host-enzyme function for successful invasion [238].
Table 17. Top 10 regulated proteins of peak stage of infection (day 3 p.i.). Proteins
classified as proof of concept data are marked with a hash mark (#) after the protein name.
Direction of regulation is indicated by symbols ( = not significant c= downregulated,
a=upregulated).
Gene
name
ID Protein name d1/d0
mean
RF
d3/d0
mean
RF
d9/d0
mean
RF
Role in Infection
Orm2 A1AG2 Alpha-1-acid
glycoprotein 2 #
a 1.63 a 3.28 a 1.35 decreases Lm CFUs in
murine liver [231]
Cyp3a16 CP3AG Cytochrome P450
3A16
 c -2.93 c -2.78
Apcs SAMP Serum amyloid
P-component #
a 1.37 a 2.69  acute-phase protein [240]
Saa2 SAA2 Serum amyloid A-2
protein #
a 2.08 a 2.66  decreases Lm CFUs in
murine liver [231]
Hpx HEMO Hemopexin # a 1.21 a 2.53  modulates
responsiveness to IFNγ
via STAT1 [241]
Isyna1 INO1 Inositol-3-phosphate
synthase 1
a 0.55 a 2.51 a 1.39
Crybb3 CRBB3 Beta-crystallin B3 a 1.08 a 2.51 a 1.01
Tmsb10 TYB10 Thymosin beta-10 a 1.22 a 2.49 a 2.81
A2mp A2MP Alpha-2-
macroglobulin-P
#
 a 2.33  acute-phase protein [158]
Cyp4a12a CP4CA Cytochrome P450
4A12A
 a 2.33 a 1.91
Peak Stage: For the peak stage of infection (day 3 p.i.) the top 10 regulation list
(Table 17) contained 5 POC-proteins including Serum amyloid P-component, Hemopexin
and Alpha-2-macroglobulin as well as both of the APPs present among the top proteins
from day 1, SAA2 and A1AG2. The other five proteins included three proteins, Beta-
crystallin B3 (CRBB3), Thymosin beta-10 (TYB10) and Inositol-3-phosphate synthase 1
(INO1), which were all upregulated stage-independently with a peak regulation at day 3
for CRBB3 and TYB10 (RF = 2.51). All three of these proteins were not described to
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be involved in infection until now. Nevertheless, inositol which is the final metabolite
of the cascade INO1 belongs to, is an important factor to facilitate survival for various
pathogens [242] and furthermore INO1 was recently shown to be upregulated on mRNA-
level in Lm infected liver [243].
In contrast to that, the last two proteins from the top 10 list (Fig 17) belonged to the
same protein family, the cytochrome P450 system and yet were divergently regulated.
While Cytochrome P450 3A16 (Cyp3a16) displayed a severe decrease in protein abundance
with RFs of -2.93 at day 3 and -2.78 at day 9 p.i., Cytochrome P450 4A12A (Cyp4a12a)
was found to be strongly increased at day 3 (RF = 2.33) and also at day 9 p.i. (RF = 1.91).
Late Stage - Clearance: For the late stage of infection analyzed, proteins involved
in clearance of bacteria were expected. Indeed, in Table 18, two proteins were found
that are implicated in clearance or sustained inflammatory signaling. For Glutathione
S-transferase P 1 (GSTP1) a strong increase in protein abundance was found (RF = 2.03).
Recently, GSTP1 was shown to be involved in suppression of excessive pro-inflammatory
signaling and attenuation of inflammation. [244, 245]. On the other hand, Thymosin
beta-10 (TYP10), which was associated with apoptosis of macrophages and neighboring
cells [246], was highly increased in abundance with a peak at day 9.p.i (RF =2.81). In
contrast to that, Thymosin beta-4, with no evident role in infection, was downregulated
on day 3 and 9 with an RF of -1.17 and -1.92, respectively. In comparison to the two
preceding stages of infection, the top 10 protein list of day 9 contained a high number of
downregulated proteins (Table 18). Along with TYB10 and GSTP1 already described
above, only Cyp4a12a was found to be increased compared to the uninfected control.
Cyp4a12a as well as Cyp2d9, Cyp3a41a and Cyp3a16, which also appeared in the top
regulated proteins list of day 3, belong to the CYP 450 system and are therefore involved
in the biotransformation of endogenous substrates and xenobiotics.
In contrast to Cyp4a12a, the other 3 CYPs were strongly decreased at day 9. Apart
from the CYPs, three other proteins, that might play a role in biotransformation proces-
ses, were found among the top 10 regulated proteins. All of those, i.e. GSTP1, Amine
sulfotransferase 3A1 and Dimethylaniline monooxygenase 3 were found to be strongly
downregulated.
In summary, the analysis of the Top-regulated proteins revealed both proof-of-concept
proteins as well as proteins which might serve as candidates for further investigation
and knock-out studies. Additionally, dynamic protein regulations highlighted distinct
processes at each stage of infection. While at day 1, Lm growth-inhibiting proteins were
found among the top regulated, at day 3, proteins which could be beneficial for Lm,
e.g. INO1 and so far non-characterized proteins showed highest regulations. In contrast,
the late stage (d9) was characterized by strong downregulation of biotransformation
enzymes as well as proteins implicated in Lm clearance and sustained inflammatory
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signaling. Especially the regulation of cytochromes hints towards a severe deregulation
of physiological liver processes.
Table 18. Top 10 regulated proteins of the late stage of infection (day 9 p.i.). Proteins
classified as proof of concept data are marked with a hash mark (#) after the protein name.
Direction of regulation is indicated by symbols ( = not significant c= downregulated,
a=upregulated).
Gene
name
ID Protein name d1/d0
mean
RF
d3/d0
mean
RF
d9/d0
mean
RF
Role in Infection
Tmsb10 TYB10 Thymosin beta-10 a 1.22 a 2.49 a 2.81 Upregulation associated
with apoptosis in
M.bovis infection [246]
Cyp3a16 CP3AG Cytochrome P450
3A16
 c -2.93 c -2.78
Sult3a1 ST3A1 Amine
sulfotransferase
 c -2.01 c -2.35
Tomm20 TOM20 Mitochondrial import
receptor subunit
TOM20 homolog
 c -2.14 c -2.11 importer of
N.gonorrheaPorB [247]
Fmo3 FMO3 Dimethylaniline
monooxygenase
[N-oxide-forming] 3
 c -2.01 c -2.03 TLR4-dependently
downregulated by LPS
stimulation [248]
Gstp1 GSTP1 Glutathione
S-transferase P 1
 a 2.12 a 2.03 Anti-inflammatory role
in LPS stimulation [244]
Tmsb4x TYB4 Thymosin beta-4  c -1.17 c -1.92 reduced by
LPS-administration and
in patients with septic
shock (blood levels) [249]
Cyp4a12a CP4CA Cytochrome P450
4A12A
 a 2.33 a 1.91
Cyp3a41a CP341 Cytochrome P450
3A41
 c -1.75 c -1.88
Cyp2d9 CP2D9 Cytochrome P450
2D9
 c -1.23 c -1.88
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4.2.2.2 Sub-lethal Listeriosis Deregulates Hepatic Biotransformation Enzymes
Previous data-analysis indicated a severe deregulation of physiological processes in the liver
especially among the enzymes facilitating biotransformation of endogenous and exogenous
substances e.g. hormones and drugs. Led by the appearance of biotransformation enzymes
in the Top-10 lists, the data set was analyzed for protein families belonging to these
metabolic pathways. In total, the data set contained 42 cytochrome P450 enzymes (CYPs)
of which 25 were significantly regulated (Tables 19 & SS5). Of all found CYPs, only three
were significantly upregulated. Cyp4a12a and Cyp2d9 showed a strong increase in protein
abundance at day 3 and 9. For both of those, gender-specific regulations were described
previously [250,251]. For the third upregulated CYP, Cyp7b1, nothing in regard to its
regulation or role in infection is known so far. Interestingly, the second isoenzyme Cyp7a1
was not significantly regulated but showed tendencies to be downregulated (Table S5),
hinting towards an opposite reaction.
However, the majority of CYPs as well as other enzymes implicated in biotransformation
(Tables S6 & S7) were identified to be dynamically downregulated. For Cyp1a2, Cyp3a11
and Cyp2b10, this behavior was already described for mRNA under endotoxin stimulation
[252] and could be substantiated in this study. For Cyp1a2 it was shown previously,
that the levels of the protein family containing Cyp1a1 and Cyp1a2 are stable, if an Lm
infection of the brain was present [253]. While Cyp1a2 was downregulated, Cyp1a1 was
not identified.
Sustained Downregulation of CYPs: A group of 4 CYPs, Cyp2a4, Cyp2b9, Cyp3a16
and Cyp3a41a showed a sustained downregulation with RFs peaking at day 9 p.i or only
slight increase of protein abundance after the peak of regulation at day 3 (Table 19,
marked with ’&’). Especially Cyp3a16 and Cyp3a41a presented high RFs of -2.93 (d3)
and -2.78 (d9) as well as -1.75 (d3) and -1.88 (d9), respectively. Interestingly, both of
them belong to the Cyp3a subfamily, which was described for their role in detoxification
of xenobiotics [256]. In contrast to that, Cyp3a25 was showing only a minor change of
abundance at the peak stage of infection while Cyp3a13 was not regulated at all.
Deregulation of Non-CYP Phase I and II Enzymes: Aside from the CYP450 enzymes,
further biotransformation enzymes of both phase I and phase II were recorded in the
data set. Of phase I, 12 enzymes, 6 of them regulated, could be detected (Table S6).
Dimethylaniline monooxygenase 2&3, aldehyde dehydroxygenase 1&4 and amine oxidase
A&B were significantly downregulated. While the aldehyde dehydroxygenases and amine
oxidases showed only a decrease at day 3 p.i., the dimethylaniline monooxygenases
displayed a sustained regulation comparable to some cytochromes mentioned above.
Additionally, 36 phase II enzymes were quantified, i.e. glutathione S-, UDP-glucuronosyl-,
and acetyltransferases (Table S7). Among them, 12 proteins showed a significantly chan-
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Table 19. Cytochrome P450 family members showing significant regulation in Lm liver
infection. Direction of regulation is indicated by symbols ( = not significant c=
downregulated, a=upregulated). Asterisk indicates a p-value of 0.05 deviating from
the standard of 0.01. Hash mark = not significantly regulated in referred study. & =
proteins show sustained regulation.
Gene name d1/d0
mean RF
d3/d0
mean RF
d9/d0
mean RF
Regulation in (Lm) infection
Cyp4a12a  a 2.33 a 1.91 LPS: decreased in male mice [250]
Cyp2d9  a 1.23 a 1.88 Lm: decrease in male mice
(mRNA) [254], LPS: decreased
(mRNA) [252]; upregulated in female
mice [251]
Cyp7b1   a 0.83
Cyp2a4 & c -0.92 c -1.52 c -1.57
Cyp8b1 c -0.71 c -0.97  
Cyp2a5 c -0.62 c -1.29  
Cyp1a2 c -0.42 c -1.60  LPS: STAT1 independent decrease
(mRNA) [252],
Lm: stable (Cyp1a1/2; brain
inf.) [253]
Cyp2c50  c -1.83  
Cyp3a11  c -1.04  LPS: STAT1 independent decrease
(mRNA) [252]
Cyp2c29  c -1.00  LPS: STAT1 independent decrease
(mRNA) [252]
Cyp4f14  c -0.75  
Cyp2f2  c -0.68  
Cyp3a25  c -0.65  
Cyp2c70*  c -0.60  
Cyp3a16&  c -2.93 c -2.78
Cyp2c37  c -2.08 c -1.78
Cyp2c40  c -1.95 c -1.81
Cyp4a14  c -1.69 c -1.46 LPS: downregulation [255]
Cyp2b9 &  c -1.60 c -1.57
Cyp4a10  c -1.47 c -1.09 LPS: STAT1 independent induction
(mRNA), protein content
reduced [252], downregulation
(gram-negative bacteria) [255]
Cyp2c54  c -1.23 c -0.95
Cyp3a41a &  c -1.75 c -1.88
Cyp39a1  c -0.73 c -0.86
Cyp2b10  c -0.89 c -0.99 LPS: STAT1 independent decrease
(mRNA) [252] #
Cyp17a1   c -1.70
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ged protein abundance and the majority of those were downregulated at day 3 and
9. Only two proteins, glutathione S-transferase P1 (GstP1) and Mu3 (GstM4), were
upregulated. While regulation of GstP1 could also be due to its mentioned role in
inflammatory responses [244,245], for GstM4, no such context was described yet.
In summary, a large fraction of biotransformation enzymes was found deregulated
in Lm-infected livers, hinting towards a profound influence of the infection on drug
metabolism and clearance.
4.2.2.3 Proteins Abundances of UBLs and Regulating Enzymes are Scarcely
Influenced
One goal of this proteomic study was to observe the dynamic regulation of proteins
involved in changes in ubiquitin and Ub-like modifiers.
UBLs: As a first step to unravel the impact of Ub-dependent processes, the data set
was analyzed for Ub and UBLs as well as their modifying enzymes. Of the known UBL
modifiers, 5 were identified and quantified.
Ubiquitin-like protein ISG15, which was already described to be increased in abundance
in Listeria infection [34], showed a significant upregulation with an RF of 1.05 at the
peak stage of infection. Additionally, the ISG15 ligase TRIM25 as well as the conjugating
enzyme UB2L6 were identified. While TRIM25 was reliably quantified and showed no
changes, UB2L6 was found in only one out of three replicates and there showed an
increase in abundance through all time points.
Furthermore, NEDD8 was quantified as well as its conjugating enzyme UBC12. Both
of them showed no consistent regulation during all stages of infection. For UFM1, another
UBL-modifier, the protein itself as well as the E3 UFM1-protein ligase Ufl1 and one of
two known UFM1-specific proteases Ufsp2 [36] were quantified reliably throughout all
three replicates, but showed no changes in protein abundance.
The Small ubiquitin-related modifiers 2 and 3 (SUMO 2/3) were identified only in one
out of three replicates and showed no apparent changes in abundance in this replicate.
Additionally, SUMO-conjugating enzyme UBC9, which was recently shown to be degraded
during Lm infection in mouse liver [25], as well as SUMO-activating enzyme subunit
1 and 2 (SAE1/2) and E3 SUMO-protein ligase RanBP2 were quantified, but showed
no significant regulation. Additionally, ATG12 was identified in 2 of 3 replicates (non-
regulated) as well as its activating enzyme ATG3 and the conjugating enzyme ATG7,
which were both non-regulated.
Ubiquitin itself was identified in all replicates but was not quantified due to disabled
protein grouping in the data analysis. Manual evaluation of ubiquitin revealed mean
regulation factors of 0.64 (d1), 0.58 (d3) and 0.32 (d9), hinting towards slightly elevated
Ub-levels.
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Figure 34. Percentage of quantified proteins related to Ub and UBLs in the data set
and occurrence among the regulated proteins. (A) Percentage of Ub-related
proteins among all quantified as well as all regulated proteins. Specificities of proteins
in the groups are indicated by a color code. Proteins with dual specificity for Ub
and UBL were counted once for the UBL and not listed in the Ub-category (green).
(B) Underrepresentation of protein-functions among the regulated data points as
annotated by GO terms. Analysis of GO terms category “Molecular Function” utilizing
FunRich [257] revealed a depletion of protein activities implicated in signaling in
significantly regulated proteins compared to the whole data set. Besides phosphorylation-
dependent processes (blue), proteins with ubiquitin protein ligase (E3 ligases), ubiquitin-
specific protease (DUBs) and ubiquitin protein transferase activities (E2 conjugating
enzymes) as well as ubiquitin-binding proteins were underrepresented as indicated by
the negative fold changes (regulated/all proteins).
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Ub-related Proteins: To obtain an overview over the quantified and regulated Ub-
related proteins, the protein numbers for the UBLs themselves, E1, E2, E3/4 and
deconjugating enzymes, as well as UB-binding proteins, were determined for the whole
data set (total) and regulated proteins (reg.) (Fig 34A). In contrast to the UBLs, for
E1 activating and E2 conjugating enzymes, no proteins were found regulated, while
in the whole data set 0.38 and 0.41 % of the proteins belonged to those categories
and even showed different specificities against Ub, SUMO, NEDD8, UFM1 and ATG
(Fig 34A). For E3/4 ubiquitin ligases, the majority of proteins found (1.04 %) had a
described specificity for Ub as had both of the regulated ligases RNF213 and RNF135. For
deconjugating enzymes, again, no regulated members where found. The most abundant
Ub-related group contained proteins which were implicated in Ub-binding. In this group,
all proteins that either contain a Ub-binding domain, bind Ub in processes of conjugation
or deconjugation or were tagged as “Ub-binding” by UniProt KB were included. In
sum, Ub-binding proteins constituted 12.8 % of all quantified proteins and 6.3 % of the
regulated proteins (Fig 34A). Although the percentages for the different groups were
relatively small, it was prominent that an even smaller portions of the regulated proteins
belonged to the analyzed groups, if any.
To verify this observation and to examine whether the observed effect was specific
for Ub-related proteins or more general, an enrichment analysis for GO terms using
FunRich [257] was carried out. The analysis revealed a general decrease of protein
activities implicated in PTM regulation in the GO category “Molecular Function” for
regulated proteins vs. the whole data set (Fig 34B). Proteins with activities regulating
phosphorylation, e.g. “protein ser/thr kinase activity” showed even stronger decrease
(blue bars) than Ub-related functions (green bars). Furthermore, also “kinase-binding”
proteins and proteins with “prot ser/thr phosphatase activities” were underrepresented.
Regarding ubiquitination, proteins with “ubiquitin protein ligase activity” (E3/4) were
4.2 fold decreased in the regulated proteins and proteins with “ubiquitin protein transfe-
rase activities” were also depleted (1.9 fold). Furthermore, proteins that non-covalently
bind ubiquitin were also underrepresented as illustrated by an -1.7 fold change of the
function “ubiquitin binding” (Fig 34B).
In summary, the significantly regulated proteins showed a strong decrease in protein
numbers performing functions that belong to the ubiquitin-machinery and in ubiquitin
binding as well as in phospho-regulating activities and kinase binding compared to the
numbers in the whole data set. Although about 100 proteins which are associated with
ubiquitination or ubiquitin-related modifiers were quantified, only two of those proteins
were found to be significantly regulated, indicating a high importance and key role of
those two Ub-ligases in Lm infection. To further elucidate the functions and roles of the
candidate ligases, network analyses were carried out for both of them.
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Figure 35. RNF135 - Integration into
the RIG-I pathway in Lm liver in-
fection. All proteins presented were quanti-
fied in this study and significant regulation
is indicated by red bars. RNF135 was found
to be significantly upregulated at the early
stage of infection (RF = 0.66). The substrate
of RNF135, Probable ATP-dependent RNA
helicase DDX58 (RIG-I), was also found and
displayed a significant increase in abundance
at day 3 (RF = 0.55 ). Furthermore, several
proteins interacting with DDX58 were identi-
fied, i.e. MAVS (IPS-1), IFIH1 (MDA5) and
DHX58 (LGP2). DHX58 was also found to be
upregulated with an RF of 1.05 (d3). Further-
more, a second Ub-ligase of DDX58, TRIM25,
was quantified and showed stable protein
abundance. Tear-shape: ubiquitin; +: acti-
vation; green color: implicated in ubiquitin-
related process.
Ub-ligase RNF135: The first protein, the E3 ubiquitin protein ligase RNF135/Riplet
was found to be significantly upregulated at the early stage of infection (RF = 0.66).
RNF135 was recently described to ubiquitinate the probable ATP-dependent RNA helicase
DDX58 by K63-linked chains and to thereby activate DDX58 [258,259]. To assess the role
of RNF135 regulation in this study, protein interactions were determined using STRING
(version 10) [260] and subsequently, associated data points were extracted (Fig 35). Indeed,
DDX58 was quantified in the data set and showed a significant upregulation at day 3
(RF = 0.55), thereby revealing a later response than RNF135. Apart from RNF135 and
DDX58, E3 ubiquitin protein ligase TRIM25, which was also described to ubiquitinate
and activate DDX58 [261], was detected with unchanged protein abundance throughout
the infection. Additionally, two further RIG-I like receptors, Interferon-induced helicase
C domain-containing protein 1 (IFIH1)/Melanoma Differentiation-Associated protein
5 (MDA5) and Probable ATP-dependent RNA helicase DHX58/LGP2, were identified.
While IFIH1 was unchanged, DHX58 showed an increased protein amount at day 3
(RF = 1.05). Furthermore, Mitochondrial antiviral-signaling protein (MAVS)/IPS-1,
which acts downstream of the RIG-I like receptors, was identified but showed no regulation
(Fig 35). In summary, proteins directly and indirectly influenced by RNF135 were
identified and their regulation in Lm infection could be described in the complex setting
of whole liver. It is feasible that RNF135 activates DDX58 by ubiquitination and together
with DHX58 modulates the immune response in a Lm specific manner.
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Figure 36. Schematic representation regulation of RNF213 expression as well as an
analysis for putative pathway components of the E3 ubiquitin protein ligase.
All proteins presented were quantified in this study and significant regulation is indicated
by red bars. (A) Mechanism of transcriptional regulation of RNF213. The ubiquitin
ligase RNF213 was found to be upregulated at day 1 and 3. Recently, it was described
that RNF213 transcription was regulated by STATs, presumably STAT1. STAT1, 2
and 3 were identified and showed an increased protein abundance as indicated. After
transcription, RNF213 is known to ubiquitinate itself and to form homo-dimers to
perform its ATPase function. (B) Co-expressing proteins according to String DB
analysis. All listed proteins were reported to be co-expressed with RNF213 and the
association score between them is indicated by the colored boxes. Proteins in bold print
were quantified in the data set. The asterisk indicates that RSAD2 was only found in
one replicate. All present proteins were found to be regulated with similar dynamics as
RNF213.
Ub-ligase RNF213: The second protein RNF213/Mysterin, which is also an E3 ubiquitin
protein ligase, presented a significantly increased protein abundance at day 1 (RF = 0.64)
and day 3 p.i. (RF = 0.99) (Fig 36A). It was recently described that RNF213, which is
not only a ubiquitin ligase but also a big AAA+ ATPase, on the one hand ubiquitinates
itself and on the other hand forms homo-dimers while converting ATP to ADP [262,263].
Furthermore, it was described, that RNF213 was probably transcriptionally regulated
by a member of the STAT-proteins [264]. In this study, STAT1, 2, 3, 5a, 5b and 6 were
identified, but only STAT 1,2 and 3 presented changes in protein abundances (Fig 36A).
To identify potential interaction-partners or substrates, the RNF213 interactome was
analyzed via STRING [260]. No direct interaction partners or substrates were found,
but co-expressing proteins were identified (Fig 36B). All proteins listed showed a high
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association score, indicating co-expression across different conditions in micro-arrays. It
is therefore tempting to speculate, that those proteins are either direct substrates of
RNF213 or at least participate in the same pathways. Indeed, from 10 predicted proteins,
4 were identified in this study: PARP14, IFIT3, STAT1 and RSAD2. Notably, all of the
identified proteins were also found to be significantly upregulated. IFIT3 and STAT1
showed even higher changes in protein abundance at the peak of regulation with a 2.92
and 3.4 fold increase. PARP14 showed a displaced dynamic with a significant regulation
only at day 1 p.i. (RF = 0.63). For RSAD2, regulation was not determined as significant
as the protein was only found in one out of three replicates. Nevertheless, all of these
proteins might be interaction partners or putative substrates of RNF213.
In summary, it was obvious that proteins belonging to the ubiquitin cascade were
underrepresented in the regulated data set. Nevertheless, two candidate E3 ubiquitin
ligases, RNF135 and 213, were found to be significantly upregulated and around both of
them, a network of additional, quantified proteins emerged. Surprisingly, RNF135 was
described in association with anti-viral responses although the background here was a
bacterial infection.
4.2.3 Deubiquitinating Enzymes in Hepatic Listeriosis
In contrast to all other groups of Ub-related proteins, for DUBs, tools are available
to enrich active members of this enzyme family and thereby not only gain in-depth
information on their abundance but also activity. To overcome the limited coverage and
information content of the proteome data, the activity-based probe (ABP) HAUb-VME
was utilized to analyze and enrich DUBs.
In brief, DUBs were enriched by HA-immunoprecipitation and finally, a iTRAQ-labeling
approach was utilized for quantitative analyses by LC-MS/MS measurements. For the
DUB-analysis, lysates from the same liver pieces as used for proteome and cytokine-
profiles were utilized, allowing direct comparison across the data sets. In addition to
that, the DUB-enrichment via ABPs allowed for an insight into the activity-status of the
DUBs.
In total, 52 DUBs were quantified in the analysis, which amounts to 62.8 % of all
annotated DUBs in mouse as compared to 26 identified DUBs in the proteome approach.
In Table 20, numbers of identified DUBs assigned to the DUB-families and the percentage
of coverage are presented. In summary, DUBs from five families were found, among them
31 members of the largest DUB-family, the USPs, and 4 out 5 UCHs. Furthermore, 16
OTU-domain containing and 1 MJD-domain containing DUBs were quantified. Although
JAMM DUBs are metalloproteases and do not directly interact with the ABPs, 58.3 % of
the annotated JAMM DUBs (7/12) were identified in the data set. This interaction could
be due to complex formation or unspecific interactions. MCP-induced protein 1, which is
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Table 20. Numbers of quantitatively identified DUBs in hepatic Lm infection in com-
parison to the numbers of annotated DUBs. USP: Ubiquitin-specific proteases,
UCH: Ubiquitin c-terminal hydrolases, OTU: Ovarian tumor domain containing, MJD:
Machado-Josephin Disease domain containing, JAMM: Jab1/MPN/Mov34 metalloen-
zyme domain containing, MCPIP: MCP-induced protein (single protein).
DUB-family # annotated # identified coverage
USP 49 31 63.3 %
UCH 5 4 80 %
OTU 16 11 68.8 %
MJD 3 1 33.3 %
JAMM 12 7 58.3 %
(MCPIP) 1 0 0 %∑ 86 54 62.8 %
the only member of MCPIP-“family” with proven DUB-activity, was not detected.
Of the 52 identified DUBs, 46 were quantified in 2 out of 3 replicates. The 6 DUBs
identified in only one replicate, UCHL1, OTULIN, USP1, USP37, USP42 and USP46
were clearly identified, adding to the number of expressed DUBs in the liver, but were
excluded from the analysis of significant regulations. In total, 46 DUBs were used for
further analyses (Fig 37). In general, the heat map indicated a high level of noise between
the replicates as the regulation factors differed markedly in some cases, e.g. USP12,
USP16 and USP48, UCHL5 and OTUB1. Although the dataset is median-normalized, the
regulation factors, especially in replicate I, showed a tendency to be increased as illustrated
by the predominating red color (Fig 37). For the analysis of statistically significant
regulations, the same stringent algorithm as utilized for the proteomic experiments and
described in section 3.8 was used [218]. As the positive regulation factors show a wider
spread than the negative factors, upregulations presented in the heat map. e.g. for
USP25, USP9X and VCPIP1, were eye-catching but not determined to be significant.
Significantly Regulated Candidate DUBs: Nevertheless, two DUBs were found to be
significantly downregulated (Fig 37). UCHL3 showed a significantly decreased probe-
binding at day 1 p.i. in all three replicates. The mean regulation factor of -0.51 indicated
a 1.4 fold decrease in bound UCHL3 as compared to the uninfected control. Recently,
UCHL3 mRNA was shown to be significantly decreased in Lm-infected livers at day 3
p.i. indicating a change in abundance rather than in activity [243].
USP2, the second candidate DUB, showed a significant decrease in binding of about
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Figure 37. Regulation of active DUBs
quantified in hepatic Lm infection. The
columns show the regulation factors of each
distinct DUB in a day-wise manner. Downre-
gulation is represented in blue, upregulation in
red, gray signifies that DUBs were not found
and significance in regulation is indicated by
two asterisks (p-value < 0.01). Protein names
of regulated proteins are displayed in bold.
Although the data were median-normalized
before the extraction of DUBs, the regulation
factors are considerably higher for up- than
for downregulation. Nevertheless, two DUBs,
USP2 and UCHL3 showed significant regulations.
USP2 was found to be downregulated at day 3
p.i. with a mean RF of -0.68 which corresponds
to a 1.6 fold decrease. UCHL3, in contrast,
showed an 1.4 fold decreased protein abundance
at day 1 p.i. (mean RF = -0.51). Apart from
those two, a cluster of DUBs containing VCPIP,
USP9X, USP25 and USP34 was conspicuous,
revealing putative candidates for upregulation,
but was not statistically significant. A heat map
showing all regulation factors is found in the
Supplementary data (Fig S12).
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1.6 fold (mean RF = -0.68) at day 3. The regulation factors of day 1 and 9 showed
inconclusive results with a tendency to slight upregulation at day 1. Notably, USP2
mRNA was described to first increase at 4 and 24 hours after infection and then decrease
at later time points [243], which could explain the results illustrated in the heat map
(Fig 37).
To evaluate the candidate DUBs, UCHL3 and USP2, the protein-amount was de-
termined via western blotting. Therefore, frozen lysates from the liver pieces were
thawed, applied to SDS-PAGE and subsequently transferred to PVDF-membrane to
detect UCHL3 or USP2 and, after stripping, actin to normalize the samples. For USP2,
no signal could be detected at the anticipated molecular weight.
UCHL3: A generic blot of UCHL3 and corresponding actin is presented in Figure 38A.
The western blot analysis was repeated three times for each of the replicates. The
evaluation of those data confirmed the downregulation of UCHL3 at day 1 p.i. revealed
by the mass spectrometric analysis. Even though the values showed considerable variations
between the individual experiments, the mean regulation factor revealed a decrease in
abundance also at days 3 and 9 (Fig 38B). Especially for days 1 and 9 p.i., the western
blot confirms the results displayed in the heat map (Fig 37) and furthermore clarifies
that the decrease of UCHL3 was due to downregulation of the protein rather than change
in activity.
Figure 38. UCHL3 protein abundance and regulation in Lm infected liver. Liver lysates
of all three replicates were utilized for western blotting against UCHL3 and actin to
quantify UCHL3 throughout the infection(A) Prototypic blot of UCHL3 and actin
for replicate III. (B) Regulation of UCHL3 throughout the infection. The distinct
experiments are indicated by different symbols and the day-wise mean is indicated by a
black bar. All values were normalized using actin and then regulation factors over the
naive control were calculated. The dotted line represents the trend of mean regulation.
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In summary, of 52 DUBs which were identified due to DUB-enrichment in Lm infected
liver samples in comparison to 18 DUBs in the proteome samples, two were significantly
influenced in their binding behavior to HAUb-VME. Both, UCHL3 and USP2 showed a
decrease in binding at day 1 and 3 p.i., respectively. For UCHL3 western blot analyses
confirmed and nominalized information about the regulation and revealed a decrease
in abundance rather than activity. Thus, this study adds 2 novel candidates to the
repertoire of DUBs which are effected by Listeria infection and probably have profound
impact on the immune response similar as described for the deubiquitinase CYLD.
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4.3 Clinical Manifestations - Deubiquitinating Enzymes in
Sepsis Patients
4.3.1 Analysis of Deubiquitinase Activities in Sepsis Patients
Manifestations of listeriosis include meningoencephalitis, focal infections and sepsis,
which have an especially high prevalence among the elderly and immunocompromised
patients [164]. Although intensive care units (ICUs) utilize a varying diagnostic repertoire
to reveal sepsis in patients, the mortality is up to 30 % of all cases.
Since sepsis is an infection with a systemic response, immune cells circulating in the
blood should be able to represent the immunological state of the organism better than
body fluids as cells can respond to signaling molecules and other cells and adapt their sta-
tus accordingly. Furthermore, PBMCs are easily extracted from whole blood of patients.
However, cells contain a complex repertoire of proteins and other components making
it unfeasible to monitor all changes between the individual samples. To asses a cellular
representation of the immune status, this study focused on the idea of a targeted biomar-
ker approach utilizing one prominent enzyme class. DUBs are implicated in regulation of
immunity and bacterial infection especially in immune cells (subsection 1.2.2) and tools
to monitor DUB-activity are readily available. Hence, this study aims to clarify whether
DUBs are suitable for the discrimination between healthy, SIRS and sepsis patients.
Therefore, PBMCs from patients showing different conditions as well as control samples
were collected. Thereby, samples for the following patient states were collected: OP
control, systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic
shock. OP control group patients had had a surgery but did not show signs of SIRS or
bacterial infection. All patient samples as well as patient information were acquired from
the surgical ICU of the university medical center Magdeburg in cooperation with Dr.
Uwe Lodes.
Utilizing the collected samples, this study pursued three goals:
1. to clarify whether DUB patterns can be extracted from this material,
2. to validate if the pattern have predictive power for the different stages of sepsis vs.
healthy controls,
3. and to identify single DUBs which are predictive for certain states of sepsis-
progression.
4.3.1.1 Characterization of Samples and Available Patient Information
In total, 59 samples of 50 ICU patients were collected over the course of one and a half
years, and the mortality rate was 30 % averaged for patients showing any septic state.
116
4 Results
Notably, 2 patients exhibiting SIRS later developed severe symptoms and died, while
in the OP control class, all patients survived. If patients were sampled more than once,
they showed individual sepsis periods at each sampling point. The numbers of samples
belonging to each class, OP control, SIRS, sepsis, severe sepsis and septic shock, were
highly divergent with 24 septic shock samples and only 6 samples in the SIRS and sepsis
class each. Furthermore, 10 severe sepsis and 13 OP control class samples were collected
(Fig 39A).
To obtain a further insight in the patient characteristics, age and medication of the
patients was analyzed and is presented below (Fig 39B&C).
Age: 32 samples were collected from male patients with a mean age of 65.8 years and
27 from female patients with a mean age of 69.6 years (Fig 39B). The weighted mean
difference of ages accounting for the gender-specific life expectancy gap was calculated
using the 2010-2012 life tables published by the German Federal Office of Statistics [265]
and amounted to 2.8 years, meaning that women in the sample group on average get
2.8 years older than men. The actual difference between both mean ages (3.9 years)
was larger than it could be expected and hints towards a deviation from the anticipated
age-distribution (+1 year). If only the samples for which patterns could be acquired
were taken into account (black dots), the effect was even more prominent, with a sample
difference of 4.9 years as compared to expected difference in age of 2.9 years. Whenever
more than one sample from a patient was collected, the same age was also plotted more
then once, thereby treating the samples as independent from each other.
Medication: Although Listeria monocytogenes (Lm) is a causative agent of septicemia,
Lm could not be identified in the samples. Only in 10 patient samples, pathogens
could be identified and only 3 of them yielded a precise identification of the bacteria
implicated in sepsis. Nevertheless, the administration of antibiotics in all patients was
summarized (Fig 39C). In total, 44 patients received up to 4 antibiotics. The two most
frequently used substances were Meropenem against Gram-negative bacteria (23) and
Vancomycin against Gram-positives (17). Additionally, further antibiotics targeting
Gram-positive (Erythromycin and Linezolid), Gram-negative (Cefuroxim) and both kinds
of pathogens (Piperacillin/Tazobactam, Sultamicillin, Ciprofloxacin, Gentamicin and
Trimethoprim/Sulfamethoxazol) were given. Furthermore, the antimycotica Caspofungin
and Flucanazol, as well as Metronidazol targeting anaerobic bacteria and protozoa were
administered. The patients undergoing selective intestine decontamination (SID) received
multiple antibiotics, which were not individually listed in the ICU reports. The use of
antibiotics targeting Gram-positive bacteria in general hints towards the presence of
Lm, which is suspected especially in Sultamicillin treated patients. On a closer look,
Sultamicillin is essentially Ampicillin, which is the standard treatment for Lm, fused to
a β-lactamase inhibitor. Additionally, in some patients, Gentamicin was administered,
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Figure 39. Summary of patient characteristics sampled during their hospitalization at
the ICU. (A) Sample numbers for each sampling category and success in extracting
DUB patterns across the classes. Of 59 samples collected, most were from patients
with septic shock. (B) Age distribution of male and female patients. 19 male and 23
female patients were sampled. The mean ages were 64.6 and 69.6, respectively and are
represented by the lines. (C) Antibiotic administration among the sampled patients.
In total, 23 patients were treated with antibiotics with the most common ones being
Meropenem and Vancomycin. Patients are included in several bars, if they received
multiple antibiotics. The patients undergoing selective intestine decontamination (SID)
received multiple antibiotics, which were not individually listed in the ICU reports.
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which is also highly effective against Lm and the second antibiotic routinely used for Lm
infection. Apart from the antibiotics, about 80 different drugs were administered to the
patients, ranging from opioid pain killers to anti-hypertensive drugs. Together with a
multitude of causes for submission into the ICU, this emphasizes the diversity among the
patients and subsequently samples.
To acquire and evaluate DUB patterns from the collected samples, a reproducible
work flow which is presented below was designed in cooperation with the working group
Medical Microbiology of Prof. Dirk Schlüter (University hospital (OVGU), Medical
Microbiology, Magdeburg).
4.3.1.2 Acquisition of IB-based DUB Patterns
The work flow developed for DUB patterns of sepsis patients is schematically represented
in Figure 40. In detail, blood samples from ICU-patients were collected in sterile 15 ml
blue-cap reaction tubes which contained 7 ml of RPMI to dilute the samples. Subsequently,
the blood-RPMI mixture was added to a Ficoll cushion and PBMCs were isolated by
utilizing gradient centrifugation. After erythrocyte lysis, if necessary, pellets were stored
at -80°C until analyzed. After glass bead lysis, distinct protein amounts were incubated
with HAUb-VME and samples were then applied to SDS-gel electrophoresis using precast
4-12 % BIS/TRIS gradient gels and western blotting. Finally, after detection, 16-bit
tiff-images of all blots were acquired and used for further evaluation (Fig 40).
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Figure 40. Work flow for the generation of DUB patterns from PBMC samples and
analysis of the results utilizing the marker-fitting approach. PBMCs were
extracted from a 50 % mixture of RPMI and patient blood by Ficoll gradient cen-
trifugation and PBMC-pellets were stored at -80 °C for the following analysis. Cells
were lysed utilizing glass-bead lysis and subsequently a distinct protein amount was
labeled with 0.025 µg of HAUb-VME per µg protein for 1 h at 37°C. The signals were
recorded using an anti-HA antibody and ECL Prime detection reagent on an LAS 3000
recording device. The obtained western blots were analyzed using Advanced Image
Data Analyzer (AIDA) software. Subsequently, extracted data of each pattern was first
normalized utilizing the marker bands of the blot, and finally multidimensional scaling
(MDS) and hierarchical clustering were carried out. Additionally, this information was
utilized to assign DUBs to the distinct bands of the patterns on the basis of their
molecular weight.
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Manual Inspection: The application of the work flow (Fig 40) successfully yielded DUB
patterns for a large part of the samples. After acquisition of the first of them, the results
were manually inspected (Fig 41). Strikingly, the samples 10/01 and 11/01 (OP controls)
as well as sample 12/01 (SIRS) showed more complex and intense patterns than the other
samples, while sample 14/01, which was classified as SIRS samples but was collected
from a patient, which developed a septic shock shortly after sampling, displayed a less
prominent, even weak pattern. Moreover, samples from patients with septic shock seemed
to display only weak, if any, bands in the high molecular weight region, while for the
sepsis sample (15/01) the pattern was weaker than for the controls, but the upper MW
bands were clearly visible.
Figure 41. Exemplary DUB patterns for patients 6 to 15. For all blots, the same amount
of total protein was applied and DUB activities were visualized utilizing HAUb-VME
incubation of samples and subsequent detection with an anti-HA antibody. The color-
code beneath the sample numbers illustrates the sample class. Samples with XX/02
and XX/03 are from the same patient (XX), but represent different episodes of sepsis
during the course of treatment.
In summary, DUB patterns could be acquired for a large part of the collected samples
and manual inspection of the first results hinted towards probable differences between
the patterns of different sample classes. However, as this observation was based on only
few samples and the blots also revealed a certain heterogeneity of the patterns even in
one sample class, it became obvious, that a standardized data extraction and evaluation
method was urgently needed.
121
4 Results
Pattern Extraction: To extract the DUB patterns from the anti-HA western blots in a
standardized manner, images were loaded to Advanced Image Data Analyzer (AIDA)
software in 1D evaluation mode and lanes were marked by vertical or arbitrary rectangles
of about 115 pixel width in a way that all signals of one lane were included even in
non-vertical lanes (arbitrary mode). Then, the baseline of the intensity profile created by
AIDA was determined automatically by the following parameters: Baseline Determination-
Search level: 1, smoothed: 0 pixels. The profile of each lane was explored for visible
maxima manually and those selected were then marked as peak together optical inspection
of the original blot utilizing the parameters “position by center” and “avoid overlap” so
that the position was located in the center of the respective band.
Finally, absolute pixel values for all peaks as well as background-subtracted intensities
were exported to Microsoft Excel. Additionally, positions (absolute pixels) for the marker
bands (PageRuler prestained plus) were also extracted for each blot using the same
settings but omitting intensities.
4.3.1.3 Normalization of Patterns by a Marker-fitting Approach
To be able to compare individual DUB patterns as well as samples from different western
blots, normalization was carried out by an R-software routine developed together with
Prof. Frank Klawonn (HZI and Ostfalia University of Applied Sciences) and is described
hereafter. For each blot, the lowermost band represented unbound HAUb-VME which
has a distinct mass. To normalize the individual lanes, all determined pixel values of the
HAUb-VME band were shifted to the theoretical pixel value determined by the mass of
HAUb-VME (10.2567 Da) and all bands above were shifted accordingly, leading to an
alignment of all lanes by the highest pixel value of the blot. Additionally, all intensities
were normalized by the median intensity of the respective blot to account for differences
in development.
To compare the DUB patterns between different blots, the normalized pixel lines were
converted into a molecular weight value using the marker bands. The marker consisted
of 9 bands with 10, 15, 25, 30, 50, 65, 80, 115 and 185 kDa, which yielded an individual
pixel line. The mass ranges between these points were extrapolated by linear conjunction
of two neighboring marker bands as shown in Supplementary Figure SS11. In that way,
molecular weights in kDa were determined for each band in the blot and subsequently,
the molecular weights were back-transformed to a pixel line utilizing a golden standard
to project all DUB patterns into the same pixel range for comparison. The golden
standard marker used in this study was derived from the markers of all analyzed blots
regardless whether healthy control or sepsis samples (Fig 42). Furthermore, all bands
with a molecular weight smaller than 25 kDa were discarded from further analyses since
the smallest DUB is about 30 kDa in size when labeled.
In addition to the samples from the ICU patients, a set of healthy 19 control PBMC
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Figure 42. Golden standard
for the normalization of DUB
patterns. The marker bands of
all blots (colored dots) were used
to determine a mean marker curve
(black line), which in turn was
utilized to generate normalized
pixel values for the comparison
of DUB patterns from different
samples.
samples was generated from buffy coats provided by the Deutsches Rotes Kreuz (NSTOB,
Springe). Therefore, samples were prepared in the same manner as described for the
samples from Magdeburg. These samples are termed “healthy controls” as compared to
the OP control samples from patients which underwent surgery and were hospitalized in
the ICU.
To visualize all normalized DUB patterns, all of them were plotted onto a theoretical
blot and colored according to their class affiliations. Intensities were not integrated in
this illustration, therefore only showing the presence or absence of bands among the
patterns (Fig 43).
In general, samples were not evenly distributed among the classes and patterns could
only be acquired for about 70 % of the ICU and 78 % of all samples (Table 21). The
best represented classes were septic shock (24) and OP control (13) which yielded 16
and 11 patterns, respectively. The other categories contained fewer samples and only 4
patterns for SIRS and sepsis and 6 patterns for severe sepsis could be collected. Especially
for patients showing a SIRS, sample numbers are problematic as two of the patients
developed sepsis after the taking of the blood sample. Therefore, the SIRS samples were
split in two classes, SIRS and SIRS (septic shock), latter containing the two mentioned
samples. In summary, the obtained samples formed a very heterogeneous and biased
collection that proved difficult to analyze.
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Figure 43. Summary of all normalized DUB patterns acquired. All bands of each pattern
are displayed irrespective of the intensities. The different sample classes are indicated
by a color code: black = healthy controls, red = OP controls, dark green = SIRS, light
green = SIRS at the day of blood sampling with following septic shock, blue = sepsis,
purple = severe sepsis and orange = septic shock.
Table 21. Summary of sample numbers and acquired patterns in each sample class.
class # samples # patterns percent of patterns
healthy controls 19 19 100 %
OP controls 13 12 92.3 %
SIRS 4 2 66.7 %
SIRS (septic shock) 2 2 100 %
sepsis 6 4 66.7 %
severe sepsis 10 6 60 %
septic shock 24 16 66.7 %∑ 78 61 78.2 %
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4.3.2 Discriminating between SIRS and Sepsis
After normalization as described above, the distance between the different DUB patterns
was calculated by pair-wise comparison of all single bands of two patterns as devised by
Frank Klawonn. At first, a threshold had to be determined which defined two bands
as identical. In this study, 3 different thresholds, i.e 3.5, 7 and 10 pixels were tested.
Then, every band in pattern A was looked up in pattern B for a match. If a match was
found, the distance of both patterns increased about the difference of both normalized
intensities. If more than one match was found, the band with the smallest variance was
used and if no match was found, the distance increased by the full normalized intensity of
the band in pattern A. After determination of the distance for all bands and the addition
to yield the A to B pattern distance, the same calculations were carried out vice versa.
Finally,distances of both calculations were added up to the total pattern distance. In
that way, a distance matrix was created for all patterns.
This matrix was then utilized for multidimensional scaling as well as hierarchical
clustering of the samples with the 3 above mentioned thresholds 3.5, 7 and 10 pixels.
The dendrograms resulting from the clustering algorithm were additionally reordered as
described by Novoselova et al. to ensure that samples from the same class are adjacent
provided that the tree structure allowed this reordering [266].
Clustering and MDS with a 3.5 Pixel Threshold: As a first step, results were analyzed
by clustering and multidimensional scaling (MDS) utilizing a 3.5 pixel-threshold (Fig 44).
After reordering, the hierarchical clustering resulted in several smaller clusters but no
clear distinction between the sample classes. For the healthy controls, two main clusters
formed with only few samples not found in those clusters. In contrast, OP control
samples (red) were found in one cluster with several additional samples spread over the
dendrogram. Samples of the third larger sample class, septic shock, were split into one
larger (7 samples) and two smaller clusters (3 samples each) and further single samples.
The 3 classes with smaller sample numbers, SIRS, sepsis and severe sepsis showed only
pair-wise clustering, if any. Especially the 4 SIRS samples analyzed spread across the
whole dendrogram as shown by the green squares.
The MDS analysis showed a similar picture with no clear separation of sample classes
(Fig 44B). In general, all samples spread around zero in a continuous way. Especially
the healthy controls (black dots) showed a scattered distribution in the lower half of the
coordinate system. Additionally, some samples were found relatively close to the zero
point of the system indicating small distances between those samples. On that account,
the clustering and MDS was repeated with logarithmic scaling of the distances. Although
the effect of accumulation of samples around zero is diminished in the logarithmic MDS,
only the spread of the samples increased, but again, no clear separation of classes was
found. The logarithmic hierarchical clustering showed more small clusters as compared to
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Figure 44. Hierarchical clustering and MDS for a threshold of 3.5 pixel. (A) Hierarchical
clustering of all 61 samples. For this threshold, sample classes were not clearly separated.
While the bigger classes, i.e. controls and septic shock were found in few bigger clusters,
the samples of the other classes were either found in pairs or scattered across the
dendrogram. (B) MDS of the all samples. In accordance with the clustering, no definite
grouping of samples was detected. It is striking to note, that the healthy controls
scattered very broadly compared to the other samples.
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the non-logarithmic counterpart, especially for the controls. The only sample class that
benefited from the logarithmic scale was the severe sepsis class, which showed distinct
clusters as compared to the spread in the non-logarithmic cluster (Fig S15).
In summary, neither clustering nor MDS with a threshold of 3.5 pixel revealed conside-
rable clustering of the samples of one sample class or a distinct separation from other
classes.
7 and 10 Pixel Thresholds: Subsequently, the threshold was doubled to 7 pixels and
analyses were repeated as described before (Fig S13). As reported for the threshold of 3.5
pixels, the new value also was not able to generate a class-separation for the samples. The
MDS for the 7-pixel threshold also showed no distinction between the classes although the
spread of the samples changed notably. The clustering result of the log-values (Fig S15)
again revealed a favorable result for the healthy control class (2 clusters and 1 single
sample), while for the other classes were disrupted.
Finally, a 10-pixel threshold was applied to the samples (Fig S14A). However, a clear
clustering of classes was not visible with this threshold. The MDS also showed no signifi-
cant differences between the classes (Fig S14B). The same held true for the logarithmically
scaled MDS. The logarithmic clustering again showed a enhanced clustering of the healthy
controls very similar to the results for the log 7-pixel threshold (Fig S15).
In summary, the different thresholds of 3.5, 7 and 10 pixels as well as the logarithmic
and linear scaling of the distances between the samples revealed distinct clustering
and MDS results for the samples. Thereby, mainly the control classes (healthy and
OP controls) and the septic shock class built groups within the different dendrograms.
However, no class could be discriminated clearly from the others on the basis of this
clustering approach. Nevertheless, it is conceivable, that samples can be categorized in
two groups according to their behavior in clustering. If a sample clusters within a distinct
group of samples, a diagnosis or prognosis based on the patterns might be possible for
those patients, allowing the use of patterns as biomarkers at least for part of the patients.
On the other hand, the second group would contain the samples where no prediction was
possible based on the results of the cluster analysis.
For the MDS analysis, no concise grouping of the classes could be exposed throughout
the analyses. Therefore, with the aid of the obtained results so far, it is not possible to
determine features of DUB patterns that allow the differentiation between the sample
classes. However, there are further possibilities of evaluation, which should be examined.
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4.3.3 Identification of Prominent Deubiquitinase Signals
As the protein amount acquired from ICU samples was limited and not sufficient to carry
out a DUB-identification based on enrichment by probes (HA-IP), a theoretical approach
to identify DUBs with a potential regulatory role in sepsis-progression was developed
in cooperation with Prof. Frank Klawonn. Therefore, the molecular masses from all
cysteine-class DUBs, were extracted from UniProt KB and the mass of HAUb-VME
(10.2567 Da) was added to account for the shift in mass due to labeling of the DUBs.
Then, for each individual experiment, the masses were transformed into pixel lines
utilizing the extrapolated marker curves (Fig S11) and then the resulting pixel lines were
compared to the found pixel lines of the DUB patterns. If the difference of the two pixel
lines was smaller than 3.5 pixels, the DUB was classified as assigned.
MS-aided Support of DUB Assignment: To additionally strengthen the theoretical
DUB-assignment, HA-IPs from pooled ICU-patient samples (6, 8 and 4 samples) and
healthy control samples (5 donors, PBMCs) were carried out. Due to the relatively
small protein amounts available, DUB-identifications for the sepsis-pools were scarce
and therefore results were summarized resulting in 14 identified DUBs. As a base for
the theoretical DUB-assignment and to visualize the results from the HA-IP approaches,
a virtual blot was generated by utilizing the golden standard marker (Fig 45A). The
molecular weights were transformed into pixel lines and then displayed as virtual bands.
The gray lane represents 81 DUB-signals which are possible in theory as those DUBs
can be labeled by HAUb-VME. The second lane (black) was compiled from those DUBs
which were identified by an HA-IP either in this study or previously [96, 210]. The third,
green lane of the virtual blot summarizes all DUBs identified in a pool of 5 healthy
control PBMC samples. In total, 43 DUBs were found in this sample, of which 37 were
also theoretically detectable by HAUb-probes (Fig S16).
The red lane (Fig 45A) summarizes the DUBs identified in 3 HA-IPs of lysate pools
from sepsis-patient PBMCs. The 3 pools consisted of 18 samples in total and samples
belonged to either sepsis, severe sepsis or septic shock class, and were mixed throughout
all pools. In sum, the mass spectrometric analyses identified only 14 DUBs in all of these
pools (Fig 45A), while 19 DUBs were identified in a fourth pool, containing also OP
control and SIRS samples (data not shown).
Although single samples from ICU patients are not sufficient for HA-IP approaches
and pools do not reflect the DUB composition of individual samples, the data points
acquired from healthy control samples and sepsis sample pools validate the theoretical
approach as they confirm the presence of certain DUBs in the different sample groups.
To get an overview of the DUB-assignments, the mean and median DUB-assignment
per band in DUB patterns was analyzed (Fig 45B).
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Figure 45. Theoretical assignment of DUBs to the activity-patterns according to their
probe-modified molecular weight. The molecular weight of all known DUBs of
the cysteine protease families in an HAUb-VME labeled state was determined and
transformed to pixel lines using the marker of each experiment. Then, values were
compared with the pixel lines of the bands from DUB patterns, and the DUB was marked
as assigned, if the pixel lines varied about less than 3.5 pixels. (A) Theoretical blot
of DUB patterns. To visualize the theoretically possible DUB patterns, a theoretical
blot was generated utilizing SigmaPlot13. Based on the pixel value of the golden
Standard marker, pixel values were determined for different samples. The gray lane
illustrates the theoretical DUB pattern for all DUBs which were theoretically tag-able
with HAUb-VME and contains most signals. The second, black lane depicts signals
from all DUBs that were identified in either of the HA-IPs carried out in this study,
regardless of cell types. In the green lane, all DUBs are presented, which were identified
in a pool of PBMCs from 5 healthy donors. Finally, the red lane shows the theoretical
pattern of mass spectrometrically identified DUBs from 3 pools of sepsis samples (18
in total). (B) Mean and median assigned DUB numbers per band in DUB patterns.
The numbers of assigned DUBs for each group was normalized by the band count of
each pattern to reveal differences in assignment. (C) DUB-assignment for individual
DUBs and sample classes. The heat map illustrates the percentage of assignment
for each specific DUB listed utilizing a color code from 0 % (gray) to 100 % (bright
red). Dendrogram and DUB names were color-coded according to the presence of each
DUB in the theoretical blots. If a DUB was found in more than one sample type, the
color-code presents first sepsis pools by red coloring of DUB name and then PBMCs
in green by the colored branch. Assigned DUBs, that were confirmed by any HA-IP
experiment but not found in PBMCs or sepsis samples were marked black, and only
theoretically HAUb-VME detectable DUBs are presented in gray. Black arrows on the
right side indicate interesting DUB-assignments presented in more detail in Figure 46.
For the healthy control samples, 1.02 DUBs per band were assigned, indicating a
theoretical DUB identification rate of 100 %. That is not the case, as DUBs were not
assigned to bands with lower molecular weights, while due to the resolution limits in
gel separation, more than one DUB was assigned to bands with high molecular weight.
Interestingly, this mirrors the results from in-gel digestions of HA-IP samples in which
those bands also contained more than one DUB. Thus, the mean assignment is a valid
measure for the matching of DUB-masses and bands but does not directly reflect the
completeness of assignment. The mean and median assignments for the OP control were
0.86 and 0.83 respectively and thus 20 % lower than for the healthy controls. SIRS,
sepsis and septic shock samples showed a mean assignment between 0.91 and 0.93 but
a slightly higher median (0.94 to 1). The only sample class with diverging assignment
of DUBs per band was the severe sepsis class. There, only 0.7 DUBs (mean) or 0.52
DUBs (median) were assigned per band. As the class did not show any suspicious band
distribution (Fig 43), the cause of this drop in DUB-assignment is not easily rationalized.
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DUBs Identified by Theoretical Assignment: To further elucidate the DUBs assigned
to each sample class patterns were visualized in a heat map. To this end, the percentage
of samples in one class to which a particular DUB was assigned to was calculated
and subsequently clustered (Fig 45C) to reveal plausible patterns in DUB-assignment.
Notably, USP34 and USP24 were not assigned while USP9X and USP9Y were assigned,
albeit rarely. A closer look revealed, that those four DUBs have molecular weights way
above 300kDa. Although USP9X/Y were identified through the HA-IP in sepsis samples
pools, assignment to bands is problematic due to the high molecular weights and the
relatively low resolution of the used SDS-gels in this range. In contrast to that, the
molecular weights of all other DUBs were found to be well within the boundaries of the
assignable area.
Especially for the healthy control, SIRS and sepsis classes, groups of frequently assigned
DUBs were found, while OP control and septic shock samples revealed a more uniformly
distributed assignment, which might at least partly result form higher sample numbers in
these classes. In the healthy controls, a group of DUBs containing USP54, USP7, USP8,
USP 20, ATXN3 and USP41 was assigned. Interestingly this group should result in only
4 distinct bands in a blot, since USP7 and USP8 (about 138 kDa) as well as USP41 and
ATXN3 (about 51 kDa) would be nearly inseparable. USP54 presence should result in a
high MW band of 197 kDa and USP20 yield a 112 kDa band. Additionally, all members
of this group except for USP41 were previously identified in PBMCs (green names), but
4 of the DUBs were also found in sepsis pools (red).
A second group of commonly assigned DUBs in the healthy controls included USP36,
USP53, USP48, USP26 and BAP1 as well as USP49 and USP51. Here again, some DUBs
were practically inseparable, i.e USP48 and 53 (129 kDa) and USP49/51 (89 kDa), while
USP26 and BAP1 presence should result in individual signals. For the SIRS and severe
sepsis classes only single DUBs showed high percentage of assignment, while in the sepsis
class, a group of DUBs was uncovered. This group contained both forms of the USP17
family as well as USP1 and USP22, of which only USP22 was previously identified in
PBMCs. Astonishingly, none of those DUBs were previously identified in the HA-IP
approaches of sepsis samples.
DUB Candidates for Prediction of Sepsis-progression: Beyond these groups, few
individual DUBs showed high assignment in distinct sample classes (Fig 46A-F). Of the
DUBs assigned in samples of all classes, UCHL3 showed the highest values (Fig 46A).
In the healthy control, SIRS, severe sepsis and septic shock classes the assignment was
above 50 %. In the two remaining classes, the values were lower (16.7 and 25 %), but
nevertheless high as compared to other assignments. In contrast, BAP1 mass was assigned
to 72.2 % of the healthy control samples as well as to 16.7 and 25 % percent of OP
control and SIRS samples, but no assignment was found for the sepsis states (Fig 46B). A
similar assignment was found for USP2 (Fig 46C) with highest matching in SIRS samples
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(75 %). Furthermore USP2 was assigned to a lower extent in OP control, healthy control
and septic shock samples, but not in sepsis or severe sepsis.
Another DUB, USP1, showed a peak of assignment in sepsis (75 %) and additionally,
similar but lower assignments in SIRS and septic shock (25 and 30 %) and also low
assignment in the healthy control samples. In contrast, OTUB1 showed a generally low
but constant assignment of 15 to 25 % in healthy controls, OP controls, SIRS and sepsis,
but no assignment in severe sepsis and only 5 % in septic shock samples. Last, but not
least, USP47 showed the highest assignment (68.8 %) in septic shock samples, while it
was not assigned to SIRS and severe sepsis samples and about 25 % assignment in the
other classes.
Figure 46. Percentage of assignments for individual DUBs in distinct sample classes.
These assignment were calculated by the number of assignments in one class divided
by the number of samples. Presented DUBs were selected for their occurrence in the
different sample classes.
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In summary, the theoretical DUB assignment revealed both distinct groups of DUB
assignments as well as single DUBs with specific assignment patterns. Most interestingly,
among those DUBs, candidates which in combination reflect each sepsis state, were
defined. Although the assignment is purely theoretical, most of the candidates were
identified either in PBMCs or sepsis samples by MS-measurements. Therefore, the next
step has to be the validation of these candidates in a quantitative manner to assess
whether they can indeed differentiate healthy, SIRS and sepsis patients and even different
sepsis states.
4.4 Development of Activity-based Probes to Analyze
Deubiquitinating Enzyme Activity
4.4.1 Characterization of HAUb-VFEA for the Screening of DUB Activities
in Comparison to HAUb-VME
Activity-based probes are valuable tools in proteomic research which are able to bind
distinct groups of active enzymes covalently and enable the extraction of those proteins
from complex biological samples through the included affinity-tag or monitoring of their
activities.
The novel probe HAUb-VFEA is a classical ABP for DUBs using a C-terminal reactive
group for covalent attachment and a hemagglutinin (HA)-Tag for purification [96] and
was developed and prepared in-house (section 3.3) in cooperation with Dr. Raimo Franke
(HZI). The structures of both warheads are illustrated in Supplementary Figure S2.
Recently, HAUb-VFEA (HAUb-MF) was used to characterize the active DUB-complement
of 5 cancer cell lines (manuscript in preparation) [96,210]. Although the capability of this
probe to bind DUBs was described and evaluated, a comparison to the gold-standard,
the C-terminal electrophilic HAUb-VME, introduced in 2002 [88] and used in a number
of studies [90,94,104,106,267–269], was missing until now. Most importantly, it is also
not clarified, if the current gold-standard HAUb-VME only reacts with active DUBs and
which levels of DUB-activity HAUb-VFEA is able the discriminate.
4.4.1.1 Activity in Cell-lysates of the EL-4 Cell Line
As EL-4 cells are frequently utilized for the characterization of newly devised probes,
HAUb-VFEA was also characterized in comparison to HAUb-VME in this cell line.
Therefore, EL-4 cells were lysed and subsequently, 9.35 mg of lysates were labeled with
HAUb-VME or HAUb-VFEA or incubated without probe. After enrichment of DUBs,
samples were analyzed by LC-MS/MS measurements.
In total, 46 active DUBs were identified by mass-spectrometry in labeled samples as
compared to 11 in the non-enriched controls (Table 22). Of the former, 45 were bound
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Table 22. DUBs captured in EL-4 lysates by HAUb-VME and HAUb-VFEA. DUBs are
sorted according to their families.
∑
= total numbers of DUBs.
control HAUb-VME HAUb-VFEA
USP 9 30 29
UCH 2 4 4
OTU / 8 2
MJD / 3 1∑ 11 45 36
by HAUb-VME while 36 were detected by HAUb-VFEA. The main portion of bound
DUBs for both probes belonged to the USP-family and the differences in binding were
minimal (30 to 29) in this family. For the UCH-family, both probes even bound the same
members. In contrast to that, HAUb-VME extracted 8 OTU and 3 MJD-family DUBs
while HAUb-VFEA captured only 2 OTU DUBSs and 1 MJD-family DUB (Table 22).
To illustrate the distribution of identified DUBs, the unique spectra recorded were
normalized to the molecular weight of the individual DUBs and subsequently utilized
to create a heat map displayed in Figure 47. The data points used to create this figure
are collected in Supplementary Table S8. In general, a strong enrichment of DUBs as
compared to the control IP could be shown as fewer DUBs were identified in the control
with lower numbers of unique spectra. For the USP and UCH-family, the heat map
confirmed the relatively small differences described above also in terms of enrichment
as depicted by similar color saturation caused by similar numbers of unique spectra for
HAUb-VME and HAUb-VFEA. Additionally, four DUBs, USP17L2, USP34, USP42 and
USP45 were identified for the first time as binding an ABP by both probes alike.
Differences in identification were only found for USP10 and USP30, which were only
identified by HAUb-VME and USP3 which was solely identified in the HAUb-VFEA
samples. Beyond identification, HAUb-VFEA showed slightly stronger enrichment of
USP8, USP15 and USP19 and lower spectrum counts for USP25, USP37 and USP48 as
well as CYLD, UCHL1 and Ataxin 3 (ATXN3) as compared to HAUb-VME.
In contrast to the small differences within the USP and UCH families, HAUb-VFEA
enriched only few members of the OTU and MJD groups, either with low numbers of
unique spectra or identification only in one or two replicates.
Nevertheless, the ability of HAUb-VFEA to enrich DUBs from complex cell lysates
was clearly demonstrated. HAUb-VFEA also exhibited a tendency towards USP- and
UCH-family DUBs, where it bound DUBs as broadly as VME.
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Figure 47. Unique spectra of DUBs
captured by HAUb-VME and HAUb-
VFEA. HAUb-VME, HAUb-VFEA and
pure agarose beads (control) were used
to extract DUBs from EL-4 cell lysates.
Subsequently, the samples were analyzed by
mass spectrometry and unique spectra were
extracted. Unique spectra normalized by
molecular weight are presented in the heat
map with a color range from white (0) to
dark blue (0.57) while gray indicates that
the particular DUB was not identified in
the replicate. Application of both probes
revealed enrichment of DUBs as compared to
the control as well as distinct DUB patterns.
HAUb-VME showed a broader spectrum
of DUB-binding and for some DUBs, i.e.
USP25, USP37, USP48, CYLD, UCHL1,
ATXN3, higher numbers of unique spectra
as compared to HAUb-VFEA. In contrast,
HAUb-VFEA produced an increased spectral
count for USP8, USP8, USP15 and USP19
and solely identified USP3. In general, 4
DUBs, USP17L2, USP34, USP42 and 45
were not described to be labeled by ABPs
before and were enriched by both probes.
The family affiliations of all DUBs are given
at the right side of the figure.
4.4.1.2 Activity Towards Recombinant Enzymes
As a validation for the results of the MS-approach, the shift in molecular weight for
a panel of recombinant DUB was monitored to verify the binding behavior towards
the tested DUBs (Fig 48). For the majority of DUBs, the reactivity of the probes was
comparable to the MS measurements. For example, USP28, USP47 and BAP1 showed
comparable signals in both a approaches with similar reactivity of HAUb-VME and
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VFEA. Furthermore, the blots of USP25, CYLD and UCHL1 confirmed pronounced
binding to HAUb-VME in comparison to VFEA, while USP10, OTUB1 and JOS1 were
solely targeted by HAUb-VME.
Figure 48. Comparative shift assays of recombinant DUBs labeled with HAUb-VME
and HAUb-VFEA. Recombinant DUBs were labeled with HAUb-VME or HAUb-
VFEA and the shift in mass was subsequently analyzed by α-HIS6 western blotting.
Each individual blot shows the DUB alone, and in complex with the two probes, always
detecting the respective DUB which carried the HIS6-Tag. All DUBs were also identified
in the MS-approach where they reacted with at least one of the used probes.
Nevertheless, for a number of DUBs the results from the western blots differ from
the cell line screening results. For example, UCHL5 showed lower reactivity towards
HAUb-VFEA in the western blots while nearly equal numbers of normalized unique
spectra were generated from the HA-IP approach. Furthermore, ATXN3 showed no
binding of HAUb-VFEA in the blot, but the MS measurement provided a signal in one
of the replicates. In contrast to that, OTUB2 bound to HAUb-VFEA in the western blot
but showed no enrichment in the MS approach.
However, the strongest deviations were found for USP5, USP7 and 14. While all three
of those DUBs showed similar numbers of normalized spectra in the heat map for both
of the probes, they were not bound by HAUb-VFEA in the shift assays.
Since K63 Ub-chains were previously described as substrates for USP5 and USP7
[270–272], both DUBs were incubated with K63 tetra-Ub chains as described in subsection
3.4.4 to assess the DUB activity and to evaluate the binding behavior of USP5 and
USP7 towards the probes in the presence of the natural substrate (Fig 49). Notably,
HAUb-VFEA-binding was highly intensified by addition of K63 tetra-Ub chains in USP5,
136
4 Results
while HAUb-VME-binding showed only a slight increase in presence of the substrate
(Fig 49A). In contrast, for USP7 no differential probe-binding upon substrate addition
was observed and no binding occurred towards HAUb-VFEA as noticed before. The DUB
activity was then assessed by monitoring the cleavage of K63 tetra-Ub chains during
60 min of incubation (Fig 49B). While USP5 was found to be highly active and had
cleaved nearly all of the Ub-tetramers directly after mixing (0 min), USP7 showed only
very weak activity. Only the later time points, 30 and 60 min displayed faint bands at
the height of Ub-trimers (Ub3) and Ub-dimers (Ub2).
In summary, HAUb-VFEA was confirmed to be a broad ABP for DUBs with a preferred
binding of USP and UCH family DUBs. Incubation of recombinant DUBs with both
probes and comparison to the HA-IP data ultimately demonstrated a substrate-dependent
binding of HAUb-VFEA to USP5 which might indicate a difference in “activity-sensing”
in HAUb-VFEA as compared to HAUb-VME.
Figure 49. Characterization of recombinant USP5 and USP7 regarding activity and
probe-binding properties. (A) Probe-binding of USP5 and USP7 in presence of
K63 tetra-Ub chains. USP5 and USP7 were incubated with HAUb-VME and HAUb-
VFEA in the presence and absence of their natural substrate and the shift caused by
probe-binding was investigated by α-HIS6western blot. For USP5, substrate-dependent
binding of HAUb-VFEA was found to be enhanced as compared to HAUb-VME. In
contrast to that, addition of K63 tetra-Ub chains had no influence on probe binding.
(B) K63 tetra-Ubiquitin chain cleavage assay of USP5 and USP7. Both DUBs were
incubated with K63 tetra-Ub chains for the indicated times and samples were evaluated
by Coomassie-staining of prepared gels. USP5 showed nearly complete Ub-chain
cleavage directly after mixing (0’), while USP7 showed virtually no activity against the
Ub-chains. The amount of applied enzymes is presented in the upper Coomassie-strips.
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4.4.2 Ubiquitin-Isopeptide Probes to Mimic Ubiquitin-substrate
Conjugation
In contrast to the classical C-terminal ABPs, the so-called Ubiquitin-Isopeptide probes
(UIPPs) were designed to mimic ubiquitin moieties attached to a substrate or incorporated
into Ub-chains of different linkages. Therefore, a peptide of the target protein, the
substrate of ubiquitination, was attached to the warhead to enable the binding of DUBs
by recognition of the specific sequence surrounding of the Ub-site. A part of the UIPP-set,
the probes imitating K48 and K63-ubiquitin chains were published to introduce the
concept of UIPPs [95]. Following this, additional UIPPs were also produced in this study
in cooperation with Dr. Raimo Franke (HZI). Thus, peptides of interesting targets were
synthesized, coupled to the reactive warhead VA and finally ligated to HA-ubiquitin.
Utilized peptide sequences are listed in Table 10. Ultimately, two different sets of UIPPs
were designed with distinct goals:
1. The first set, mimicking poly-Ub chains was intended to investigate chain-linkage
specificity of DUBs.
2. The second set, which was designed to recreate ubiquitinated sites at the RTK
c-Met, is to be utilized to identify DUBs which regulate deubiquitination of c-Met.
The first set is described hereafter, while results for the c-Met UIPPs is found in subsection
4.1.3.2 of this study.
4.4.2.1 Ubiquitin-chain Mimicking UIPPs
To mimic differentially linked poly-ubiquitin chains, probes utilizing the sequence sur-
roundings of K6-, K11-, K27-, K29-, K33-, K48- and K63-ubiquitin chains were ligated.
While K6- and K11-ligation did not yield enough material, the other probes were success-
fully produced. The set of Ub linkage-specific probes, now containing K27-, K29- and
K33-UIPPs as well as the initially characterized K48- and K63-UIPPs [95] were used
to investigate recombinant DUBs for their binding specificities. To this end, the DUBs
were incubated with UIPPs and HAUb-VME for 1 h and subsequently analyzed via
SDS-PAGE and western blotting. To detect the recombinant, HIS6-tagged DUBs, an
α-HIS6antibody was used.
In general, three groups of DUB-reactivities resulted from the screen with recombinant
enzymes and corresponding western blots are shown in Figure 50. The first group of
DUBs (Fig 50, upper left) showed a broad reactivity towards all UIPPs and HAUb-VME
and contained USP15, USP21 and USP47 as well as UCHL3. Notably, both USP15
and UCHL3 showed a weaker signal for the K63-UIPP as compared to the other probes.
The second group at the lower left of Figure 50 was inactive against the UIPPs, but
reacted with HAUb-VME. This reactivity, observed for USP10 and USP14 as well as
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ATXN3, ATXN3L and YOD1, hints towards a general specificity of those enzymes either
for specific substrates or poly-Ub chains.
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Figure 50. Reactivity and specificity of Ub-chain linkage-specific UIPPs towards re-
combinant DUBs. The recombinant DUBs were incubated with HAUb-VME and
the panel of UIPPs mimicking K27, K29, K33, K48 and K63-linkage and subsequently
analyzed by α-HIS6 western blotting. HAUb-VME was also used for labeling as compa-
rison to classical C-terminal electrophilic warheads.Three groups of DUB-reactivities
towards UIPPs were detected; DUBs were either broadly (upper left), non-reactive
(lower left) or differentially reactive (right).
Most interestingly, DUBs in the third group (Fig 50, upper right) showed distinct
activities towards a specific subset of the UIPPs. USP2 for example was highly reactive
towards all of the UIPPs except for the K63-UIPP, where only a weak signal was found.
In contrast to that, USP25 showed weak reactivity towards UIPPs in general and a
stronger shift for the K29-UIPP, but no binding towards the K63-UIPP at all. The third
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USP-family member in this group, USP28 reacted strongly with the K29-, K33-, and
K48-UIPPs, but only weakly with K27- and K29-UIPPs, while CYLD, the fourth USP,
bound preferentially to the K29-chain mimic, but not to the K63-UIPP and only poorly
to the other UIPPs.
The two remaining DUBs in this group, both belonging to the UCH family exhibited the
most distinct binding patterns. UCHL5 showed pronounced binding of the K29-UIPP and
only slight reactivity towards K27- and K48-UIPPs. The other probes yielded no signal
at all, hinting to inactivity towards those UIPPs. On the other hand, BAP1 displayed
moderate binding of the K48-UIPP and very weak signals for K27- and K29-mimics.
Notably, most of these DUBs showed enhanced activities towards the K29-UIPP and a
diminished binding towards the K63-Ub-chain-mimicking probe.
The question whether the described binding preferences are truly a mirror of substrate
specificities or influenced by the steric properties of the isopeptide-constructs needs to be
discussed.
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This study aimed to survey the influence of the human ubiquitin system on bacterial
pathogenesis and host responses on three distinct levels of complexity. As a model, the
well-described Gram-positive pathogen Listeria monocytogenes (Lm) was chosen for the
characterization of activities of deubiquitinating enzymes (DUBs) as a crucial part of the
ubiquitin system and host-reaction towards infection.
On a cellular level, ubiquitination and counter-regulating DUB activities involved in
the initial signal transduction after bacterial-host contact on non-phagocytic cells were
investigated using the example of the InlB/c-Met axis of Lm invasion.
In a subsequent step, the systematic proteome and DUB-responses to Lm infection
were surveyed in a murine animal model of listerial liver infection. While InlB-mediated
invasion of hepatocytes is also a major mechanism in this infection model, host-responses
are much more sophisticated than on cellular level, including infiltrating immune cells and
their orchestrated immune response. On this level, the influence of Lm on physiological
as well as Ub-regulatory proteins was analyzed in particular.
On the third and most complex level of investigation, the diagnostic and prognostic
value of DUB activities in sepsis was tested in a pilot-study on PBMC samples of ICU-
patients and healthy controls. To optimize the access to DUB activities on all of those
levels, novel activity-based DUB-probes were developed.
Hereafter, different aspects of this thesis will be discussed in the frame of the increasing
complexity of the investigated systems.
5.1 Ubiquitin-dependent Mechanisms during Cell Invasion via
the c-Met/InlB Axis
In the first part of this thesis, ubiquitination of the receptor-tyrosine kinase c-Met as the
most proximal component of InlB-mediated Lm cell-entry was investigated. Furthermore,
candidate DUBs regulating ubiquitination of c-Met or InlB-mediated invasion in general
were determined (section 4.1).
Of the 6 generated ubiquitination-deficient K to R mutants of c-Met utilized for
the analysis, all showed permanent receptor activation upon transfection into HeLa S3
cells judging from the immunoblot results obtained as did the transfected wt control
(subsection 4.1.2). However, downstream of c-Met, Erk1/2 and Akt kinases displayed
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altered activation following stimulation with HGF or InlB, especially for the K2xR
(K1103/04R) double mutant which showed Akt hyperactivation and the quadruple
mutant K4xR, for which results hint towards a permanent activation of the c-Met
signaling axis (subsection 4.1.2).
In contrast to the signaling,intracellular localization of the mutant receptor variants did
not differ from wild-type c-Met after stimulation with HGF or InlB (subsection 4.1.2.4).
In addition to the ubiquitination-deficient mutants, candidate DUBs were analyzed
for their localization after receptor stimulation. Of the five candidate DUBs USP8,
VCPIP1, USP2, USP21 and CYLD, only two displayed changes in cellular localization
(subsection 4.1.3). Interestingly, an extensive co-localization between any DUB and c-Met,
as would be necessary for its global deubiquitination, was not observed.
5.1.1 Is De-ubiquitination of c-Met of Relevance for Ligand-mediated
Receptor-endocytosis?
Checkpoint-driven Receptor Endocytosis and Recycling: At first glance, the results
mentioned above are unexpected, as the leading model of ligand-mediated endocytosis of
RTKs follows the idea that ubiquitination facilitates the formation of protein complexes
leading to receptor internalization [273]. Hereafter, this model is referred to as checkpoint-
driven receptor endocytosis and recycling (Fig 51A).
As it was shown that Lm induces c-Met ubiquitination during cell invasion comparable
to HGF-stimulated receptors [135] and no differences were observed between HGF- and
InlB-mediated c-Met activation, the following discussion will aim at general receptor-
endocytosis mechanisms rather than HGF- or InlB-specific explanations.
In the framework of the checkpoint-driven receptor endocytosis model, ubiquitination
is necessary but also sufficient for endocytosis of the activated receptor, representing the
first checkpoint. Indeed, for c-Met as well as other RTKs, mono- and polyubiquitination
introduced by the Cbl family of E3-ligases was found to be sufficient for receptor
endocytosis following ligand stimulation [133, 134, 136]. However, evidence for the
necessity of RTK-ubiquitination is not direct for c-Met and others [273]. Instead,
mutation of the c-Cbl recruiting phosphosite Y1003 of c-Met was shown to lead to
increased receptor stability and thus, it was inferred that ubiquitination of c-Met results
in receptor internalization and degradation [275, 276]. In contrast, other studies reported
that this effect is c-Cbl dependent but Ub-independent, indicating that c-Cbl serves as a
mere adapter in the process [277,278].
Nevertheless, the endosomal sorting complex required for transport (ESCRT)-machinery
responsible for RTK-recycling was shown to be dependent upon receptor ubiquitination
when forming the early ESCRT-complexes I and II. In contrast, ESCRT-III was described
to lack ubiquitin-binding domains. At this point a second checkpoint is introduced
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Figure 51. Involvement of ubiquitination and DUBs in suggested mechanisms of c-Met
recycling and degradation. (A) Checkpoint-driven receptor recycling model. (B)
Threshold-controlled endocytosis model adapted from Sigismund et al. [274]. (C) Recy-
cling or degradation facilitated by indirect mechanisms.Cbl: Casitas B-lineage Lymp-
homa E3-ligase, Eps15: Epidermal growth factor receptor substrate 15, GRB2: Growth
factor receptor-bound protein 2, LRIG1: Leucine-rich repeats and immunoglobulin-like
domains protein 1.
into the classical model by considering the deubiquitination of c-Met at the ESCRT-
III stage as a prerequisite for sorting, degradation and probably also recycling of the
receptor [273,278,279]. Here, direct interaction between the ubiquitinated receptor and a
DUB would be necessary. For other RTKs, e.g. EGFR and PGDFR, the DUB AMSH
was described as the direct regulator of ubiquitination and therefore degradation [280].
In contrast, USP8/UBPY knock-out studies established only indirect effects on receptor
stabilization [222, 281]. For both DUBs, further investigations of their roles in c-Met
endocytosis are required, as it is not clear when and to what extend direct receptor
deubiquitination takes place [273].
The observations of this study regarding ubiquitination as well as candidate DUB
localization strongly contradict the checkpoint-driven receptor endocytosis model. In
conjunction with previous indecisive results published, an alternative model for receptor-
endocytosis, which fits the present results better, is required.
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Threshold-controlled Endocytosis: One alternative model could be a threshold-controlled
endocytosis of c-Met (Fig 51B). Recent results revealed that for EGFR, at least in some
cell lines, ubiquitination and Ub-dependent internalization occur in a ligand concentration-
dependent manner [274]. At low concentrations of ligand, EGFR was found to be activated
and internalized in a clathrin-dependent manner, while above a certain threshold, ubi-
quitination of the receptor set in. Simultaneously, clathrin-independent endocytosis was
activated, also driving receptor-degradation [274,282]. For c-Met, no such concentration
dependency was described until now. However, in light of the wt-like endocytosis of the
Ub-deficient c-Met mutants analyzed in this study, it is tempting to speculate on a similar
model for c-Met. In line with that, such a model could not only explain these results but
also unify the contradicting claims of the clathrin-dependency of ligand-mediated c-Met
endocytosis. While Clathrin-mediated endocytosis (CME) is described to be the major
endocytosis-mechanism for c-Met [283], Clathrin-independent mechanisms were proposed
depending on the model system and probably also ligand-concentrations [221]. Even
though EGFR and c-Met are not comparable in all aspects of endocytosis [273], both are
ubiquitinated by the Cbl E3 Ub-ligase, hinting at similarities regarding ubiquitination.
In contrast to the first model, the concept of threshold-controlled endocytosis does
not require deubiquitination of the receptor other than the proteasomal deubiquitination
activity to distinguish between receptors targeted for recycling or degradation. Polo
and colleagues rather suggest that the endocytic mechanism per se dictates the receptor
fate [282]. Thus, the model would also be in line with the “missing” direct interaction of
a DUB and receptor found in this study.
Indirect Ubiquitin-mediated Endocytosis and Degradation: Another alternative mo-
del would be a ubiquitin-dependent but indirect endocytosis and degradation mechanism
(Fig 51C). Recent studies of RTK endocytosis suggested that accessory proteins and not
the RTK itself can be targeted by ubiquitination and subsequently facilitate receptor
endocytosis.
For example, Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1)
was recently described to interact with EGFR and c-Met. While acting in concert with
EGFR, LRIG1 amplified direct EGFR ubiquitination and lysosomal degradation. Howe-
ver, interaction with c-Met led to LRIG1 ubiquitination and recruitment of both receptors
for lysosomal degradation without an influence on c-Met ubiquitination [284,285].
Thus, LRIG1 could be a candidate mediating Ub-dependent c-Met-degradation or
recycling in absence of direct c-Met ubiquitination. Furthermore, Oh and colleagues
identified USP8 as the DUB which regulates LRIG ubiquitination, thereby strengthening
the role of USP8 in RTK-endocytosis as an indirectly acting DUB [273,285]. However,
LRIG1-coordinated RTK-endocytosis is until now described as ligand-independent only
and therefore might not play an important role during ligand stimulation.
In contrast, Epidermal growth factor receptor substrate 15 (Eps15) was shown to
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be monoubiquitinated following EGF stimulation even at low EGF concentrations and
thereby orchestrating lysosomal degradation of EGFR [286]. As Eps15 was also found to
interact with c-Met via the adapter protein GRB2, it is likely that an ubiquitination of
Eps15 also occurs after c-Met stimulation. Interestingly, Eps15 contains an ubiquitin-
binding domain, but interacts with c-Met through GRB2-binding via a coiled-coil domain
[287].
Thus, Eps15 would be in position to regulate ligand-mediated endocytosis of c-Met
through its ubiquitination without the necessity of receptor ubiquitination. Savio and
colleagues introduced USP9X as a regulator of Eps15 ubiquitination. As USP9X is
expressed in epithelial cells and implicated in protein trafficking, it is possible that
USP9X also deubiquitinates endocytic proteins following c-Met activation [288].
In general, both alternative endocytosis models are better suited to explain the results of
this study than the classical checkpoint-driven model which requires ubiquitination of
c-Met for internalization and afterwards direct deubiquitination by a DUB to determine
receptor fate. The best fit to the results of this study is achieved by a combination of
an indirect mechanism for lower HGF or InlB concentrations (Fig 51B) paired with a
threshold-controlled endocytosis mechanism (Fig 51C), which eliminates the need for a
DUB to work directly at the receptor for deubiquitination.
Still, the precise role of Cbl-mediated ubiquitination of c-Met is unknown and needs to
be elucidated to exclude a role in endocytosis. Additionally, a second cluster of Ub-sites
is found in the multi-adaptor binding site of c-Met. As this cluster was not tackled by
site-directed mutagenesis in this study, the possibility that those sites are exclusively
responsible for Ub-mediated receptor-endocytosis cannot be ruled out with certainty.
5.1.2 DUBs Involved in Regulation of Lm Invasion
Many pathogens, e.g. viruses, fungi, parasites and Gram-negative bacteria acquired
or developed own DUBs with specificity for Ub or UBLs to influence and control host
processes [60]. Furthermore, some Gram-negative bacteria also express Ub-ligase-like
effectors, which facilitate ubiquitination of host-proteins [289]. Thus, some pathogens, e.g.
Salmonella and E.coli are able to hijack ubiquitination and deubiquitination alike while
others were only described to express either Ub-ligase like effectors or DUBs [60, 289].
Interestingly, for Gram-positive bacteria neither DUBs nor ligase-like effectors were
described until now.
Hence, for Gram-positive bacteria in general and Lm in particular, the only way
to manipulate the host Ub-system is seemingly by influencing host DUBs and ligases
via bacterial effectors. As discussed above, DUBs might not play a prominent role in
direct deubiquitination of c-Met, but nevertheless were found to effect Lm infection and
invasion [66,80]. In this study, candidate DUBs were analyzed for direct co-localization
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with c-Met. Localization of CYLD and USP21 were found to be changed following
InlB-mediated c-Met stimulation (Fig 52A).
USP21: USP21 was found to co-localize with a portion of activated c-Met after 10 to
30 min of InlB stimulation in HeLa S3 cells. It was recently described that endosomal c-Met
continues to participate in signaling and that the dynamics of endocytosis contribute to the
signaling output of the receptor [132,290]. Endosomal signaling is required for full Erk1/2
activation as well as for STAT3 nuclear accumulation [291,292]. Menard and colleagues
most recently found that following c-Met activation by HGF, the receptor either localizes
in peripheral endosomes (PE) or in perinuclear endosomes (PNE) [293]. If USP21 directly
or indirectly interacts with signaling-competent c-Met species with perinuclear localization
only, this spatial separation could lead to an altered signaling (Fig 52B). Conceivable
results of direct deubiquitination would include an impact on adaptor molecule-binding
as described for Ub-mediated complexes in immune cells [13]. Furthermore, priming
of the c-Met containing endosome for ESCRT-III-mediated degradation by removing
Ub-chains from c-Met would also be possible [279]. In contrast, deubiquitinating activity
against adapter molecules of c-Met, i.e. an indirect mechanism, could alter the signaling
output in a non-predictable manner.
CYLD: The deubiquitinase CYLD was found to relocate to speckles in the nucleus of
InlB-activated HeLa S3 cells after 30 to 60 min of activation (Fig 52A). Interestingly,
CYLD was previously described to attenuate anti-Lm immune responses via disturbance
of the IL-6/STAT3-mediated fibrin production in hepatocytes [66] and inhibition of
RIPK2 in macrophages [74]. In this study, CYLD was also found to localize in the
nucleus, thereby deviating from the mainly described target location of CYLD i.e. the
cytoplasm.
However, HPA denotes CYLD as nuclear localized, thereby confirming the obtained
results [225]. The relocalization observed might be due to recruitment of CYLD towards
a nuclear protein complex of unknown composition following c-Met activation. No
such nuclear interactions are described for CYLD so far, but of the known interactors,
Tumor necrosis factor receptor-associated factors 6 (TRAF6) [62], B cell lymphoma 3
(BCL3) [294], STAT3 and transforming growth factor beta-activated kinase 1 (TAK1) [63]
are localized in the nucleus at least partly and therefore could be targets of nuclear CYLD.
As STAT3 was already described as a direct substrate of CYLD and c-Met activates
STAT3 as a part of perinuclear endosomal signaling [292], it is tempting to speculate
that in this case CYLD also regulates STAT3 (Fig 52). However, it would be equally
possible that CYLD deubiquitinates an as yet unknown protein, e.g. an activated kinase,
to regulate nuclear functions.
At a first glance, it is unlikely that CYLD directly interacts with c-Met although it was
identified as a candidate by utilizing a c-Met-mimicking UIPP. However, the interaction
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might be restricted to a narrow temporal or spatial window of c-Met stimulation. Notably,
a 60 kDa C-terminal fragment of c-Met was reported to re-localize to the nucleus
independently of receptor stimulation in some cell lines like MDA-MB231 and also
HeLa [295, 296]. It might well be possible that CYLD is recruited to nuclear c-Met
fragments which either are not immediately detectable by the antibody utilized in this
study or influencing the signaling of those fragments by deubiquitination even at low
concentrations.
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Figure 52. Potential roles of USP21 and CYLD in InlB-mediated c-Met stimulation.
(A) Schematic representation of c-Met, CYLD and USP21 localizations in HeLa S3 cells
as observed in this study. c-Met: green, USP21: red, CYLD: blue. (B) Representation
of USP21 and c-Met as well as potential interaction partners in the perinuclear area
and nucleus of the cell.
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5.2 Regulation of Ubiquitination in Systemic, Sub-lethal
Listeriosis
While the direct roles of both ubiquitination and DUBs seem to be only minor in
ligand-mediated receptor endocytosis and thereby cell invasion, in Lm infection CYLD
is well-established as a negative regulator of immunity [66,74,75]. This study revealed
the regulation of two completely new DUB candidates which were not described in the
context of Lm infection before. Both DUBs, USP2 and UCHL3, were downregulated in a
systematic, activity-based DUB-screening in murine liver (subsection 4.2.3) . Interestingly,
both DUBs were also found to interact with a c-Met mimicking UIPP, which might
indicate an interaction with c-Met (subsection 4.1.3.2).
Additionally, the analysis of the liver proteome of Lm infected mice identified and
quantified a number of proteins implicated in the regulation of Ub- and UBL-mediated
processes. Of those, only the UBL ISG15 and two Ub-ligases, RNF213 and RNF135,
were found to be significantly regulated.
Those unexpectedly low numbers of regulations (subsection 4.2.2.3) on the one hand
indicate the partial needlessness of protein regulation to recalibrate a PTM system that
is mainly based on activation and deactivation of proteins. On the other hand, the few
regulated proteins thus gain in importance and are likely key-modulators in Ub-mediated
cellular responses to Lm infection.
5.2.1 Ubiquitination and ISGylation Orchestrate the “Anti-viral” Immune
Response in Hepatic Lm Infection
Notably, RIG-I-like receptor(RLR) signaling is usually activated as a defense response to
viruses and is a sensor for viral 5´-triphosphorylated RNA species [297]. However, DDX58
itself and the two additional RIG-I-like receptors DHX58 (LGP2) and Interferon-induced
helicase C domain-containing protein 1 (IFIH1/MDA5) are also able to detect RNA
from few intracellular bacteria. Legionella pneumophila, Shigella flexneri, Salmonella
typhimurium and Listeria monocytogenes RNAs were found to activate DDX58 or IFIH1,
however, the downstream-signaling remains unknown [298–303]. This study uncovered the
upregulation of DDX58 as well as a stable expression of IFIH1. Furthermore, it uncovered
a whole battery of proteins described for antiviral immune-responses downstream of
DDX58, which were also activated in the Lm infection setting of this study, e.g. IFITs ,
OAS1, PML and ISG15, and mostly not described in anti-bacterial responses until now
(Fig 53).
DHX58 (LGP2): Notably, DHX58 (LGP2), which was previously described as an
inhibitory factor of DDX58 was also found upregulated in this study. This result
strengthens the study of Pollpeter and colleagues, who indicated an activating role for
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Figure 53. Identified and regulated proteins involved in "anti-viral" signaling during
hepatic Lm infection. A pathway was built by Ingenuity® Pathway Analysis (IPA®) [304] using all
identified proteins from the dataset which were annotated with the GO-term “response to virus”. Lm is
known to activate DDX58 (RIG-I) by intracellular nucleic acids. All proteins illustrated were identified
in the study, proteins depicted as light red/blue shapes were found significantly regulated. Light red
outlines indicate an additional annotation of the proteins as described in anti-bacterial immunity.
CLU: clusterin, FADD: FAS-associated death domain protein, GBP1: Guanylate-binding protein 1,
GPAT1: Glycerol-3-phosphate acyltransferase 1, GTF2F1: General transcription factor IIF subunit
1, HSPB1: Heat shock protein beta-1, IFIT1/2/3: Interferon-induced protein with tetratricopeptide
repeats 1/2/3, IFITM3: Interferon-induced transmembrane protein 3, IKBKE: Inhibitor of nuclear
factor kappa-B kinase subunit epsilon, ILF3: Interleukin enhancer-binding factor 3, IRF3: Interferon
regulatory factor 3, MAVS: Mitochondrial antiviral-signaling protein, MYD88: Myeloid differentiation
primary response protein MyD88, NGAL: Neutrophil gelatinase-associated lipocalin, OAS1: 2’-
5’-oligoadenylate synthase 1, OASL. 2’-5’-oligoadenylate synthase-like protein, PCBP2: Poly(rC)-
binding protein 2, PLSCR1: Phospholipidscramblase 1, PTPRC: Receptor-type tyrosine-protein
phosphatase C, PYCARD: Apoptosis-associated speck-like protein containing a CARD-domain
(ASC), RSAD2: Radical S-adenosyl methionine domain-containing protein 2.
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LGP2 in Lm infection [305]. It is tempting to speculate that the activation of LGP2 is
Listeria-specific, as it was not described for other bacterial pathogens before.
RNF135 and USP2: Most interestingly, the Ub-ligase RNF135 and the DUB USP2
were both previously described to regulate DDX58 (RIG-I) activity. The E3 Ub-ligase
RNF135 was shown to ubiquitinate DDX58 at the repressor-domain and thereby to
induce activation of DDX58 and association with TRIM25 and TANK-binding kinase 1
(TBK1) [258,259]. In this study, RNF135 was found upregulated at day 1 post infection
indicating an early DDX58-activation by ubiquitination, which then probably led to
increased DDX58 expression through a positive feedback loop via IRF3.
In contrast, USP2b was recently described to remove K63-linked Ub-chains from TBK1,
thereby inhibiting TBK1 kinase activity [306]. As USP2b was found to be the major
isoform of USP2 in murine liver [307], it is assumable that USP2 detected in this study
is indeed the isoform USP2b.
USP2 was found significantly down-regulated at day 3 p.i. and thereby most likely
supports the activation of DDX58 via TBK1-deubiquitination during the peak phase
of infection. A recent mRNA study from B. Izar reported a significant increase of
USP2-cDNA in the first 4 h of infection in murine liver and a subsequent decrease at
later time points [243].
All of those results hint towards a fundamental and tightly timed regulation of RLR-
signaling following Lm infection by ubiquitination. The acquired datasets of this study
(subsections 4.2.2.3 & 4.2.3) thus revealed two proximal regulators of RIG-I signaling as
well as their temporal regulation in Lm infection (Fig .53).
ISGylation & Ubiquitination: The ubiquitin-like molecule ISG15 is one of the proteins
expressed following IRF3-activation and rapidly upregulated following type I IFN response
to viral infection [5]. As found in this study and also previously described, ISG15 is
increasingly expressed during Lm infection. Interestingly, ISG15-knockout cells were
described to be more susceptible to Lm but not to S. flexneri or S. typhimurium and
those two pathogens also did only weakly induce ISG15 expression [34]. Thus, it seems
that ISGylation is of special benefit in the defense of Lm infection in contrast to other
pathogens and ISG15 expression is activated in an Lm-specific manner. One candidate
could be the aforementioned DHX58/LGP2, which could influence the detailed activation
of RLR-signaling, as it seems also to be Lm-specific.
ISG15 was also found to modify DDX58 and thereby inhibit its activity in a negative
feedback-loop [308], as well as several other proteins which are part of RLR-signaling or
the “anti-viral” response in general (described as ISGylated in UniProt KB or PTMScout
[230,309], see Fig 53). Therefore, it is likely that ISG15 exhibits this feedback functionality
also during Lm infection, thereby further shaping the RLR-signaling.
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Apart from ISGylation, for many of the identified and quantified proteins presented
in Figure 53, ubiquitination or SUMOylation sites were experimentally detected and
reported in the PTMScout database [309]. Even though no ligases or proteases are
described for those sites and the conditions of occurrence might not be clear, their
presence implicates a certain degree of Ub-mediated protein regulation. Especially for
regulated proteins in the pathway, Ub-conjugation could be of importance to facilitate
protein degradation to enable shut-down of the host-defense pathway in the clearing
phase of infection.
Therefore, it would be of high interest to analyze UBL-modifications in Lm infection
on a systematic level by means of proteomics.
5.2.2 Novel Ub-modifying Proteins in Lm Infection
Apart from RNF135 and USP2, two additional Ub-regulating proteins, the Ub-ligase
RNF213 and the Deubiquitinase UCHL3, were found to be significantly regulated.
However, neither of those was described in context of infection before and putative roles
in Lm infection are therefore purely theoretical.
RNF213: As pointed-out in the results section (4.2.2.3), RNF213 is described as an
Ub-ligase with dual function as ATPase and was found significantly upregulated at day 1
and 3 after infection. The STRING DB analysis of the RNF213-interactome revealed
only proteins which were co-expressed together with the ligase and no direct interaction
partners. However, co-expressed proteins could be substrates of RNF213 or act jointly in a
pathway. Among those co-expressed proteins, USP18 and UBA7 are listed. Both of those
proteins not identified in this study are implicated in conjugation of ISG15 as activating
and deISGylating proteins respectively, at least in human [41,310]. This strongly hints
towards a combined ubiquitination and ISGylation function of RNF213. Additionally,
STAT1, IFIT3, IRF7, MX2, RSAD2 and IGTP, which were also co-expressed, are all
implicated in interferon-related immune responses according to their assigned GO terms
at the UniProt KB (GO version 142). In light of the affiliation of the co-expressed
protein, RNF213 might be a novel regulator of infection-induced ISGylation with a
broader activity window than RNF135.
UCHL3: UCHL3, which was found to be significantly downregulated during Lm liver
infection in this study, is not well described in literature. UCHL3-knockout mice exhibit
an elevated stress response and germ cell apoptosis [311,312]. As UCHL3 is closely related
to the DUB UCHL1, it might be that UCHL3 exhibits similar functions, as described in
other cases [312,313]. If that is the case, probable functions would be regulation of the
innate immune response and signaling via the Akt, Erk1/2 pathways also influencing Lm
invasion [80,314,315]. However, all those assumptions are highly speculative.
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5.3 The Time-resolved Hepatic Proteome of Lm Infection -
Research Reference and Clinical Guide
Apart from the Ubiquitin-related processes, the proteome of Lm-infected livers of course
revealed a manifold of protein regulations, both previously described and novel in the
context of Lm infection. This study was carried out in a mouse model system, however
mouse and human genomes are highly similar (97.5 %) and orthologous genes feature
a sequence similarity of 78.5 % [316, 317]. On the proteome level, mouse ranks in the
third place regarding the number of orthologous proteins (87 %) as determined by the
inParanoid tool, which compares proteome datasets [318]. Thus, it is highly likely that
results inferred from the model system are also of importance for research in the human
system.
Even though a cell type-resolved proteome of murine liver uncovered about 11.500 proteins,
an earlier quantitative study of the whole liver proteome could only detect about 2200
proteins [319,320]. However, even fewer comparative studies of non-infected and infected
liver on the proteome level were carried out and this study represents the first time-
resolved proteome of Lm infected murine liver. He and colleagues recently published the
liver proteome of Toxoplasma gondii-infected mice, containing 3600 quantified proteins
in two comparative conditions. They uncovered about 300 regulated proteins, with a
p-value < 0.05 [321].
The liver proteome analyzed in this thesis resulted in 3666 quantified proteins of which
522 were found to be significantly regulated with a p-value < 0.001, amounting to 14 % of
the total proteins (subsection 4.2.2). Furthermore, the analysis involved 3 time-points of
infection as well as a control, indicating a superior resolution of the proteome regarding
the course of infection and detection of significant protein regulation. Thus, this study
constitutes a base to guide further research on the influence of Lm infection on organs in
vivo.
Among the regulated proteins determined, many were identified to be proof-of-concept
data as described in the results section (4.2.2). A GO-annotation enrichment analysis of
the regulated proteins vs. the whole dataset utilizing the Gene Ontology enRIchment
anaLysis and visuaLizAtion tool (GOrilla) confirmed the general regulation of proteins
annotated as belonging to immune- and defense responses, e.g. acute-phase response, as
well as the cytokine response especially to IFN-β (Fig 54). From the significantly enriched
categories, two might be of special interest for further investigations (yellow star, Fig 54).
Firstly, proteins exhibiting a “defense response to virus“ could be of high interest to
better characterize the Lm-dependent immune response, as discussed extensively above
(5.2.1).
Proteins Involved in “Response to stress” are Interesting Candidates for Further
Research: A second category of interest is “response to stress”. There, proteins which
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Figure 54. Enriched GO terms regarding biological processes involved in immune re-
sponses and immune regulation. Regulated proteins were analyzed for their GO
annotation in the category biological processes and enrichment against the whole dataset
was calculated utilizing GOrilla tool (GO version 142) [322]. The p-values illustrated
are corrected for multiple testing. Processes discussed in more detail are marked with
a yellow star.
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are involved in “any process that results in a change in state or activity of a cell or
an organism [...] as a result of a disturbance in organismal or cellular homeostasis [...]”
are annotated [323]. Thus, subtracting the proteins annotated as involved in a defense
response from those responsive to stress should reveal novel candidate proteins, which
were previously not defined to be involved in defense responses, but were found regulated
in this study, hinting towards involvement in Lm infection and clearance or deregulation
by Lm.
For example, the protein disulfide isomerase 2 (PDIA2) found among the top-regulated
proteins at day 1 p.i. as well as PDIA3, PDIA4 and PDIA6 (all upregulated) were also
annotated as stress responders. Host PDIs in general were reported to be implicated in
Chlamydia cell entry and infection with the mouse polyomavirus [238,324].
Furthermore, overexpression of ISG15 was recently shown to lead to PDI clustering [34],
linking PDIs and ISGylation.
As a second example, the actin-bundling protein Plastin-2, which was also annotated
in this group and upregulated in this study, was found to be essential for the control of
pneumococcal infection in mice, and plastin was even described to be involved in listerial
actin assembly [325,326].
Among proteins annotated as stress responders, many were found to be additionally
annotated as implicated in actin-cytoskeleton remodeling or apoptosis, both processes
well known to be influenced by Lm [327,328]. This observation emphasizes the potential
of the proteome dataset obtained in this study as a basis for future research.
Apart from immune-related processes, metabolic processes were also found to be highly
enriched, indicating the severe influence of listeriosis on the physiology and metabolism
of liver (Suppl. Fig S18). For example, cellular respiration (oxidation-reduction process),
as well as cellular lipid and fatty acid metabolism were found to be deregulated during
Lm infection among other processes. Of special interest in the context of Lm infection is
the regulation of steroid metabolic processes and amino-acid metabolism and catabolism.
Furthermore, the epoxygenase P450 pathway was found to be enriched 4 times among the
regulated proteins, hinting towards a severe deregulation in drug metabolism (discussed
below).
In general, the dataset defines the temporal liver proteome response during sub-lethal
listeriosis for the first time and thus provides a valuable atlas of protein regulations as
well as novel candidate proteins for future research.
5.3.1 Influence of Biotransformation Enzyme Regulation on Drug
Metabolism of Listeriosis Patients
In total, this study identified about 100 proteins implicated in phase I and II biotrans-
formation, of which 46 % were significantly regulated (subsection 4.2.2.2). The most
prominently deregulated group of drug-metabolizing enzymes was the cytochrome P450
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family with over 60 % of significantly regulated proteins. This severe and sustained
downregulation found for many of the CYPs likely disrupts the hepatic drug-metabolism
as well as metabolism of endogenous substances. Especially in elderly and immunocom-
promised listeriosis patients, impairment of the drug-metabolism might lead to severe
side-effects not only in listeriosis treatment but also in treatment of unrelated conditions.
However, regulation of CYPs is not easily extrapolated from mouse to human, since
distinct differences between the murine and human CYP-family were described [329].
Nevertheless, for 16 of the 25 regulated CYPs quantified in this study, human orthologs
could be determined (Table 23). For 9 of those CYPs a single homolog was predicted
in human, while for another 2 CYPs prediction varied depending on the search routine
used, resulting in 2 homologs each (HomoloGene [330] / inParanoid [318]). Nelson and
colleagues suggested that for the one-to-one homologies, direct transfer of functions from
mouse to human might be meaningful [329].
For, e.g. Cyp2f2 and its human ortholog CYP2F1, it has be shown that both detoxify
naphthalenes although toxicity differs between men and mice [331]. For the human
homologs of Cyp7b1, Cyp8b1 and Cyp39a1, a role in bile-acid metabolisms was implicated
as curated in the ReactomeKB [332]. Similarly, Ccp4a10 (human CYP4A11) and
Cyp4a12a (human CYP4A22) are also not involved in xenobiotic conversion, but rather in
fatty acid metabolism and Cyp17a1 is described to participate in steroid metabolism [333].
In contrast to the CYPs discussed above, the human homologs of Cyp1a2, Cyp2b10,
Cyp2c29 and Cyp4f14 are involved in activation or degradation of xenobiotics.
Cyp1a2 (CYP1A2): CYP1A2 was described to be the human homolog of the murine
Cyp1a2 with a sequence homology of 73 % on amino acid level as determined by
using NCBI HomoloGene database [330]. Zanger and colleagues reviewed the Top-200
prescribed drugs in the U.S. and found that 9 % of those are partially or exclusively
processed by CYP1A2. Among the metabolized drugs described were antidepressants,
anti-psychotics, cardiovascular drugs, antiemetics, preventing vomiting, and muscle
relaxants [334]. Especially the latter three categories of medication might be readily
expected in the elderly or chronically ill patients. For example, tizanidine, metabolized by
CYP1A2, was described in managing spasticity in multiple sclerosis and other conditions
[335, 336]. The most interesting example for this study probably is theophylline, an anti-
asthmatic drug, which is mainly metabolized by CYP1A2 and has a narrow therapeutic
range [334,337]. For this substrate, intoxication is commonly described both following
drug interactions and infections. Furthermore, a prolonged half-time could be observed in
sepsis patients with multiple organ dysfunction syndrome [337–340]. Thus, theophylline
exemplifies the direct and grave sequelae of CYP-impairment.
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Table 23. Human CYP homologs of murine cytochrome P450 enzymes. Homology and
sequence identity on protein level were determined using NCBI HomoloGene database
[330]. Substrates and functions are inferred from UniProt KB entries and ReactomeKB
if not otherwise stated [230, 332]. Subscript letters indicate orthologs determined on
gene (g) or protein (p) level.
mouse
Cyp(s)
human
ortholog
aa seq.
identity
[%]
substrates/function of human CYP
Cyp1a2 CYP1A2 73 9 % / Top-200 prescribed drugs in theU.S [334]
Cyp2a4,
Cyp2a5 CYP2A6 84, 85
cyclophosphamide, ifosphamide
(anti-cancer drugs), phenacetin [341]
CYP2A7 82, 84 drug metabolism
CYP2A13 87, 89 drug metabolism
Cyp2b10 CYP2B6 79 4 % / Top-200 prescribed drugs in theU.S [334]
Cyp2c29 CYP2C8g 71 more than 100 drugs [342]
CYP2C18p 77 antipyrine, diclofenac, verapamil [343]
Cyp3a16,
Cyp3a41a,
Cyp3a11
CYP3A5
70,
72,
73
37 % / Top-200 prescribed drugs in the
U.S [334]
Cyp4f14 CYP4F12g 75
astemizole, terfenadine, ebastine
(antihistamines) [344,345],
fingolimod [346]
CYP4F2p 80 vitamin E, K1; leukotrienes [347–349]
Cyp2f2 CYP2F1 82 naphtalene (polyaromatichydrocarbon) [331]
Cyp7b1 CYP7B1 67 bile acid metabolism
Cyp8b1 CYP8B1 75 bile acid metabolism
Cyp39a1 CYP39A1 76 bile acid metabolism
Cyp4a10 CYP4A11 78 fatty acid metabolism
Cyp4a12 CYP4A22 75 fatty acid metabolism
Cyp17a1 CYP17A1 67 steroid metabolism
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Cyp2b10 (CYP2B6): Human CYP2B6, the ortholog of Cyp2b10, also plays a major
role in drug-metabolism by metabolizing a range of drugs [334]. In contrast to CYP1A2,
none of the substrates described so far for CYP2B6 is catabolized exclusively by this Cyp.
Consequently, impairment of CYP2B6 would probably not abolish the metabolization of
one of the substrates, but could, depending on the mechanism, lead to slower activation,
degradation of drugs or formation of an intermediate product.
Cyp2c29 (CYP2C8 & CYP2C18): Cyp2c29 and its human homolog on gene-level
CYP2C8 show 71 percent of sequence identity and CYP2C8 was recently described to
process more than 100 drugs [342]. However, the most probable ortholog on protein level
as determined by the inParanoid tool [318] is CYP2C18, which displayed a sequence
identity of 77 %. Therefore, it is not clear which of the human proteins would be
influenced in listeriosis. Nevertheless, both human CYPs metabolize a multitude of
xenobiotics with analgesics and antihypertensives among the known substrates [342,343].
In contrast to the one-to-one homologs discussed above, for some CYPs no direct
homologs could be determined due to gene-duplication or deletion on either, murine or
human, side.
CYP2A - subfamily: The human CYP2A subfamily contains 3 members, 2A6, 2A7 and
2A13, which were all determined to be orthologous or paralogous to the 2 murine CYPs
2a4 and 2a5 identified in this study [341]. Thus, no direct relation between the individual
proteins could be established. Additionally, the time point-resolved regulation detected
in this study indicated differential regulation dynamics of the murine Cyps. However, all
of the human isoforms were found to be involved in metabolism of xenobiotics.
A similar picture was also seen in the CYP3A subfamily. There also, the results of
this thesis revealed differential regulations of the murine Cyps, which also compromised
the transferability towards the human system.
While the interference with pharmacokinetics and drug disposition by both Lm infection
and infection in general, is known for many years, it is still not well understood and
probably underestimated [337,350].
W. Renton recently reviewed this topic and specified several scenarios in which the
effect of CYP-impairment could have detrimental results [337], all of which fully fit this
study. Clinical significance will emerge, e.g. when clearance of drugs with a narrow
therapeutic index, like theophylline, is primarily dependent on a single CYP, or when
not only the CYP-phase of detoxification but also other phases or substrate-transport
are disturbed, of which the latter is likely in Lm infection. Furthermore, increasing
incidence of Lm infection in the elderly and immunocompromised as well as chronically
ill patients leads to an averagely higher number of drugs present in the infected patients
as compared to otherwise healthy outbreak patients [109]. Consequently, inhibition or
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induction of CYPs due to other drugs and cross-reactions might additionally add to their
deregulation.
A further clinically relevant aspect is the high polymorphism of the CYPs, leading
to individual variations resulting in “good” and “bad” metabolizing alleles of many
CYPs [351]. Especially for the before-mentioned drugs with a low number of metabolizing
CYPs, an allele leading to a slow metabolism could, in combination with infection, lead
to an impaired activation of clearance of those drugs [337].
In general, it became evident that although the deregulation of the drug-metabolism
observed in this study is obvious and systemic, the impaired functions in human are not
easily deducible from the mouse data due to non-unique relationships between murine and
human CYPs. Nevertheless, the dataset readily presents clues for further investigation in
an adequate system, e.g. humanized mice or artificial human chip-based microtissues [352]
and draws attention to the general deregulation of physiological processes and the probable
clinical implications.
5.4 DUBs as Biomarkers in Diagnosis and Progression of Sepsis
This study aimed to examine whether DUB activities of blood lymphocytes are suitable
molecular markers for diagnosis or progression of sepsis in order to aid the search for
urgently needed but still missing clinically utilizable markers which are able to outperform
the subjective scoring systems in place at the moment [353].
DUB activity patterns were obtained for 71 % of all samples and analyzed by statistic-
aided pattern evaluation. However, it was not possible to derive a clear statement about
the predictive power of those patterns (subsection 4.3.2), despite the promisingly looking
early results (Fig 41 & subsection 4.3.1.2).
In fact, the approach to characterize DUB activities as a biomarker was both ambitious
and highly experimental, as no comparable studies were conducted so far. In general,
only few studies interpreted DUB activity patterns in a comparative way [102,103]. Ovaa
and colleagues profiled USPs in virus-infected and malignant human cells, revealing
activity patterns dependent on tissue origin and activation status of immune cells and
high heterogeneity between patterns [102]. On this basis, Rolen and colleagues profiled 25
cervical tumor biopsies and their healthy counterparts, revealing up- or downregulation
of 6 DUB activities. However, the authors did not utilize the full DUB pattern for
discrimination of cancer and healthy samples and denoted that the sample number was
too low to make a point regarding association of USP-activities with clinical stages of
the biopsies [103]. Nevertheless, the results of both studies validate the feasibility of the
approach of DUB activity-profiling used in this study.
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5.4.1 Sample and Pattern Heterogeneity Hampered the Assessment of
Predictive Power
Due to limited sample access, a set-up which included all blood-leukocyte samples
received from the surgical ICU was chosen for this pilot study, which was organized as a
case-control study.
Among them, samples from patients with septic shock and septic conditions in general
were dominating while SIRS samples were considerably underrepresented, especially as
two of the SIRS-classified patients developed a septic shock afterwards. For the OP
control samples, which represent the second control group beside SIRS, numbers are also
smaller than for the case groups (Tab 24). This imbalance poses one serious difficulty for
the evaluation of this pilot study, as case-control study results are most reliable if case
and control numbers are similar or if controls even outnumber cases 4 to 1 [354].
Table 24. Patient characteristics leading to high sample heterogeneity. The septic group
includes all samples from patients with sepsis, severe sepsis and septic shock. *: Two of
the patients, whose blood was drawn to serve as a SIRS sample developed a septic shock
afterwards, reducing the number of certain SIRS samples with a pattern to 2.
septic SIRS OP
# samples (f/m) 40 (19/21) 6 (1/5) 13 (7/6)
# samples w/ patterns 26 4 (2*) 12
avg. age 64.9 69.3 68.8
age span 31 - 88 57 - 85 46 - 80
avg.# of drugs administered 11.2 8.3 6.9
span of drugs 5 - 21 4 - 13 3 - 11
avg.# of antibiotics administered 2.0 0.7 0.3
span of antibiotics 0 - 4 0 - 2 0 - 2
% samples from patients w/ tumor 52.5 83.3 76.9
Apart from the sample imbalance, several other factors might have influenced the
predictive power of the results (see Tab 24):
• The ratio of samples from female and male patients differed for the SIRS group
(1:5) as compared to septic and control samples with an approximate 1:1 ratio.
This indicates that the SIRS group is not representative regarding the gender-
distribution.
• Case and control samples were not age-matched and the average ages differed
noticeably among the groups. The average age in the septic group was 4.4 years
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higher in the SIRS and 3.9 years higher in the OP control group, probably due to
lower sample numbers in the later groups. If age had an influence on the activity
patterns, it would have distorted the results for the different groups.
• The average numbers of administered drugs were higher in the septic group as
compared to SIRS and OP control. This trend even held true if antibiotics were
not included.
• The fraction of patients with a tumor removal was about 50 % in the septic group,
but above 75 % in the other groups, hinting towards a confounding association
between sepsis occurrence and the primary disease of the patients. Of the case pa-
tients without tumor, 17 displayed a primary inflammatory disease, e.g. peritonitis,
which might positively correlate with the development of sepsis.
In summary, all of the above mentioned characteristics probably influenced the DUB
activity patterns without being recognized, thus raising the sample heterogeneity to a
level difficult to manage with the small group sizes currently available.
5.4.2 Does the Cellular Composition of the Sample Influence the Resulting
Pattern?
As mentioned briefly above, previous studies of DUB activity patterns revealed distinct
patterns dependent on cell or tissue types as well as cellular activation status [102,103,210].
Thus, it might be possible that the cellular composition of the patient PBMCs influenced
the manifestation of the DUB activity patterns in the different samples.
Indeed, for erythrocytes, a putative contaminant of PBMCs, distinct but simple DUB
activity patterns were observed (data not shown). For other cell types present in PBMCs
of patients, no DUB activity patterns are available at present.
However, the compiled immune status of each patient recorded at the OVGUMagdeburg
contained data for different cell populations also present in PBMCs and therefore should
provide an impression of the average variation of prominent cell types.
Interestingly, the measured values were found to vary considerably, often leaving the
reference ranges, thus indicating changes in all cell populations as compared to the
healthy state. In contrast, the overall means as well as the individual means for the
septic, SIRS and OP-groups were found to lie in close proximity to each other as well
as well inside of the reference range for most of the cell types (Fig 55). The highest
differences were detected for total leukocytes, which showed highly increased numbers in
the septic group compared to mild increase in SIRS and OP-groups. However, even those
variations were small compared to the total variations between the extreme measured
values of each cell type.
Those considerable inter-patient variations mirrored by the immune status values
suggest that the cellular composition of the PBMCs is highly dynamic and distinct between
160
5 Discussion
Figure 55. Variation of cell types in patient samples determined as part of the patient
immune status. The floating bars contain all measured values from smallest to
the largest. All cell types marked in blue are also part of the PBMCs. The green
bar represents the reference range for each cell type, the black line represents the
overall mean, the dark red (septic), gray (SIRS) and gray dashed lines represent the
mean for each sample group, provided that they deviated visibly from each other.
Gpt / L: Gigaparticle per liter, WBC: white blood cells (leukocytes).
individual patients rather than only between the patient groups. If the DUB activity
patterns were distinct between different (immune) cell types as suggested previously
[102,103], this versatile composition of PBMCs would have a massive impact on the DUB
activity patterns acquired.
Thus, higher numbers of control samples would have been needed to obtain average
patterns typical for control or SIRS samples, which could then be compared with septic
patterns.
In summary, different factors were discussed, which likely have an influence onto
the inconclusive results of this pilot study. Some of them, e.g. differences in age, me-
dication and tumor-abundance could be avoided by careful selection of case-patients
and sampling of additional suitable control (SIRS and OP) samples. The role of in-
dividual cell types in the manifestation of DUB activity patterns, in contrast, could
be clarified at least for healthy donors by generation of cell type specific reference patterns.
In contrast to the pattern-based evaluation discussed above, the complementary
approach for the theoretical identification of active DUBs contributing to patterns by
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MS-aided bioinformatics proposed a panel of candidate DUBs, UCHL3, BAP1, USP2,
USP1, OTUB1 and USP47 (subsection 4.3.3), which might have predictive power and
should be validated. Possible next steps, thus, will be elucidated in the outlook section
of this thesis.
5.5 Probe-development
As part of this study, novel activity-based probes (ABPs) were designed and produced to
close gaps in the current repertoire of DUB-specific ABPs (see introductory section 1.3)
regarding the activity-based reactivity of C-terminal probes and substrate specificity of
context-introducing probes.
The characterization of the novel C-terminal probe HAUb-VFEA revealed a slightly
weaker reactivity as compared to the gold-standard HAUb-VME (subsection 4.4.1) but
additionally uncovered a potential substrate-dependent binding of DUBs, hinting towards
a distinct “activity-sensing” in HAUb-VFEA (Fig 49), which will be discussed below.
Additionally, two sets of Ubiquitin-isopeptide probes (UIPPs) were designed to examine
their value in the determination of linkage specificities of DUBs as well as to detect DUBs
that potentially regulate ubiquitination at the RTK c-Met. Therefore, both variants of
the UIPP-concept described in the introduction (1.3.2) were utilized.
The linkage specificity screening revealed the reactivity of 10 DUBs towards UIPPs
mimicking K27, K29, K33, K48 and K63 (subsection 4.4.2.1). Of the 4 designed substrate-
specific UIPPs targeting c-Met Ub-sites, only the c-MetK962-UIPP was produced and,
during screening of recombinant DUBs, uncovered 3 candidate DUBs, of which 2, USP21
and CYLD, were found to be at least putative interactors of c-Met (subsection 4.1.3.2).
Nevertheless, the uses and limits of the UIPP-concept will also be illuminated in more
detail.
5.5.1 Activity-based Capture of DUBs?
Generally, probes utilized for the labeling and enrichment of DUBs as described in the
introduction, are referred to as activity-based probes, but the definition of this term
remains ambiguous. Cravatt and colleagues outline ABPs as probes reporting on the
reactivity and structure of enzyme active sites, working on the bases on catalytic activity,
while Fonović and Bogyo only state that ABPs covalently modify the active sites of
enzymes [86,355]. More recently, Heal and colleagues described ABPs as directly detecting
the formation of a catalytically active site, and Yang and Liu described detection of
enzymes by ABPs as dependent on a protein’s enzymatic or binding activity under certain
conditions [82,356].
In summary, those reviews imply, that enzymes, in order to be reactive towards ABPs,
need to fulfill the following requirements:
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• The enzymes targeted must possess an active site, which is aligned in a manner
allowing for catalytic activity.
• An active-site amino-acid which allows an attack and covalent binding of the probe
needs to be present. In case of the cysteine-protease DUBs labeled in this study,
the nucleophilic attack of the ABP targets the active-site cysteine.
Indeed, several publications showed that exchange of the active-site cysteine of DUBs
abolished binding to HAUb-VME completely [80,97,357]. However, it was also shown that
HAUb-VME and Ub-aldehyde are capable of inducing a realignment of DUB active-sites
into the active conformation [267,358]. In general, the activity of DUBs is regulated by
a manifold of mechanisms, e.g. by PTMs, substrate binding, conformational changes
induced by own domains or binding proteins and even target binding (reviewed in [359]),
but it is not clear, which of those mechanisms would influence ABP-binding.
Activity Sensing of HAUb-VFEA: The novel ABP HAUb-VFEA further characterized
in this study did only weakly react with recombinant USP5 and not at all with USP7
(Fig 49). While USP7 was shown to be inactive, USP5 showed activity towards K63
poly-Ub chains and, when pre-incubated with the poly-Ub chains, showed an increased
reactivity with HAUb-VFEA but not HAUb-VME.
This binding behavior of HAUb-VFEA in vitro points towards a substrate dependent
binding mode in which the K63 poly-Ub chain probably realigns the active center of
USP5 to activate the enzyme as described previously [360]. Only then is HAUb-VFEA
able to bind to the now active DUB, thus representing the concept of activity-based
probes more consequently then HAUb-VME, which was also found reactive towards USP5
in absence of the substrate.
A similar consideration holds true for USP7, which was in an activatable state but
inactive in the assays of this study and not labeled by HAUb-VFEA in vitro, while in
situ it was readily reacting with the probe as demonstrated by the HA-IP from EL-4 cell
lysate (Fig 47).
In summary, HAUb-VME-binding to DUBs rather mirrors the general competence
to be active, independent of the actual activity, as it is able to rearrange the enzymes’
active-sites by itself as described before, while HAUb-VFEA seems to react only with
DUBs, whose active-site does not require further rearrangement. However, at this point,
it is not clear whether HAUb-VFEA is also able to discriminate DUB activity regulated
by PTMs or additional binding proteins.
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5.5.2 Uses and Limitations of the Ubiquitin-Isopeptide Probe Concept
5.5.2.1 Determination of DUB Linkage Specificity
For 10 DUBs, linkage specificities were detected utilizing the UIPPs designed and
produced in this study. In general, the review of previous studies probing the linkage
specificities of DUBs with ABPs and Di-Ub chains and comparison to the results of this
study revealed a higher degree of consistency between the different studies utilizing ABPs
than between ABP and Di-Ub based results (Tab 25).
Table 25. Linkage specificities reported for DUBs in this study as compared to previ-
ous results. The column “UIPP specificity” presents the results of this study. Results
from Iphöfer et al. and McGouran et al. were obtained utilizing ABPs [95,97]. Results
from Ritorto et al. [272] and others rely on cleavage of Di-Ub, except for those marked
with a p, which were also ABP-based [98,270,361]. ***: high reactivity, **: medium re-
activity, *: low reactivity.
DUB UIPP-specificity McGouran et al. Iphöfer et
al.
Ritorto et al.
(Di-Ub)
others
USP15 all K27**, K29**, K33*,
K48*, K63*
K48 = K63 low linkage
specificity
K11, K63
USP21 all / / low linkage
specificity
K6, K11,
K29, K48p,
K63p
USP47 all K27**, K29**, K33*,
K48*, K63*
K48 = K63 /
UCHL3 all K27**, K29*, K33*,
K48*, K63*
K48 > K63 low or no
activity
USP2 K27***, K29***,
K33***, K48***,
K63*
/ / low linkage
specificity
K6, K11,
K29, K48p,
K63p
USP25 K27*, K29**,
K33*, K48*
K27*, K29**, K33*,
K48*, K63*
/ low linkage
specificity
K27-, K29-
USP28 K27*, K29***,
K33***, K48***,
K63*
K27*, K29**, K33*,
K48*, K63*
(low) K48
> K63
low linkage
specificity
K63high
CYLD K27*, K29**,
K33*, K48*
/ / low linkage
specificity
K63high
K6, K63
UCHL5 K27*, K29***,
K48*
all * K48 > K63 low or no
activity
BAP1 (low) K27*, K29*,
K48*
/ (low) K48
< K63
low or no
activity
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For the DUBs with a broad specificity, e.g. USP15, USP21 and USP47, this observation
might not be relevant, as they react both with ABPs and Di-Ubs. However, UCHL3
for instance seems to be only minimally reactive towards Di-Ub [272,361], at least in in
vitro assays, while it readily reacts with all UIPPs used in this study including the c-Met
mimicking UIPP. Furthermore, UCHL3 could be retrieved from cell lysates with UIPPs
as well as other Di-Ub ABPs [95,97], which strongly hints towards activity in vivo.
Similar observations were also made for USP25 and USP28. While Di-Ub-based assays
indicate that K27 and K29 chains are not a substrate of USP25, both this study and
McGouran and colleagues suggest low reactivity against K27 and higher activity against
K29-chains in unison, although the latter study used an IP approach while the results of
this study are based on recombinant enzymes. USP28, in contrast, showed high reactivity
against K63 and moderate activity against all chain-types tested, while the UIPP and
Di-Ub ABP results suggest rather low activity against K63 chains (Tab 25).
Additionally, it became apparent that the in vitro assay results and former IP results
generated with UIPPs were not congruent. In detail, UCHL5 and BAP1 did not react
with the K63-UIPP in those assays but were identified following a UIPP-IP carried out
previously [95]. This might be due to additional specificity-facilitating proteins or factors
in complex cell lysates and is not be thought of as an inconsistency per se, especially
since for both DUBs reactivity against Di-Ubs in vitro was also found to be very low [272].
In summary, it is not obvious whether specificity data obtained by ABPs or Di-Ub
cleavage assays are more reliable for prediction of DUB-linkage specificities. Markedly,
the results differ obviously and partially even contradict each other. However, while
Di-Ub cleavage assays are restricted to in vitro assays with both recombinant substrate
and enzymes, Di-Ub-mimicking ABPs allow to profile DUB-specificity both in vitro and
in a more natural environment, i.e. cell lysate. Thus, it is likely that results obtained
by ABPs, when agreeing in vitro and in situ, are the more reliable estimates of linkage
specificity.
5.5.2.2 Mimics of Substrate Specific Ub-sites
In contrast to the UIPPs used to profile linkage specificity, this study also described
UIPPs mimicking ubiquitinated c-Met to capture the deubiquitinating enzyme. During
design and production of the set of 4 peptides, limitations of the approach regarding
peptide-synthesis and warhead ligation became perceptible.
Peptide Properties: A challenge during synthesis and ligation of the warhead peptides
was posed by the overall properties of the peptides. Both in solid-state peptide synthesis
and the ligation of the UIPPs, high hydrophobicity is problematic [362]. While the
peptide of the successfully ligated c-MetK962-UIPP contained 4 highly hydrophilic amino
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acids apart from the warhead-modified lysine (*) (Fig 56A) and thus possessed a good
solubility in aqueous solution, the peptide warhead of the c-MetK1259-UIPP was more
hydrophobic (Fig 56B) and not easily soluble in water as determined by PepCalc [363].
Although it would be possible to add solvents like dimethyl sulfoxide (DMSO) to the
peptide up to 1 % final concentration, the protocol for ligation would need to be verified
or even revised regarding solvent addition beyond that. Alternatively, a different chemical
approach of UIPP production could reduce the problems in peptide handling if it allows
harsher conditions during ligation of warhead and peptide.
hydrophilic 
hydrophobic 
* 
* 
hydrophilic 
hydrophobic 
A: c-Met (958-70) 
B: c-Met (1254-1264) 
Figure 56. Amino acid properties of peptides synthesized for c-Met-UIPPs. The images
were generated using PepCalc [363]. Light blue: basic, rose: acidic, gray: aliphatic, dark
green: polar, light green: aromatic amino acids. For each amino acid the height and
direction of the colored bar represents the impact on hydropathy. The star (*) denotes
the position of the warhead, influencing the properties of the lysine.
Additional Lysines in Chosen Peptide Sequences: In general, it is possible to synthesize
all conceivable peptides of substrate proteins. However, if the sequence of interest contains
additional lysines apart from the ubiquitinated one, an orthogonal protecting group
would be required during synthesis for protection of the lysine side-chain [95]. While this
approach is generally feasible, it complicates synthesis. Thus, in this study, additional
lysines were changed to alanine. This approach needs careful considerations, as amino
acid exchanges can influence peptide properties and interfere with formation of secondary
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structures, which likely occurs in UIPPs [95].
Despite the limitations and challenges in UIPP design and synthesis, the concept is
up to now the only activity-based approach which allows the production of substrate-
mimicking DUB ABPs in contrast to Di-Ub mimics [83]. Pao and colleagues recently
presented an approach utilizing a recombinant E2 enzyme, which was modified to harbor
a warhead-linked Ub, but this technique relies on recombinant production of the substrate
protein [364]. The UIPP concept in contrast is depending on the success of the solid-phase
peptide synthesis, which can be challenging, but is carried out in a well-defined artificial
environment as compared to protein expression.
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This study aimed to close gaps in the knowledge about the involvement of deubiquitinating
enzymes (DUBs) and ubiquitination (Ub) in Listeria monocytogenes(Lm) infection. On
that account, three main research questions were posed concomitant with three levels of
complexity of the model systems and samples investigated to solve these questions:
1. Are ubiquitination and DUB-activities involved in InlB/c-Met-mediated cell inva-
sion of Listeria? At the cellular level, the involvements of c-Met ubiquitination and
DUB-activities in InlB-mediated invasion were investigated in HeLa S3 cells. In total, 6
“ubiquitination-resistant” lysine to arginine mutants of c-Met were generated, including
single mutants of lysines 962, 1103, 1104 and 1259 as well as a double (K1103/04R) and a
quadruple mutant. The immunoblot-based pre-characterization of those mutants revealed
differential Erk1/2 and Akt phosphorylation especially for the double and quadruple
mutants, hinting towards changes in down-stream signaling. In contrast to that, the
cellular receptor-dynamics and localization following physiological (HGF) or pathogenic
(InlB) activation were found to be wt-like for all mutants.
As first DUB-candidates responsible for direct deubiquitination of c-Met, USP8 and
VCPIP1, which were previously found differentially phosphorylated after c-Met activation,
were microscopically analyzed but showed no colocalization.
To identify other DUBs, which are potentially able to remove Ub from c-Met, a novel
concept of substrate-specific activity-based probes, called UIPPs, was utilized. As a first
step, the concept was validated by a profiling of the specificity of DUBs with 5 UIPPs
resembling K27, K29, K33, K48 and K63-linked Di-Ubs. The results obtained for 10
recombinant DUBs were in accordance with results from other activity-based Di-Ub
probe concepts published previously. Following, four c-Met specific UIPPs were designed
and one of those, the UIPP mimicking c-Met ubiquitinated at K962, was successfully
produced. A screening of recombinant DUBs for reactivity with this UIPP revealed 7
reactive DUBs, of which 3 were further analyzed microscopically.
Of those, USP21 was detected in the vicinity of a distinct portion of c-Met following
receptor activation. The second candidate, CYLD, re-localized within the nuclei during
c-Met activation of the cells, but did not visibly co-localize with c-Met.
As CYLD was described to be of importance in Lm infection, it seems likely that it is
also involved in c-Met-mediated signaling during Lm invasion and furthermore also in
the physiological pathway.
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In general, the results support a model of receptor endocytosis driven by an, at least
partly, Ub-independent mechanism which only utilizes ubiquitination of c-Met accessory
proteins for determination of the receptor fate. This kind of mechanism, described previ-
ously for the EGF-receptor, would also be independent of direct c-Met deubiquitination,
rendering a DUB-activity redundant at this point.
2. Does Lm infection deregulate Ub-mediated processes and DUB-activities in vivo?
This question was investigated utilizing whole livers from a murine infection model of
systemic, sub-lethal listeriosis. At first, the suitability of the model system for proteomic
analyses was determined and the chosen time-points were characterized.
Expression profiles for 6 cytokines (IL-1β,IL-6, IL-12, IL-18, TNFα and IFNγ) as well
as the profiles of the major populations of infiltrating innate and adaptive immune cells
validated the suitability of the system and furthermore defined the individual time-points
regarding their immune status. Thus, the set-up represented three distinct stages of
infection:
• the early stage (day 1 p.i.), characterized by rising cytokine amounts and infiltrating
innate cells (macrophages, monocytes, neutrophils and NK cells),
• the peak stage (day 3 p.i.), characterized by peaking cytokine profiles as well as
bacterial numbers and
• the late stage (day 9 p.i.), characterized by decreasing cytokine amounts and the
infiltration of B and T cells.
Based on the characterized model system, a workflow for proteomics of liver samples was
established and allowed a comparative time course analysis of liver proteome responses
utilizing 12 individual mice in 3 independent replicates.
Despite of the inter-mouse variability of the samples, 3666 proteins were quantified
throughout the study. Of those, 522 were determined as significantly regulated at least at
one time-point, while only 15 were found to be permanently regulated. These results indi-
cate an extensive and highly dynamic regulation of the liver proteome during Lm infection.
The proteins found regulated in this study included both, proof-of-concept data as
well as novel candidates for further research, e.g. knock-out studies, to elucidate the
candidates’ roles in Lm infection. Thus, the dataset can be regarded as a comprehensive
resource for basic research in Lm infection in terms of host reactions as well as candidate
proteins for functional studies.
Most interestingly, an extensive and sustained deregulation of the cytochrome P450
(CYP) enzyme family implicated in drug metabolism was demonstrated. Of 42 detected
CYPs, 25 were significantly regulated and 4 of those did not show recovery of protein
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amounts even at day 9 p.i. Additionally, non-CYP phase I and phase II drug-metabolizing
enzymes were also deregulated. 50 % of the phase I and 33 % of the phase II enzymes
identified were also found to be heavily deregulated during Lm infection. As with the
CYPs, most of those proteins were down-regulated, jointly suggesting a substantial
impairment of the liver-mediated drug-metabolism in listeriosis.
Of the murine CYPs, 9 were found to possess direct human homologs which play
major roles in drug activation and degradation. Thus, the results are a valuable starting
point for analyses in humanized mice or other systems and furthermore underline the
importance of continuous monitoring of listeriosis patients to prevent drug intoxication.
While other physiological processes were both extensively identified and found regulated
in this study, protein groups playing a role in regulation of ubiquitination or Ub-binding
were also substantially identified, representing 15 % of all proteins, but only sparsely
regulated. Of the 6.7 % of regulated proteins belonging to the aforementioned categories,
6 % were found to be Ub-binding. Of course, for Ub and UBLs as post-translational
modifications, changes in protein-abundance are not mandatory prerequisites for changes
in activity. Hence, the significant regulation of the two Ub-ligases RNF135 and RNF213
detected in this study might be of high importance, as they both were found to distinctly
and dynamically upregulated during Lm infection.
Apart from the general proteomic analysis, DUBs were enriched and analyzed by the
activity-based probe (ABP) HAUb-VME to characterize DUB-regulation during Lm
infection. The immunoprecipitation approach resulted in the quantification of 52 DUBs of
which two, USP2 and UCHL3, were found to be significantly downregulated. Both were
not described for Lm infection so far, rendering both as promising and novel candidates
for further research.
Markedly, both the Ub-ligase RNF135 and the DUB USP2 are implicated in regulation of
ISG15-dependent RIG-I like receptor (RLR) immune-signaling which was found regulated
during Lm infection in a pathogen-specific way. The regulation of RLR-signaling is
based on ISGylation and ubiquitination, which should therefore be directly analyzed to
complement the current knowledge of Ub-mediated signaling in Lm infection.
As mentioned above, DUBs were enriched utilizing the gold-standard probe HAUb-
VME. At the moment, it is unaccounted for whether the ABP is only reactive towards
active DUBs. To overcome this uncertainty, HAUb-VME and the novel probe HAUb-
VFEA were comparatively profiled for their reactivity with DUBs in cell lysates and
against recombinant enzymes. Both showed broad DUB binding, but HAUb-VFEA
bound to a lower total number of DUBs in both approaches. However, in vitro assays
utilizing the recombinant DUBs USP5 and USP7 and their natural substrate K63-poly-Ub
chains revealed that HAUb-VME reacted with both DUBs irrespective of their actual
cleavage-activity. In contrast, HAUb-VFEA only bound to the active DUB in presence
of the substrate.
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Thus, HAUb-VFEA proved to be a more selective as well as consistent in activity-
sensing towards recombinant DUBs, suggesting HAUb-VFEA as a valuable profiling tool
for DUB-activities.
3. Can DUB activities serve as molecular biomarkers for the diagnosis or prognosis of
sepsis? The third part of this thesis tried to answer the question whether DUB-activities
of blood PBMCs are potential biomarkers for the diagnosis or prognosis of sepsis.
To this end, PBMC-samples from ICU patients showing signs of either sepsis, severe
sepsis or septic shock were collected and compared to patients with SIRS, surgery
only and healthy control samples. First, an approach was established to portray the
individual immune status of each patient by a cellular DUB-activity profiling. Additionally,
evaluation routines were developed, which allowed standardized comparison of the DUB-
patterns between patients and to theoretically identify the single DUB-activities in a
mass spectrometry aided approach.
The immunoblot-based analysis yielded 26 patterns from septic patients (sepsis, severe
sepsis or septic shock) as well as 4 from patients with SIRS, 12 from OP controls and 19
from healthy control samples. First results did show promising differences, however, the
overall pattern analyses did not yield clear discrimination between any of the examined
groups. In general, the patterns showed a high heterogeneity and the study evaluation
was compromised by the relatively few samples available, especially for the SIRS and
sepsis groups. Nevertheless, a suggestion for an alternative approach, identifying two
groups of patients for analyses, is possible. The first group would contain those pa-
tients which show patterns very similar to a prototypic pattern e.g. of sepsis, that thus
can be assigned to one distinct class. The second group, in contrast, would comprise
those patients which could not be assigned with this method. This evaluation could at
least allow classification or prediction of the sepsis state for a part of the patients sampled.
In contrast to the inconclusive results outlined above, the MS-aided theoretical DUB
assignment resulted in a number of candidate DUBs, which were predicted with differing
frequencies for the sample classes. Those DUBs, i.e. USP1, USP2, USP47, UCHL3,
BAP1 and OTUB1, should be validated for their predictive power by utilizing a combined
approach of specific antibodies and ABP-labeling to determine their activity status (see
outlook).
In essence, this study contributes to the understanding of DUB-activities involved in
Lm invasion and infection at different degrees of complexity. On the cellular level, two
novel DUB candidates were found which might be involved in c-Met-mediated cell invasion
of Lm but in any case do contribute to our understanding of physiological c-Met signaling.
Furthermore, the proteome and DUB-activity results obtained from the sub-lethal murine
infection model of listeriosis add novel candidate Ub-ligases and DUBs involved in the
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regulation of immune signaling to the current knowledge and additionally characterize
the influence of Lm infection on the host physiology, thus serving as a resource for further
research. While DUB-activity patterns in general could not be established as biomarkers
for sepsis diagnosis or progression in samples from ICU-patients, a theoretical approach
of DUB assignment aided by mass spectrometry suggested 6 DUB-candidates, which
should be further investigated and putatively provide predictive power.
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7.1 Listerial Deconjugase- and Ligase-activities
While in Gram-negative bacteria and other pathogens like viruses and protozoa, numerous
Ub-ligase-like effectors and UBL-deconjugation enzymes are expressed [60,289], no such
enzymes are described for Gram-positive bacterial pathogens. With respect to the similar
intracellular live style in close contact with the host, it seems unlikely that Listeria
does not possess enzymes of those functions while Gram-negatives like Salmonella and
Legionella do. Moreover, recent results demonstrated that Lm wields influence on distinct
ubiquitin-like modifiers, e.g. SUMO [25].
Thus, it would be of high interest to examine the Lm proteome for ligase-like effectors
or DUBs. While for ligase-like effectors, no screening system is described and candidates
from other pathogens required laborious manual validation [365,366], screening for DUBs
would be readily realizable by using ABPs.
Utilizing ABPs, it would be possible to directly screen lysates harvested from bacteria
in general and under distinct conditions, e.g. nutrient deprivation or high temperatures,
for DUBs. In this way, permanently active deconjugases as well as those activated in
special conditions only would be assessable.
To investigate DUB-activities related to infection, screening of cellular lysates of infected
cells would also be a promising approach, as exemplified by Misaghi and colleagues, who
identified a Chlamydia trachomatis DUB active only during infection utilizing HAUb-
VME [367]. For Lm, a similar approach, either using HeLa S3 cells or even primary
hepatocyte spheroids is conceivable [368]. Additionally, it would also be feasible to infect
those cells with fluorescently or magnetic bead-labeled Lm and then isolate bacteria from
the infected cells [369, 370]. Subsequently, the isolated bacteria could then be directly
profiled for active DUBs without the inference from host proteins. Furthermore, taking
advantage of the modular setup of ABPs, the specificity element could be changed from
ubiquitin to other UBLs, e.g. NEDD8 or SUMO, without changing the warhead. Thereby,
it would be possible not only to detect DUBs but also activities of deconjugating enzymes
of other UBLs under the same conditions.
Obviously, putative deconjugating activities need to be identified for further charac-
terization. The ABP-approach would allow identification of a putative bacterial DUB
by utilizing an HA-IP workflow. Next steps would include the determination of the
candidates’ role in Lm infection utilizing Lm knockout strains as well as the recombinant
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expression of the candidates for in vitro assays, e.g. determination of cleavage specificities
and putative substrates.
Should putative listerial deconjugating enzymes not possess a cysteine-based activity,
reactivity towards ABPs would, of course, be unlikely. In that case, a feasible way to
investigate deconjugating activities would be the incubation of recombinant Ub-chains
with bacterial lysates to obtain first hints.
7.2 From DUB Patterns to Identified DUB Biomarkers
The heterogeneity among the available samples complicated the analysis of the predictive
power of DUB-activity patterns and did not allow the clear allocation of all samples to
the different classes based on clustering of their patterns. Nevertheless, the clustering
did reveal samples which were similar to each other and clustered together.
To lessen the influence of sample heterogeneity on the predictive power of the patterns,
an approach based on standard patterns obtained for each sample class might be suitable.
Thereby, the extracted data would have to be processed class-wise, calculating the mean
or summed intensities of the patterns pixel-wise, thus calculating a standard pattern
which represents the average properties of a pattern. As a first step, a statistical algorithm
is needed for building the standard patterns as well as to calculate the difference of an
individual pattern from all standard patterns, and then assign it to the class with the
smallest difference. “Summed” standard patterns which are built from the signals with
the highest intensities might be suitable for the discrimination, as they show distinct
differences between the classes (Fig 57). Another possibility would be the use of “median”
or “mean” standard patterns. For all of these approaches, testing of the available samples
utilizing the leave-one-out method [371] would allow the determination of a threshold for
a good assignability to a class, minimizing both false-positives and -negatives.
The DUB-activity patterns generated in this study represent the entirety of activity-
competent DUBs in each of the samples. However, identification of individual DUBs
is not easily realizable by this approach without the utilization of a great number of
antibodies. In contrast, mass spectrometry allows identification of enriched DUBs but
relatively high amounts of protein are needed.
The MS-aided theoretical DUB-assignment (subsection 4.3.3), a combination of both
approaches, resulted in a number of candidate DUBs which could be of use as diagnostic
and progressive markers in sepsis.
The logical next step of those theoretical results is of course the validation utilizing
samples from patients exhibiting different sepsis states. The most straight-forward
approach would be immunoblotting of the candidate DUBs to confirm their presence
in the respective samples. However, in this way, the activity information for the DUBs
would be lost.
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To preserve this information, labeling of the total DUB-activities utilizing ABPs could
be carried before western blotting. In contrast to the screening approach which generated
the patterns, staining with a DUB-specific antibody would reveal the activity pattern
of this single DUB only. As described recently [372], the blot would show two bands at
different molecular weights if a DUB becomes inactive and thus nonreactive towards the
ABP. Increased concentrations of active DUB, in contrast, would result in one band with
increasing signal intensity at a molecular weight corresponding to
the DUB including covalently linked ABP.
First of all, the 6 candidate DUBs identified in this thesis should be tested utilizing a
combination of ABPs and DUB-specific antibodies. If those candidates do not suffice to
cover all stages of sepsis conveniently, the results of the theoretical assignment indicate
additional DUBs. A bioinformatics approach could be used to determine the DUBs most
predictive for each stage, based on the identification rates which were determined for all
DUBs. Thus, additional DUB-activities can be proposed for inclusion into the panel.
In general, the results from the validation could furthermore be combined with other
Figure 57. Schematic representation of
standard "summed" patterns for all sample
classes. Standard “summed” patterns were built
from the class-wise sum of bands of the respective
samples. Bands with an intensity higher than
3 times the median intensity of the samples are
depicted in black, higher than 2x in dark gray,
higher than the median in gray and all below in light
gray. The merged band patterns depict a summed
distribution of signal-intensities which might emerge
in a pattern of each sample class. Comparison of
an individual patient-pattern to those standard
patterns could then allow a classification of the
samples.
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prospective biomarkers to yield more robust results [179].
The most promising biomarkers for the combination with DUB-activities would be
those, which might complement the putative predictive powers of DUB-activities. As the
experimental design used in this study is based on drawing venous blood from patients,
most of the current biomarker candidates could be detected in the serum which is also
extracted during gradient centrifugation without great effort.
For example, a combination of DUBs with C-reactive protein or procalcitonin could be
considered for support of diagnosis, while angiopoietins, proadrenomodullin or endocans
would aid the prognostic powers. If a general boost in predictive power is needed, a
combination with sTREM-1 or sCD14 would also be feasible, as these molecules are
accessible in serum after proteolytic cleavage, too.
7.3 18O labeling as a Method for Quantitative Determination
of Ubiquitin Modifications in Patient Samples
DUBs increasingly come into the focus of attention in clinical research which led to a
number of adapted approaches and workflows for systematic DUB-analyses in such samples.
In contrast, analysis of ubiquitination events, which would complement the knowledge
of Ub-mediated processes, is currently mainly carried out for single candidate proteins.
One major constraint in realizing an unbiased screening approach for ubiquitination sites
are the insufficient quantitation methods for the predominant workflow for identification
of ubiquitinated peptides. By this approach, called ubiquitin-remnant enrichment,
ubiquitinated peptides are enriched utilizing an antibody and subsequently analyzed
by mass spectrometry to yield information about the localization of Ub-sites and their
dynamics [373].
The Ub-remnant method itself is well established [374], however, it is incompatible with
chemical labeling strategies like iTRAQ and tandem-mass tags (TMT), as the antibody
will not recognize the iTRAQ- or TMT-modified ubiquitinated peptides (Fig 58A) [374].
Labeling after enrichment of Ub-peptides is possible in theory, but the additional label
at the di-glycine residue complicates the analysis of those peptides, resulting in a low
number of Ub-sites even at high sample amounts in a recent study [375].
Thus, for clinical samples, which cannot be labeled metabolically, e.g. primary cells
and tissues, only label-free quantification is available at the moment. However, this
technique is not very reliable for quantification based on single peptides [376] which is
common in Ub-remnant datasets. To introduce robust Ub-remnant analyses for such
samples, a different labeling technique has to be utilized.
One feasible concept is the utilization of C-terminal 18O labeling. This labeling strategy
introduces heavy oxygen into the C-terminus of peptides by utilizing trypsin in heavy
water to exchange both available 16O molecules and creates a mass shift of 4 Da [8, 377].
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Figure 58. Advantages of 18O-labeling for the quantitative analysis of enriched ubiqui-
tinated peptides. (A) Status of the ubiquitinated (GG-modified) lysine of a peptide
following iTRAQ or 18O-labeling. The modified lysine is highlighted in light blue, both
glycines which remain after ubiquitination in light green. The iTRAQ or 18O-labels are
highlighted in red. (B) Schematic representation of a mass spectrometric workflow for
18O-labeling and subsequent enrichment of ubiquitinated peptides (GG-enrichment).
Oxygen 18 is presented as a red circular shape, oxygen 16 in gray, both in water
molecules and in-cooperated in the C-terminus of peptides.
In contrast to iTRAQ- or TMT-labeling, the di-glycine residue of ubiquitinated peptides
is not modified further by this method, presumably allowing for labeling ahead of the
Ub-remnant enrichment and more convenient mass spectrometric detection (Fig 58B).
However, a disadvantage of 18O labeling is that only two conditions may be compared
in one experiment. Nevertheless, as labeling with heavy water is relatively cheap as
compared to all other labeling techniques [377], the approach would still be viable with a
higher amount of samples and certainly for the model systems presented in this study.
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For clinical samples, the most crucial limitation would be the sample amount. To
isolate ubiquitinated peptides successfully, at least 1 mg of total protein is needed [378].
This would amount to approximately 1-2x107 PBMCs, which would be achievable for
most of the patient sepsis samples received so far, but leaving little scope for additional
DUB-activity analyses due to different cell lysis protocols. Doubling the amount of blood
drawn to 14 ml would certainly suffice for the analysis and be acceptable even for ICU
patients.
In summary, 18O labeling would be particularly promising for the analyses of patient
samples, as it would allow to both quantitatively analyze the proteome and the ubiqui-
tination sites in parallel. Thus, establishing and utilizing this technique especially for
clinical samples could make valuable information on changes in ubiquitination available
for clinical issues.
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Appendix
Supplementary Data
Supplementary Figures
Figure S1. K1259 is ubiquitinated in HeLa S3 cells after 30 min of HGF stimulation.
Ub-sites were pulled from HeLa S3 cell lysates by Ub-remnant enrichment. The spectrum presents
the tryptic peptide containing the GG-modified K1259 and was manually validated. Blue peaks
present y-ions, red peaks b-ions. Green peaks represent different mother-masses. Mascot scores and
measurement errors are given.
glycine vinylformicacid (VA) 
glycine vinylmonofluoroethylamide (VFEA) 
glycine vinylmethylester (VME) 
Figure S2. Structures of C-terminal electrophilic warheads
used in this study. VA is the precursor-structure used to produce
VFEA and the peptide-mimicking UIPP-warheads.
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Figure S3. VCPIP1 localization during HGF stimulation in HeLa S3 cells. HeLa cells
were stimulated with 10 nM HGF for the indicated time periods and subsequently stained for c-Met
(green), VCPIP1 (red) and DNA content (blue). Finally, samples were analyzed via epifluorescence
microscopy. The white bar represents 10 µm. The negative control (0 min(neg)) shows cells which
were only starved, but not stimulated. The HEPES control is stimulated with the buffer of HGF for
60 min.
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Figure S4. VCPIP1 localization during InlB stimulation in HeLa S3 cells. HeLa cells
were stimulated with 10 nM InlB for the indicated time periods and subsequently stained for c-Met
(green), VCPIP1 (red) and DNA content (blue). Finally, samples were analyzed via epifluorescence
microscopy. The white bar represents 10 µm. The negative control (0 min(neg)) shows cells which
were only starved, but not stimulated. The MES control is stimulated with the buffer of InlB for
60 min.
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Figure S5. USP8 localization during HGF stimulation in HeLa S3 cells. HeLa cells were
stimulated with 10 nM HGF for the indicated time periods and subsequently stained for c-Met
(green), USP8 (red) and DNA content (blue). Finally, samples were analyzed via epifluorescence
microscopy. The white bar represents 10 µm. The negative control (0 min(neg)) shows cells which
were only starved, but not stimulated. The HEPES control is stimulated with the buffer of HGF for
60 min.
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Figure S6. USP8 localization during InlB stimulation in HeLa S3 cells. HeLa cells were
stimulated with 10 nM InlB for the indicated time periods and subsequently stained for c-Met
(green), USP8 (red) and DNA content (blue). Finally, samples were analyzed via epifluorescence
microscopy. The white bar represents 10 µm. The negative control (0 min(neg)) shows cells which
were only starved, but not stimulated. The MES control is stimulated with the buffer of InlB for
60 min.
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Figure S7. Localization of USP2 at distinct time points of InlB stimulation in HeLa
S3 cells. All cells were stimulated with 10 nM InlB for the indicated time periods. Subsequently,
stimulation was abolished by fixation of cells. Finally, the cells were stained for c-Met (green), USP2
(red) and DNA content (blue), and USP2 localization was evaluated. The white bar represents
10 µm. The 0 min (neg) sample was only rested but not stimulated. The MES control is stimulated
with the buffer in which InlB was present for 60 min.
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Figure S8. Localization of CYLD at distinct time points of InlB stimulation in HeLa
S3 cells. All cells were stimulated with 10 nM InlB for the indicated time periods. Subsequently,
stimulation was abolished by fixation of cells. Finally, the cells were stained for c-Met (green), CYLD
(red) and DNA content (blue), and CYLD localization was evaluated. The white bar represents
10 µm. The 0 min (neg) sample was only rested but not stimulated. The MES control is stimulated
with the buffer in which InlB was present for 60 min.
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Figure S9. Localization of USP21 at distinct time points of InlB stimulation in HeLa
S3 cells. All cells were stimulated with 10 nM InlB for the indicated time periods. Subsequently,
stimulation was abolished by fixation of cells. Finally, the cells were stained for c-Met (green), CYLD
(red) and DNA content (blue), and USP21 localization was evaluated. The white bar represents
10 µm. The 0 min (neg) sample was only rested but not stimulated. The MES control is stimulated
with the buffer in which InlB was present for 60 min.
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Figure S10. Statistical characterization of proteomic data from Lm infected liver
samples. All plots were created using R software package (A) Boxplots of all samples are depicted.
The plots indicate the variation in each individual sample by the box, representing 50 % of all data
points and containing the median, which was normalized to zero as well as whiskers, which depict
the quartiles. (B) Day-wise scatter plots of the replicates show a strong correlation at day 3 p.i. and
weaker correlations at day 1 and 9 p.i.. (C) Individual day-wise Pearsson correlation factors for the
dataset as calculated by R software.
Figure S11. Extrapolation of marker pixel lines of ICU patient samples and healthy
control samples utilized in this study for the read out of band molecular weight. (A)
Extrapolation of markers from blots of ICU patient samples. (B) Extrapolation of markers from
blots of healthy control samples. Lines between the determined marker bands were determined by
linear conjunction of neighboring bands.
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Figure S12. Regulation of active
DUBs quantified in hepatic Lm
infection illustrating RFs for each
replicate. The columns show the
regulation factors of each distinct DUB
in a day-wise manner listing the three
replicates individually. Downregulation
is represented in blue, upregulation
in red, gray signifies that DUBs
were not found and significance in
regulation is indicated by two asterisks
(p-value < 0.01). Protein names of
regulated proteins are displayed in bold.
In general, the heat map revealed a high
level of noise between the replicates
with partly contradictory regulations for
single DUBs.
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Figure S13. Results of hierarchical clustering and MDS for a threshold of 7 pixel.
(A) Hierarchical clustering of all 61 samples. (B) MDS of the all samples. Hierarchical clustering
and MDS were carried out for all samples utilizing R software.
234
Figure S14. Results of hierarchical clustering and MDS for a threshold of 10 pixel.
(A) Hierarchical clustering of all 61 samples. (B) MDS of the all samples. Hierarchical clustering
and MDS were carried out for all samples utilizing R software.
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Figure S15. Results of hierarchical clustering of sepsis samples with different pixel
thresholds. Hierarchical clustering was carried out for all samples utilizing R software. The
thresholds on the left site describe the pixel difference that determines whether to bands were
considered the same in different DUB patterns. The addition log indicates a logarithmic scaling of
the data. Clusterings with double median were narrowed down to signals which showed intensities
above the double median intensity of each individual experiment. The following color-code was
used: 1 (black) = healthy controls, 2 (red) = OP controls, 3 (dark green) = SIRS, 3 (light
green) = patients with SIRS but succeeding septic shock, 4 (blue) = sepsis, 5 (purple) = severe
sepsis, 6 (orange) = septic shock.
Figure S16. Heat map of DUBs identified
via HA-IP in pool of 5 healthy control
samples. Gray names indicate DUBs which
were identified, but are in theory not reactive
towards HAUb-VME. The blue color indicates
the peak-area of proteins as determined by PD.
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Figure S17. Shift-assays of the c-MetK962-UIPP to identify DUBs which potentially
remove Ub from the probed site. All recombinant DUBs were incubated with c-MetK962-UIPP
for 1 h at 37°C and subsequently evaluated by western blotting using an α-HIS6 antibody for
detection. A shift in the lane with UIPP as seen for CYLD, USP2, USP21, UCHL3, BAP1, USP15
and OTUB1 indicates binding of the probe to the respective DUB.
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Figure S18. Enriched GO terms regarding biological processes involved in physiological
metabolism during Lm infection. Regulated proteins were analyzed for their GO annotation in
the category biological processes and enrichment against the whole dataset was calculated utilizing
GOrilla tool ( GO version 142) [322]. The p-values illustrated are corrected for multiple testing.
Processes, which are discussed in more detail are marked with a yellow star.
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Table S1. c-Met ubiquitination sites as annotated in PhosphositePlus DB.
[1] Kim, W., Bennett, E.J., Huttlin, E.L., Guo, A., et al., Systematic and quantitative assessment of
the ubiquitin-modified proteome. Mol. Cell 2011, 44, 325–40.
[2] Wagner, S.A., Beli, P., Weinert, B.T., Nielsen, M.L., et al., A proteome-wide, quantitative survey
of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell. Proteomics 2011, 10,
M111.013284.
[3] Wagner, S. & Beli, P., Weinert, B.T., Scholz, C., et al., Proteomic analyses reveal divergent
ubiquitylation site patterns in murine tissues. Mol. Cell. Proteomics 2012, 1578–1585.
Site Org. Sequence Domain Source
K189 human AKVLSSVk
DRFINFF
Sema [1]
K223 human VRRLKETk
DGFMFLT
Sema [1]
K324 human LQAAYVSk
PGAQLAR
Sema [1]
K765 human STITGVGk
NLNSVSV
IPT/TIG
(3.)
[1]
K962 human LKKRKQIk
DLGsELV
/ [1],[2]
K1104 human LLDNDGKk
IHCAVKS
kinase CST curation set
K1161 human LVVLPYMk
HGDLRNF
kinase [1]
K1190 human GFGLQVAk
GMKYLAS
kinase [1]
K1193 human LQVAKGMk
YLASKKF
kinase CST curation set
K1232 human LARDMYDk
EYYSVHN
kinase [1]
K1240 human EYYSVHNk
TGAKLPV
kinase [1]
K1529
K1257
human
mouse
LESLQTQk
FTTKSDV
kinase Ub-remnant of HGF-stimulated
HeLa S3 cells (Fig S1), [3]
K1318 human PLYEVMLk
CWHPKAE
kinase CST curation set
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Table S2. Parameters used for mass spectrometric measurements. HCD = Higher-energy
collisional dissociation, CID = collision induced dissociation. Letters in brackets denote the analysis
settings used in d = DUB-enrichment, p = proteome, m = DUB-enrichment in method development.
parameter value (p/d) value (s) value (m)
mass
spectrometer
3 3 1, 2
method
duration
175 min 175 min 215 min
gradient
duration
120 min 120 min 180 min
gradient
composition
3.7% - 31.3 %
solvent B
3.7% - 31.3 %
solvent B
3.7% - 31.3 %
solvent B
flow rate
(load/run)
6 μL/min,
30 µL/min
6 μL/min,
30 µL/min
6 μL/min,
30 µL/min
MS-mode data-dependent data-dependent data-dependent
method type Top N Top N Top 10
survey cycle 3 s 3 s /
collision
technique
HCD CID CID
detector orbitrap ion trap ion trap
scan range 350 - 1500 350 - 1500 400 - 2000
collision
energy
38 35 35
charge states 2-4 2-4 2-4
max.
collection
time
60 ms 30 ms 100 ms
repeat count 1 1 1
exclusion
duration
30 s 30 s 50 s
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Table S3. Primers used for site-directed mutagenesis of pcDNA 3.1 c-Met-eGFP. All
primers were designed to exchange lysine (K) to arginine (R) to produce ubiquitination-deficient
mutants. The mutated codon is marked in bold letters in each sequence. Tm = melting temperature.
Name Primer sequence (5’ to
3’)
Base exchange Tm [°C] GC content
[%]
c-Met
K962R
for
GGCTGAAAAAGAG
AAAGCAAATTAGA
GATCTGGGCAGTG
AAA ⇒AGA 79.5 43.6
rev CACTGCCCAGATC
TCTAATTTGC
TTTCTCTTTTTCA
GCC
TTT ⇒TCT
c-Met
K1103R
for
GGACAATGATGGC
AGGAAAATTCACT
GTGCTGTG
AAG⇒AGG 78.0 47.1
rev CACAGCACAGTGA
ATTTTCCTGCCAT
CATTGTCC
CTT⇒CCT
c-Met
K1104R
for
GGACAATGATGGC
AAGAGAATTCACT
GTGCTGTG
AAA ⇒AGA 78.0 47.1
rev CACAGCACAGTGA
ATTCTCTTGCCAT
CATTGTCC
TTT ⇒TCT
c-Met
K1103R
K1104R
for
GGACAATGATGGC
AGGAGAATTCACT
GTGCTGTG
AAG ⇒AGG
AAA ⇒AGA
77.8 48.6
rev CACAGCACAGTGA
ATTCTCCTGCC
ATCATTGTCCAAC
CTT ⇒CCT
TTT ⇒TCT
c-Met
K1259R
for
GGAAAGTCTGCAA
ACTCAAAGGTTTA
CCACCAAGTCAG
AAG ⇒AGG 79.4 44.7
rev CTGACTTGGTGGT
AAACCTTTGAGTT
TGCAGACTTTCC
CTT⇒CCT

Appendix
Table S4. Proof-of-concept: Acute-phase proteins and complement activating compo-
nents found in this study.
[1] Gruys, E., Toussaint, M.J.M., Niewold, T.A., Koopmans, S.J., Acute phase reaction and acute
phase proteins. J. Zhejiang Univ. Sci. B 2005, 6, 1045–56.
[2] Bode, J.G., Albrecht, U., Häussinger, D., Heinrich, P.C., Schaper, F., Hepatic acute phase
proteins - Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with
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Table S5. Identified but non-regulated members of the cytochrome P450 family.** =
found in 2 out of three replicates, * = found in one replicate. Regulation, if observed, was not
significant for all listed proteins.
[1] Pan, J., Xiang, Q., Ball, S., Scatina, J., et al., Lipopolysaccharide-mediated modulation of
cytochromes P450 in STAT1 null mice. Drug Metab. Dispos. 2003, 31, 392–397.
Gene name d1/d0 mean
RF
d3/d0 mean
RF
d9 /d0 mean
RF
Regulation in (Lm) infection
Cyp3a13 0.19 0.46 -0.08
Cyp2a12 -0.04 -0.52 -0.62
Cyp2d11 -0.07 -0.54 -0.25
Cyp2d26 -0.19 -0.40 -0.63
Cyp4f3 0.20 -0.29 -0.38
Cyp2d10 -0.13 -0.39 -0.39
Cyp2e1 -0.28 -0.36 -0.41 LPS: stable (mRNA), protein content
reduced (STAT1 dependent) [1]
Cyp4v2 -0.09 -0.29 -0.11
Cyp20a1 0.00 0.13 -0.19
Cyp4b1 -0.43 0.01 -0.19
Cyp2j5 -0.14 -0.10 -0.09
Cyp27a1 0.01 -0.36 -0.19
Cyp51a1 0.36 -0.29 -0.20
Cyp7a1** -1.23 -1.98 -0.83
Cyp2j6* 0.16 -0.09 -0.21
Cyp2b19 ** 0.04 -1.42 -1.88
Cyp2c55 ** 0.18 0.10 0.30
Table S6. Non-cytochrome phase I proteins of biotransformation quantified in Lm in-
fected liver. Significant regulation is indicated by symbols (c= downregulation,a= upregulation)
Gene name Protein name d1/d0
mean RF
d3/d0
mean RF
d9 /d0
mean RF
Por NADPH-cytochrome P450 reductase -0.05 -0.42 -0.40
Fmo2 Dimethylaniline monooxygenase 2 0.03 c -0.60 c -0.83
Fmo3 Dimethylaniline monooxygenase 3 -0.31 c -2.01 c -2.03
Fmo1 Dimethylaniline monooxygenase 1 -0.06 -0.61 -0.46
Fmo5 Dimethylaniline monooxygenase 5 -0.06 -0.30 -0.06
Fmo4 Dimethylaniline monooxygenase 4 -0.09 -0.33 -0.34
Adh1 Alcohol dehydrogenase 1 -0.31 c -0.90 -0.85
Adh4 Alcohol dehydrogenase 4 -0.32 c -0.68 0.38
Adh5 Alcohol dehydrogenase 5 -0.09 -0.14 -0.26
Akr1a1 Alcohol dehydrogenase [NADP(+)] -0.12 -0.08 -0.24
Maoa Amine oxidase A -0.11 c -0.58 -0.47
Maob Amine oxidase B -0.28 c -0.96 -0.75
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Table S7. Phase II proteins of biotransformation quantified in Lm infected liver. Sig-
nificant regulation is indicated by symbols (c= downregulation, a= upregulation). ** = found in
2 out of three replicates, * = found in one replicate.
Gene
name
Protein name d1/d0
mean RF
d3/d0
mean RF
d9 /d0
mean RF
Gsto1 Glutathione S-transferase omega-1 -0.18 c -0.61 -0.68
Gstp1 Glutathione S-transferase P 1 0.24 a 2.12 a 2.03
Gstm6 Glutathione S-transferase Mu 6 -0.14 c -0.54 0.20
Gstt1 Glutathione S-transferase theta-1 -0.12 c -0.86 c -1.14
Gstt2 Glutathione S-transferase theta-2 -0.27 c -0.58 -0.77
Gstm3 Glutathione S-transferase Mu 3 -0.14 -0.26 a 1.63
Gsta2** Glutathione S-transferase A2 -0.34 c -0.71 -0.19
Gstm1* Glutathione S-transferase Mu 1 -0.17 -0.27 2.79
Gsta1 Glutathione S-transferase A1 -0.01 0.45 -0.05
Gstm2 Glutathione S-transferase Mu 2 -0.10 -0.45 -0.56
Gsta4 Glutathione S-transferase A4 -0.21 -0.50 -0.53
Gsta3 Glutathione S-transferase A3 -0.09 -0.33 -0.16
Gstm5 Glutathione S-transferase Mu 5 -0.14 -0.03 -0.36
Gstm7 Glutathione S-transferase Mu 7 -0.02 -0.39 0.18
Mgst1 Microsomal glutathione
S-transferase 1
-0.35 -0.26 0.18
Gstk1 Glutathione S-transferase kappa 1 0.03 -0.34 -0.60
Ugt2a3 UDP-glucurono-syltransferase 2A3 -0.13 c -0.61 -0.91
Ugt1a1 UDP-glucurono-syltransferase 1-1 0.35 c -0.83 -0.89
Ugt2b17 UDP-glucuronosyltransferase 2B17 -0.14 -0.06 0.01
Ugt3a1 UDP-glucuronosyltransferase 3A1 -0.21 -0.38 -0.81
Ugt1a9 UDP-glucuronosyltransferase 1-9 0.02 -0.42 -0.38
Ugt1a6 UDP-glucuronosyltransferase 1-6 0.12 0.11 -0.02
Ugt3a2 UDP-glucuronosyltransferase 3A2 0.00 -0.55 -0.61
Cml1 Probable N-acetyltransferase
CML1
-0.38 c -1.05 -0.27
Acat1 Acetyl-CoA acetyltransferase,
mitochondrial
-0.06 c -0.46 c -0.73
Baat Bile acid-CoA:amino acid
N-acyltransferase
-0.06 c -0.53 -0.23
Nat2 Arylamine N-acetyltransferase 2 0.03 0.00 -0.17
Hgsnat* Heparan-alpha-glucosaminide
N-acetyltransferase
0.03 0.06 0.12
Naa50 N-alpha-acetyltransferase 50 0.04 0.20 -0.10
Naa38 N-alpha-acetyltransferase 38, NatC
auxiliary subunit
0.02 0.20 0.34
Naa15 N-alpha-acetyltransferase 15, NatA
auxiliary subunit
0.07 0.33 -0.04
Acat2 Acetyl-CoA acetyltransferase,
cytosolic
-0.06 -0.37 -0.48
Cml2 Probable N-acetyltransferase
CML2
0.04 0.27 0.40
Naa16** N-alpha-acetyltransferase 16, NatA
auxiliary subunit
-0.18 -0.01 -0.19
Gnpnat1 Glucosamine 6-phosphate
N-acetyltransferase
-0.06 0.02 -0.19
Naa10* N-alpha-acetyltransferase 10 -0.03 0.12 -0.13
Table S8. Overview of identified DUBS and recorded unique spectra in the HA-IP
approach comparing HAUb-VME and HAUb-VFEA. To be considered for this table, DUBs
had to be identified by 1 peptide, with a Scaffold 3.0 minimum protein probability of 99 % and
a minimum peptide probability of 95 %. Additionally, all identifications with only one unique
spectrum, marked in red in the table, were discarded before further evaluation. Furthermore, the
molecular weight extracted from Uniprot DB and used for normalization is listed for each DUB.
contr. I contr. II contr. III VME I VME II VME III VFEA I VFEA II VFEA III MW [kDa]
USP1 35 31 33 31 30 28 87.456
USP3 1 5 3 1 58.868
USP4 1 8 90 69 83 101 77 87 108.343
USP5 1 9 11 72 64 75 80 76 81 95.833
USP7 3 9 135 103 125 133 118 130 128.475
USP8 1 62 43 63 78 72 67 122.611
USP9X 4 3 156 127 138 162 144 148 209.711
USP10 20 16 27 1 1 87.134
USP12 3 2 7 4 4 5 42.914
USP14 1 4 5 76 61 78 82 61 73 56.002
USP15 1 4 86 67 73 87 79 83 112.419
USP16 39 35 45 50 38 42 93.406
USP17L2 5 3 3 4 2 1 60.219
USP19 4 69 52 82 87 80 88 150.549
USP20 18 16 19 21 18 14 36.429
USP22 4 1 6 5 3 4 59.954
USP24 1 63 47 81 53 48 61 294.001
USP25 63 53 76 29 9 20 121.420
USP28 37 37 42 40 27 31 119.318
USP30 2 2 58.221
USP33 41 32 32 41 34 36 102.728
USP34 60 47 60 11 3 9 408.214
USP36 8 7 7 10 6 7 119.913
USP37 38 32 38 18 10 15 110.063
USP38 1 50 51 59 53 55 53 116.102
USP42 3 22 25 25 22 19 24 146.223
USP45 12 9 13 14 17 15 90.361
USP46 13 10 12 13 11 15 42.442
USP47 5 128 115 129 127 122 123 157.455
USP48 1 67 53 68 20 9 18 120.631
CYLD 1 52 39 52 17 7 12 106.586
UCHL1 18 15 15 10 2 6 24.838
UCHL3 4 28 31 20 27 20 25 26.152
UCHL5 1 1 48 39 40 43 32 32 37.617
BAP1 1 33 29 32 34 31 30 80.492
OTUB1 2 2 4 31.27
OTUB2 2 1 27.300
OTUD4 1 1 3 1 123.055
OTUD5 4 2 9 60.306
OTU6B 4 3 6 1 33.758
OTU7A 7 6 7 7 5 5 100.797
ZRANB1 7 4 11 2 80.934
VCIP135 7 5 11 134.503
Ataxin 3 22 15 19 2 1 1 40.533
JOS1 2 1 3 23.152
JOS2 3 2 3 20.776
List of Figures
1 Ub/UBL beta-grasp fold and ubiquitin structure . . . . . . . . . . . . . . 6
2 Mono- and polyubiquitination and their associated cellular functions . . . 7
3 Conjugation and deconjugation of UBLs . . . . . . . . . . . . . . . . . . . 11
4 Modes of action leading to DUB specificity . . . . . . . . . . . . . . . . . 14
5 Molecular reaction mechanism of papain-like cysteine protease DUBs . . . 16
6 Reaction mechanism of JAMM metalloprotease DUBs . . . . . . . . . . . 17
7 Key features of activity-based probes targeting Ub/UBLs . . . . . . . . . 20
8 Modes of DUB-probe binding and different probes resembling diubiquitin 22
9 Invasion, replication and cell-spread of Lm in epithelial cells . . . . . . . . 24
10 Overview of c-Met activation, signaling and receptor recycling . . . . . . . 26
11 Infection of Lm in vivo causing Listeriosis . . . . . . . . . . . . . . . . . . 28
12 Immune responses to hepatic Lm infection . . . . . . . . . . . . . . . . . . 29
13 Manifestations reported for listeriosis cases in Germany in 2014 . . . . . . 31
14 Emergence and progression of sepsis . . . . . . . . . . . . . . . . . . . . . 33
15 Biomarkers in sepsis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
16 Omics approaches to detect novel biomarkers for sepsis . . . . . . . . . . . 39
17 Evaluation strategy of transfection efficiency by flow cytometry . . . . . . 51
18 Response of c-Met, Erk 1/2 and Akt kinases upon HGF and InlB stimula-
tion in HeLa S3 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
19 Activity of transfected and endogenous c-Met in resting cells and after
stimulation with HGF and InlB . . . . . . . . . . . . . . . . . . . . . . . . 74
20 Activation of Erk 1/2 following stimulation of endogenous and transfected
c-Met . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
21 Activation of Akt after stimulation in comparison to non-stimulated and
non-transfected cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
22 Localization-analysis of wild type c-Met-eGFP in HeLa S3 cells . . . . . . 79
23 Localization of wt c-Met-eGFP after HGF-stimulation in high, medium
and low-expressing cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
24 Localization of wt c-Met-eGFP after InlB-stimulation in high, medium
and low-expressing cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
25 Localization of Ub-deficient c-Met mutants in HGF-stimulated HeLa S3 cells 84
26 Localization of Ub-deficient c-Met mutants in InlB-stimulated HeLa S3 cells 85
247
List of Figures
27 VCPIP1 localization during HGF and InlB stimulation in HeLa S3 cells . 87
28 USP8 localization during HGF and InlB stimulation in HeLa S3 cells . . . 88
29 Reactivity of recombinant DUBs towards the c-MetK962-UIPP . . . . . . . 90
30 Localization of USP21 at sequential time points of InlB stimulation in
HeLa S3 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
31 Localization of CYLD during distinct time points of InlB stimulation in
HeLa S3 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
32 Characterization of the course of Lm infection in murine liver samples . . 95
33 Protein quantification and regulation dynamics of Lm infected mice liver
samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
34 Percentage of quantified proteins related to Ub and UBLs . . . . . . . . . 107
35 RNF135 - Integration into the RIG-I pathway in Lm liver infection . . . . 109
36 RNF213 expression regulation, putative pathway components and substrates110
37 Regulation of active DUBs quantified in hepatic Lm infection . . . . . . . 113
38 UCHL3 protein abundance and regulation in Lm infected liver . . . . . . 114
39 Patient characteristics sampled during their hospitalization at the ICU . . 118
40 Work flow for the generation of DUB patterns from PBMC samples and
analysis of the results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
41 Exemplary DUB patterns for patients 6 to 15 . . . . . . . . . . . . . . . . 121
42 Golden standard for the normalization of DUB patterns . . . . . . . . . . 123
43 Summary of all normalized DUB patterns acquired . . . . . . . . . . . . . 124
44 Hierarchical clustering and MDS for a threshold of 3.5 pixel . . . . . . . . 126
45 Theoretical assignment of DUBs to the activity-patterns according to their
probe-modified molecular weight . . . . . . . . . . . . . . . . . . . . . . . 130
46 Percentage of assignment for individual DUBs in distinct sample classes . 132
47 Unique spectra of DUBs captured by HAUb-VME and HAUb-VFEA . . . 135
48 Comparative shift assays of recombinant DUBs labeled with HAUb-VME
and HAUb-VFEA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
49 Characterization of recombinant USP5 and USP7 regarding activity and
probe-binding properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
50 Reactivity and specificity of Ub-chain linkage specific UIPPs towards
recombinant DUBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
51 Involvement of ubiquitination and DUBs in suggested mechanisms of c-Met
recycling and degradation . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
52 Potential roles of USP21 and CYLD in InlB-mediated c-Met stimulation . 147
53 Identified and regulated proteins involved in "anti-viral" signaling during
hepatic Lm infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
54 Enriched GO terms regarding biological processes involved in immune
responses and immune regulation . . . . . . . . . . . . . . . . . . . . . . . 153
248
List of Figures
55 Variation of cell types in patient samples . . . . . . . . . . . . . . . . . . . 161
56 Amino acid properties of peptides synthesized for c-Met-UIPPs . . . . . . 166
57 Schematic representation of standard "summed" patterns for all sample
classes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
58 Advantages of 18O-labeling for the quantitative analysis of enriched ubi-
quitinated peptides. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
S1 K1259 is ubiquitinated in HeLa S3 cells after 30 min of HGF stimulation . 217
S2 Structures of C-terminal electrophilic warheads used in this study . . . . . 217
S3 VCPIP1 localization during HGF stimulation in HeLa S3 cells . . . . . . . 219
S4 VCPIP1 localization during InlB stimulation in HeLa S3 cells . . . . . . . 221
S5 USP8 localization during HGF stimulation in HeLa S3 cells . . . . . . . . 223
S6 USP8 localization during InlB stimulation in HeLa S3 cells . . . . . . . . 225
S7 Localization of USP2 at distinct time points of InlB stimulation in HeLa S3
cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
S8 Localization of CYLD at distinct time points of InlB stimulation in HeLa S3
cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
S9 Localization of USP21 at distinct time points of InlB stimulation in HeLa S3
cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
S10 Statistical characterization of proteomic data from Lm infected liver samples232
S11 Extrapolation of marker pixel lines of ICU patient samples and healthy
control samples utilized in this study . . . . . . . . . . . . . . . . . . . . . 232
S12 Regulation of active DUBs quantified in hepatic Lm infection - full RFs . 233
S13 Results of hierarchical clustering and MDS for a threshold of 7 pixel . . . 234
S14 Results of hierarchical clustering and MDS for a threshold of 10 pixel . . 235
S15 Results of hierarchical clustering of sepsis samples with different pixel
thresholds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
S16 Heat map of DUBs identified via HA-IP in pool of 5 healthy control samples236
S17 Shift-assays of the c-MetK962-UIPP to identify DUBs which potentially
remove Ub from the probed site . . . . . . . . . . . . . . . . . . . . . . . . 237
S18 Enriched GO terms regarding biological processes involved in physiological
metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238
249
List of Tables
1 Known ubiquitin-like modifiers and regulatory enzymes . . . . . . . . . . 10
2 DUB-families, member numbers and reaction mechanisms . . . . . . . . . 13
3 Secondary antibodies utilized for western blot analytics and immunofluo-
rescence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4 Primary antibodies utilized for western blot analytics and immunofluores-
cence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5 Recombinant deubiquitinating enzymes used in this study . . . . . . . . . 47
6 Cell media used for maintenance of cell lines and cultivation of cells . . . 49
7 Properties of used cell lines . . . . . . . . . . . . . . . . . . . . . . . . . . 49
8 Marker combinations used to determine populations of liver leukocytes in
L.m. infected mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
9 C-terminal electrophilic warheads prepared for and used in this study . . 56
10 Isopeptide warheads produced for or utilized in this study . . . . . . . . . 57
11 Main HA-Ub populations monitored by MALDI-TOF/TOF for determi-
nation of purity in probe ligation . . . . . . . . . . . . . . . . . . . . . . . 59
12 Primers used to validate pcDNA 3.1 c-Met eGFP sequence utilizing MWG
biotech sequencing service . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
13 Mascot parameters used for protein identification . . . . . . . . . . . . . . 69
14 Proteome Discoverer and Scaffold 3.6.5 parameters used to filter the
datasets and to validate the reliability of the data . . . . . . . . . . . . . . 70
15 Properties of the analyzed time-points forming distinct stages of Lm infection 96
16 Top 10 regulated proteins of the early stage of infection (day 1 p.i.) . . . . 100
17 Top 10 regulated proteins of the peak stage of infection (day 3 p.i.) . . . . 101
18 Top 10 regulated proteins of the late stage of infection (day 9 p.i.) . . . . 103
19 Cytochrome P450 family members showing significant regulation in Lm
liver infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
20 Numbers of quantitatively identified DUBs in hepatic Lm infection in
comparison to the numbers of annotated DUBs . . . . . . . . . . . . . . . 112
21 Summary of sample numbers and acquired patterns in each sample class . 124
22 DUBs captured in EL-4 lysates by HAUb-VME and HAUb-VFEA . . . . 134
23 Human CYP homologs of murine cytochrome P450 enzymes . . . . . . . . 156
250
List of Tables
24 Patient characteristics leading to high sample heterogeneity . . . . . . . . 159
25 Linkage specificities reported for DUBs in this study as compared to
previous results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
S1 c-Met ubiquitination sites as annotated in Phosphosite Plus DB . . . . . . 239
S2 Parameters used for mass spectrometric measurements . . . . . . . . . . . 240
S3 Primers used for site-directed mutagenesis of pcDNA 3.1 c-Met-eGFP . . 241
S4 Proof-of-concept proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
S5 Identified but non-regulated members of the cytochrome P450 family . . . 244
S6 Non-cytochrome phase I proteins of drug metabolism quantified in Lm
infected liver . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244
S7 Phase II proteins of drug metabolism quantified in Lm infected liver . . . 245
S8 Overview of identified DUBS and recorded unique spectra in the HA-IP
approach comparing HAUb-VME and HAUb-VFEA . . . . . . . . . . . . 246
251
Acknowledgments
Acknowledgments
Zuerst möchte ich meinem Doktorvater Prof. Lothar Jänsch danken. Nicht nur für die Betreuung
während meiner Doktorarbeit sondern auch für die fachliche und persönliche Unterstützung
während der gesamten Zeit vielen Dank. Die hinter mir liegende Zeit hat mich sehr geprägt und
zu meiner persönlichen Entwicklung beigetragen.
Ebenso möchte ich Prof. Susanne Engelmann herzlich für die Übernahme des Zweitgutachtens
und Prof. Klemens Rottner für die freundliche Zusage den Prüfungsvorsitz zu übernehmen, danken.
Bei meinen Kooperationspartnern möchte ich mich für ihre Unterstützung innerhalb der
einzelnen Teilprojekte meiner Arbeit bedanken. Besonders erwähnen möchte ich Dr. Raimo
Franke: Danke für spannende Diskussionen und eine tolle Zusammenarbeit, auch wenn die Peptide
es nicht immer gut mit uns gemeint haben. Auch danke ich Antje Ritter und Tatjana Arnold für
die technische Umsetzung der Synthesen, sowie, für die Proteinproduktion: Dr. Joop van den
Heuvel, Daniela Gebauer, Nadine Konisch und Claudia Hanko.
Weiterhin auch einen großen Dank an Prof. Schlüter für die hervorragende Zusammenarbeit
sowie an Dr. Uwe Lodes für die Probensammlung und -bereitstellung. Auch bei Dr. Nishanth
Gopala und Anette Sohnekind möchte ich mich herzlich für die großartige Kooperation sowie
technische Unterstützung bedanken.
Ein lieber Dank geht an die gesamten CPROs, die während der zurückliegenden Jahre dafür
gesorgt haben, dass die Arbeitsatmosphäre immer angenehm war und nie das Gefühl aufkam,
dass man alleine da steht. Danke an Dr. Manfred Nimtz, Dr. Josef Wissing und Dr. Marco van
Ham für die Unterstützung bei technischen Fragen sowie an Kathrin Goltz, Undine Felgenträger
und Kirsten Minkhart für die technische Assistenz -Feueralarm!- und die schönen Stunden neben
der Arbeit.
Außerdem ein herzliches Danke an Mario Schmidt, Nicole Amsberg, Dr. Björn Bulitta und
Dr. Maxi Heyner für Diskussionen und Unterhaltungen, ob fachlich oder privat und die kleinen
und großen Hilfen im Labor und außerhalb.
Tausend Dank möchte ich auch Prof. Frank Klawonn sagen: die Engelsgeduld bei der Auswer-
tung der Sepsis-Daten und die Unterstützung bei allen statistischen Fragen sowie ein offenes Ohr
haben merklich dazu beigetragen, dass diese Arbeit so weit gediehen ist und ihre jetzige Qualität
hat.
Ein ebenso großer Dank gilt Dr. Uwe Kärst, für die immer passende Literatur zum Thema,
das unermüdliche Korrekturlesen und für die Aufbauarbeit, besonders während des Schreibens
dieser Arbeit. Hier ist das laute „JA“ für dich.
Der letzte und größte Dank an dieser Stelle ist an meine Freunde und meine Familie gerichtet.
Ich danke meinen Eltern für ihre unendliche Unterstützung und den unerschütterlichen Glauben
an mich; ihr seid meine Wurzeln im Leben.
Außerdem danke ich Simone, Lisette und Rebekka, dafür, dass sie immer da sind auch wenn
ich mich manchmal rarmache.
Zuletzt möchte Henning danken: für jede einzelne Sekunde deiner Zeit und die schier unerschöp-
fliche gute Laune. Du bist wahrlich meine Sonne und hast mich das Fliegen gelehrt. Danke!
252
